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Abstract
INTRODUCTION: Chronic myeloid leukaemia (CML) is a clonal myeloproliferative 
disorder of the haemopoietic stem cell (HSC), with a variable clinical course. 
Chronic phase (CP) disease, typically of 4-5 years duration, progresses to 
accelerated (AP) and then blastic phase (BP), with the latter behaving as a 
particularly aggressive acute leukaemia of either myeloid (MBP) or lymphoid (LBP) 
lineage. Treatment is most successful when delivered in CP, and accurate 
prognostic indices are required to individualise treatment. Increased telomere 
shortening has been described during progression of CML, and may be of 
prognostic relevance. Paradoxically, teiomerase activity (TA, as determined by the 
TRAP assay) has been shown to be elevated in the CP stem/progenitor cell 
(CD34^) compartment; however this may not accurately reflect telomere 
maintenance in-vivo. We sought to further define the prognostic significance of 
telomere shortening at diagnosis of CML, monitor the rate of telomere loss during 
the disease and characterise expression of the major teiomerase components 
(hTR and hTERT) in CD34^ selected cells at diagnosis and during disease 
progression.
METHODS: Peripheral blood leucocyte (PBL) telomere length measurement was 
performed by flow-FISH on cohorts of normal individuals, patients at diagnosis and 
all stages of CML. To define the degree of telomere shortening in individual 
patients at diagnosis ex-vivo expanded (BCR-ABE) T-cells were used as an 
internal control for ‘normal’ somatic cell telomere length. Expression of hTERT and 
hTR was quantified by Q-RT-PCR and hTERT mRNA splice variants detected by 
RT-PCR. CD34^ selected cells from CML patients were confirmed as BCR-ABL^ 
by FISH. TA was determined by TRAP assay.
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RESULTS: Telomere shortening in CP and AP CML patients progressed at 10-20 
times the rate of age-related shortening observed in the normal control group. 
Furthermore, high-risk prognostic score patients at diagnosis had significantly 
shorter telomeres than low-risk patients. High purity CD34^ selected cells from 
CML, as compared to normal, demonstrated increased TRAP activity which 
correlated with the proportion of cycling cells. However, hTERT mRNA expression 
was not significantly elevated. Unexpectedly, Q-RT-PCR for hTR demonstrated a 
mean five-fold reduction in levels in the CML samples, raising the possibility that 
telomere homeostasis is disrupted in CML. In BP samples, hTERT expression was 
significantly lower in MBP than LBP and this was mirrored by a corresponding shift 
in hTERT splicing patterns. MBP hTERT expression correlated inversely with 
telomere length.
CONCLUSIONS: In summary, increased TRAP activity is not synonymous with 
telomere maintenance in CML, and dysregulated expression of hTR may 
contribute to the telomere loss observed in these patients. Indeed TRAP activity 
appeared largely dependent on the proportion of cycling cells. In the context of 
progressive (i.e. BP) disease, hTERT expression is lineage and telomere length 
dependent, thus explaining inconsistent reports of TA levels in BP samples. We 
have also demonstrated that subtle shifts in splicing of hTERT mRNA is likely to 
have a regulatory role in primary HSC. In prognostic terms telomere shortening in 
CML is greatest in high-risk score patients at diagnosis, and occurs rapidly during 
disease progression. These data further emphasise the potential clinical utility of 
telomere length measurement for prognostic modelling and monitoring of disease 
progression.
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1. Introduction and Aims
1.1 Normal haemopoiesis
Haemopoiesis is the process by which pluripotent haemopoietic stem cells (HSC) 
generate the multiple cell lineages necessary to sustain life, a process which is 
estimated to generate in the region of 10^  ^ cells per day. All mature circulating 
blood cells are derived from a relatively small number of HSCs via a successive 
series of intermediate progenitors displaying steadily increasing lineage 
commitment (Figure 1-1). Such a hierarchical model of haemopoiesis has 
provided a paradigm for the development of other tissues and, more recently, 
leukaemogenesis and tumourigenesis.
Candidate human HSCs can be isolated and characterised functionally (e.g. by the 
ability of single cells to reconstitute multilineage haemopoiesis in a mouse model 
or by the ability to establish long-term cell culture in-vitro) and by 
immunophenotyping. The latter is commonly performed in the clinical and 
laboratory setting using the CD34 antigen (a surface glycoprotein) as a surrogate 
HSC marker (Berenson, et al 1988). The properties of CD34^ cells are well 
characterised from both a research and clinical perspective (in the context of bone 
marrow and peripheral blood stem cell transplants), although it is now apparent 
that even the CD34^ progenitor cell population is in itself extremely 
heterogeneous.
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Figure 1-1 A summary of haemopoietic development
A simplified schematic of haemopoietic development from a pluripotent HSC. Such 
cells are characterised by ability to self-renew, pluripotency, extensive proliferative 
capacity and rarity (approximately 1 in 10® total nucleated bone marrow cells). 
Each HSC has an enormous capacity to generate large numbers of mature cells 
over many years, perhaps even for the duration of a human life; in the mouse a 
single HSC can reconstitute the entire haemopoietic system for the lifespan of the 
animal (Osawa, et al 1996). Lineage-committed primitive progenitors are derived 
from the HSC, and are functionally and immunophenotypically defined as common 
lymphoid and common myeloid progenitors (CLP and CMP respectively). Their 
mature, terminally-differentiated progeny are broadly divided into two groups of 
cells; lymphoid (small box, top right) and myeloid (medium box, lower right). The 
term ‘myeloid’ in its proper sense refers to all cells that are not lymphoid. In its 
most common usage however it generally refers to granulocytes (neutrophils) and 
monocytes. While in general terms neutrophils survive only for a few hours, 
lymphocytes may survive for decades. The implications of this hierarchical 
organisation, for both the clinical utility of HSC and leukaemic cell biology, are 
largely self-evident; only true HSCs can contribute to long-term multilineage 
regeneration post stem cell transplant (with committed progenitors providing only 
transient engraftment) (Jordan and Lemischka 1990) and leukaemias arising in the 
HSC compartment may give rise to multi-lineage clonally-derived progeny. Chronic 
myeloid leukaemia (CML) is the archetypal example of an HSC malignancy.
True HSCs (as defined above) most likely represent a tiny proportion of CD34^ 
cells: CD34^ cells that are negative (or low) for CD38, thy-1 and CD71 are 
enriched for HSC activity (Miller, et a! 1999). Such primitive cells are
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predominantly quiescent (i.e. in Go) (Gothot, et al 1997), and it has been estimated 
by mathematical modelling that they divide, on average, only once every 1-2 years 
(Vickers, et a! 2000). Unfortunately such cells are difficult to study ln-vltro\ in 
addition to their rarity, the mechanism of self-renewal vs. differentiation is not 
clear, and candidate HSC will expand and differentiate in culture conditions, with 
acquisition of lineage specific markers and concomitant loss of stem cell 
phenotype. The majority of cells displaying CD34^ therefore represent progenitor 
populations of varying lineage commitment. That said however, the utility of the 
CD34 antigen remains of central importance with regards stem / progenitor cell 
isolation, manipulation and therapies.
Although HSC have an enormous capacity to self-renew and /or differentiate, this 
capacity is finite; murine HSC can only be serially transplanted 5-7 times in mice 
before haemopoiesis is exhausted (Harrison, et al 1978). Although it is possible 
that extrinsic stress may contribute to this observation {I.e. ex-vivo handling of 
cells, engraftment in a hostile bone marrow microenvironment etc.) the concept 
that an intrinsic mechanism is operating, perhaps by registering accumulated cell 
divisions, is an attractive one. The discovery therefore that telomeres (DNA-protein 
‘caps’ which exist at all eukaryotic chromosomal termini) shorten with each cell 
division In-vltro (Harley, et al 1990), and with age In-vlvo (Vaziri, et al 1994) 
subsequently implicated this as one such potential mechanism. In support of these 
data, the widely conserved enzyme teiomerase (via its ability to reinstate lost 
telomeric DNA-repeat sequence. Figure 1-2) enables cells to bypass replicative 
senescence (the consequence of unchecked telomere shortening) and confer 
cellular immortality (Bodnar, et al 1998). In a haematological context, teiomerase 
deficient murine HSC are considerably less able to undergo serial transplantation 
than wild-type (Allsopp, et a! 2003a) and human HSC from umbilical cord blood 
(UCB, with long telomere sequence) have greater proliferative potential than BM
Chapter 1,18
HSC from older donors (Holyoake, et al 1999b). Thus for successful ex-vivo 
expansion of HSC (e.g. for tissue engineering or gene therapy, all long-held 
ambitions of HSC biologists) the ability to manipulate teiomerase is likely to be 
critical.
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Figure 1-2 Telomere lengthening is mediated by teiomerase
Eukaryotic chromosomal DNA ends in a 3’ overhang of G-rich telomeric DNA. In 
conjunction with the RNA template component of teiomerase (hTR), the reverse 
transcriptase hTERT catalyses the addition of telomeric repeats. The 5’ end is 
extended by conventional DNA-synthesising machinery. By this process cells can 
maintain telomere length and abrogate the effects of replicative loss. In certain 
circumstances telomere elongation is also possible.
In parallel with an increased understanding of normal HSC biology, there has 
arisen a steadily increasing groundswell of opinion that considers many 
leukaemias (and indeed many cancers) to be disorders arising at the stem cell
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level. Both acute and chronic myeloid leukaemia (AML and CML respectively) are 
now well characterised as stem cell malignancies (with varying degrees of 
downstream maturation or differentiation-arrest) (Lapidot, et al 1994). What seems 
increasingly likely is that the conventional approach to therapy for these disorders 
(e.g. combination chemotherapy) does not target the leukaemic stem cell 
population; this leads to relapse in a large proportion of cases. Conversely 
therapies that do eliminate these cells (e.g. allogeneic stem cell transplant, or 
alloSCT) are often curative. Novel approaches, tailored to target the malignant 
stem cell compartment, are therefore required. One such target is teiomerase, 
given its ability to maintain the replicative ability of these putative target cancer 
stem cells. Determining how teiomerase is expressed (and ultimately regulated) 
and defining the telomere dynamics within these disorders is paramount to 
developing future anti-telomerase treatment strategies.
1.2 Chronic myeloid leukaemia
It is fair to say that CML, despite its relative rarity (it has an incidence of 
approximately 1 in 100,000), is the most extensively characterised of the 
haematological malignancies. Interest in the pathogenesis of CML was the catalyst 
which led to the evolution of modern cancer cytogenetics and molecular biology, 
the advent of chemotherapy, the establishment of alloSCT as a routine (and 
curative) procedure, effective immunotherapy (in the form of interferon therapy, 
donor lymphocyte infusion and non-myeloablative allogeneic transplant) and, most 
recently, the proof-of-principle that molecularly targeted therapy works, in the form 
of imatinib mesylate. From a pathological viewpoint it is a fascinating disorder to 
study: in its early or chronic phase (CP) it is a single-gene disease {i.e. a 
consequence of the BCR-ABL fusion gene), and behaves in a relatively benign 
fashion characterised by myeloid expansion. Typically, excess neutrophils.
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basophils, eosinophils (at all stages of maturation) and platelets accumulate in the 
haematopoietic compartment, and if unchecked may result in a grossly elevated 
white blood cell count (WBC, occasionally in excess of 400-500 x 10^ /1) with 
clinically apparent sequelae of hypervicosity (Sawyers 1999). Crucially these cells, 
although produced in vast excess and with immature forms visible in the peripheral 
blood, are functional. Patients may therefore survive for several years with 
relatively innocuous cell-count controlling chemotherapy such as hydroxyurea. 
Without disease modifying treatment however (such as interferon-alpha, alloSCT 
or very likely imatinib mesylate therapy), there is an almost 100% certainty of 
disease progression to blastic phase (BP, a particularly aggressive acute 
leukaemia characterised by maturation arrest in the lymphoid or myeloid lineage) 
and death, in conjunction with additional cytogenetic and molecular abnormalities.
CML was the first human malignancy to be linked to an acquired genetic 
abnormality, in which the 3’ end of the c-ABL gene from chromosome 9 replaces 
the 3’ end of the BCR gene on chromosome 22 (Groffen, et al 1984, Shtivelman, 
et al 1985). Detection of the resulting abnormally small chromosome 22 (the 
Philadelphia or Ph chromosome (Rowley 1973)) by bone marrow (BM) 
cytogenetics continues to be the mainstay of CML diagnosis and monitoring 
(typically with quantitative karyotypic analysis of 20-30 metaphases from a BM 
aspirate). More recently however, with the spectacular success of imatinib 
mesylate (a selective BCR-ABL kinase inhibitor (O'Brien, et al 2003)), sensitive 
peripheral blood BCR-ABL real-time (Q) RT-PCR has become important for 
monitoring of these patients (Lin F, Drummond MW et al, Blood In Press).
The molecular and phenotypic consequences of BCR-ABL acquisition in the HSC 
compartment have been extensively studied and are too numerous to discuss fully 
here. Briefly, the BCR-ABL product is most commonly a 210 kDa oncoprotein
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that has transforming activity in primary mouse BM and cell lines, 
and can induce many of the typical phenotypic features of CML cells upon 
transfection into primary human CD34^ cells (Daley, et al 1990, Evans, et al 1993, 
Zhao, et al 2001). Crucial to the transforming ability of the BCR-ABL oncoprotein, 
in conjunction with its constitutively active tyrosine kinase activity, Is its 
cytoplasmic location (in contrast to the nuclear location of p i45 '^^ '^-) (Konopka and 
Witte 1985, Van Etten, et al 1989). Autophosphorylation of 
(Pendergast, et al 1993) leads to recruitment of GRB2, a small adapter protein that 
can activate the RAS pathway (Ma, et al 1997). Nuclear signalling is mediated by 
phosphorylation of JAK2 and STAT1/STAT5 (llaria and Van Etten 1996), and 
together such signals contribute to the growth factor independence of BCR-ABL 
containing cell lines. Additionally, p210® '^ '^^®  ^mediated activation of the PI(3)K/Akt 
pathway (Skorski, et al 1995) and increased expression of BCL-2 (Sanchez-Garcia 
and Grutz 1995) increases resistance to apoptosis. Given the complexity of these 
downstream events, there is considerable potential for BCR-ABL tyrosine kinase 
activity to alter teiomerase activity. As yet such effects remain uncharacterised, but 
worthy of further study.
In terms of CML HSC biology, a crucial consequence of BCR-ABL acquisition 
appears to be increased cell turnover, as demonstrated by 3H-thymidine suicide 
assays (Ponchio, et al 1995) and high-resolution cell cycle analysis of primitive 
leukaemic progenitors (Holyoake, et al 1999a). The demonstration of increased 
telomere shortening in the clonally derived peripheral blood leucocytes (PBL) of 
CML patients (Iwama, et al 1997) is supportive of these in-vltro observations, and 
has formed the basis for subsequent studies (Boultwood, et al 1999, Boultwood, et 
al 2000, Ohyashiki, et al 1997b)) including this current body of work. Utilising
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telomere length measurement as a surrogate marker of BCR-ABL^ HSC turnover 
(and hence disease progression) may potentially a useful prognostic tool.
The need for such tools is significant: despite all evidence to date pointing to BCR- 
ABL acquisition as a single genetic event in CP CML, patients display a 
particularly heterogeneous clinical course with respect to duration of CP. Although 
the median duration of CP is approximately 4 - 5  years, in clinical practice this 
varies widely, with some 10% of CML patients living beyond 8 years (Cervantes, et 
al 1994). At least some of this heterogeneity is due to the recently described 
deletions on the derivative-9 chromosome, which occur in 15% of patients 
(apparently at the time of the Philadelphia translocation) and result in poor 
prognosis disease (Huntly, et al 2001). It appears likely that this is due to the loss 
of an as yet unidentified tumour-suppressor gene. Thus, the classical description 
of CML as a ‘single-gene’ disease would appear to be misleading, from both a 
molecular and clinical standpoint. One of the few certainties of the disorder is that 
without effective disease modifying treatment all CP CML patients will eventually 
progress to BP, often via a less well defined accelerated phase (AP, Figure 1-3) 
(Spiers 1977), (Kantarjian, et al 1987). Predicting disease progression is therefore 
crucial for individual patient management decisions.
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Figure 1-3 Timecourse of CML progression, and relationship to clinical, 
morphologic and cytogenetic features.
Ionising radiation remains the only clear aetiological factor in the causation of 
CML. Based upon look-back studies by the Hiroshima Foundation, the mean time 
to clinical development after the atomic explosion was seven years (Ichimaru, et al 
1981). A typical triphasic disease pattern is illustrated, with median duration of 
each phase shown. Occasional patients may have a biphasic picture, and 
progress rapidly to BP without the ill-defined AP. Patients may even present in BP. 
A common feature of disease progression is the development of additional non- 
random cytogenetic abnormalities (in approximately 70-80% (Griesshammer, at a!
1997) of patients), the most common of which are illustrated. In about 15% of 
patients progressive disease is associated with -7, -17, +17, +21 and -Y  (Deutsch, 
at a! 2001) . At the molecular level, loss of wild-type p53 function is a relatively 
common abnormality, being associated with 25% of myeloid BP (Ahuja, at a!
1989). (The WHO clinical and laboratory criteria which define these different 
stages, and which are used to classify our patient material, are defined in Table 
2-1 and Table 2-1 (Vardiman, ef a/2001) in the Materials and Methods Section)
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1.3 Defining the clinical problem
Because treatment becomes less effective with advanced disease, identification of 
patients at risk of rapid disease progression at diagnosis is vital for the 
development of risk-adapted treatment strategies. AlloSCT, the only established 
curative intervention for CML, achieves optimal survival benefit when carried out 
within the first year of diagnosis (Gratwohl, et al 1998). This procedure carries 
considerable transplant related morbidity and mortality however (up to 30%, even 
for well selected patients), and it is therefore likely to be of greatest benefit to (and 
most acceptable to) patients who are likely to progress quickly. A major (and 
ongoing) focus of CML research has therefore been the development of robust, 
accurate and routinely applicable prognostic scoring systems (Hasford, et al 1998, 
Sokal, et al 1984). The most contempary of these, the European or Hasford score 
(Hasford, et al 1998), utilises 6 routinely collected clinical data points (age, spleen 
size, platelet, blast, eosinophil and basophil counts) to generate a high-, 
intermediate- or low-risk score for any individual patient, with regards to response 
to interferon therapy. In general terms, for a patient in the low risk category 
receiving interferon a median survival of 98 months may be expected (or longer if 
the patient undergoes a complete cytogenetic response on BM cytogenetics). 
Such an individual may therefore elect to pursue the route of conventional {i.e. 
non-transplant) therapy. Conversely, a high-risk patient, with no likelihood of a 
significant benefit from interferon therapy and an expected median survival of 42 
months, may assess the ‘up-front’ risk of alloSCT as acceptable.
While such systems are very useful in studying populations of patients (e.g. for 
comparing two or more arms of a clinical trial) they are somewhat less applicable 
to individual treatment decisions. Identification of biological markers of prognosis
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is therefore of the utmost importance. It is within this context that telomere length 
measurement, both as an indicator of HSC turnover and a surrogate marker of 
genomic instability, may be a useful prognostic tool.
CML has served as a paradigm for the concept of haematopoietic stem cell (HSC) 
malignancy and tumour evolution, and the relative ease with which primary human 
material can be obtained, manipulated and studied has undoubtedly facilitated 
this. In terms of telomere dynamics and telomerase it is therefore a logical disease 
to study; telomere length can give insight into Ph  ^ HSC turnover and (indirectly) 
genetic stability, the role of telomerase in early and late tumourigenesis can be 
determined and (dys)regulatory mechanisms identified, and finally (and ultimately 
most importantly) the clinical significance of these observations can be assessed. 
Critically, the myriad downstream effects of the BCR-ABL protein may well impact 
on telomerase function, although to date no conclusive studies have been 
performed. Incorporating knowledge of telomere biology into meaningful 
prognostic indices and novel and effective treatment strategies must be seen as 
the ultimate aim.
1.4 An introduction to teiomere and telomerase biology
A functional definition of the telomere was initially provided by early genetic 
studies. It was observed that maize chromosomes with ‘broken ends’ were 
unstable, resulting in end-to-end fusions, ring or dicentric forms, thus 
demonstrating that the structural integrity of chromosome termini was a 
requirement for genomic stability (McClintock 1941, McClintock 1942). These early 
observations have been confirmed experimentally in yeast, where loss of a 
telomere results in eventual chromosomal loss (Sandell and Zakian 1993). Upon
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disruption of telomeres the cell will attempt to repair the break, thereby generating 
fusions between the telomeres of different chromatids. Such fusions occur when 
the number of telomere repeats drops to a critical level and in the absence of an 
effective telomere maintenance mechanism (Blasco, et al 1997). Observations 
such as these therefore support the notion of telomere length as an indicator of 
telomere function, namely as a stabilising DNA ‘cap’.
The non-coding DNA of telomere sequence is unique; an identical hexameric 
telomere repeat sequence has been described for trypanosomes (Blackburn and 
Challoner 1984), slime moulds (Forney, e ta l 1987), humans and other vertebrates
(Moyzis, et al 1988); namely (TTAGGG/CCCTAA)n often repeated thousands of
times . Although different sequences have been described in other organisms (for 
example G1.3T for the baker’s yeast Saccharomyces cerevisiae (Shampay, et al 
1984)) they share the common property of a G-and C-rich strand orientated in the 
5’ to 3’ direction containing multiple sequence repeats (from a few hundred base 
pairs in length in ciliates and yeasts to thousands in vertebrates). In addition to 
these properties, an overhanging single-strand 3’ G-rich terminus is also a highly 
conserved feature (Henderson and Blackburn 1989). Such conservation almost 
always implies biological importance.
How the telomere maintains genomic stability without being recognised as a 
double stranded DNA break has been the subject of intense research. In addition 
to its capping role, the telomere is also involved in the alignment of chromosomes 
during metaphase (Liu, et al 2002) and the spatial organisation of chromosomes 
within the nucleus (de Lange 1992). Although recent evidence for a telomere- 
position effect on transcription of sub-telomeric genes in human cells (Baur, et al 
2001) has further broadened the list of potential telomeric functions, in comparison 
to the capping role they remain relatively less well characterised.
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1.4.1 Telomere shortening
Semi-conservative replication of DNA presents a unique problem: the process only 
works in the 5’ to 3’ direction, and DNA polymerase requires binding of an RNA 
primer. Olovnikov and Watson predicted the consequences of this long before the 
telomere was characterised, and termed it the ‘end-replication problem’ (Olovnikov 
1971, Watson 1972). This predicted the loss of a small 5’ nucleotide segment as 
DNA synthesis took place, with progressive replication induced telomere 
shortening (Figure 1-4).
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Figure 1-4 Replication of a linear DNA duplex molecule and the end- 
replication' problem.
The 3’ end of the molecule is replicated continuously to the very end, having 
started at the opposite, and 5’, terminus. However synthesis of the lagging strand 
(also in the 5’ to 3’ direction) is discontinuous because of the requirement for RNA 
primer binding and unidirectional growth of the new strand. Upon removal of the 
RNA primers, the gaps in the discontinuous lagging strand are filled in and ligated. 
However there is no provision for such a process at the immediate 5’ end, thus 
leaving a gap. Since the DNA duplex is antiparallel each daughter molecule will be 
shortened on their 5’ end after replication with successively shorter daughter 
chromosomes resulting from further cycles of cell division.
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This mechanism has the attractive feature (both from an experimental and 
biological standpoint) of behaving as a ‘mitotic clock’ (Harley, et al 1990), 
suggesting a mechanism whereby cells could sense a ‘maximum’ number of 
divisions, and then stop dividing (senesce). Such cell behaviour has been 
observed In-vitro since the 1960s (Hayflick and Moorhead 1961). It was however 
clear that telomere shortening did not occur in all cells, as those that proliferate 
indefinitely (such as unicellular eukaryotes, immortalised cell lines and germline 
cells) were shown to maintain their telomeres at a constant length over time. 
Indeed sperm telomeres are longer than somatic telomeres and do not decrease 
in length during organismal aging (Allshire, et al 1989, Cooke and Smith 1986, 
Levy, et al 1992) as do somatic cells. In most eukaryotic cells this is achieved by 
the presence of an enzyme called telomerase, an RNA dependent DNA 
polymerase with the ability to add telomeric repeats, abrogate replicative loss and, 
as described below, bypass senescence.
Mammalian telomeres show a species-specific length setting (Kipling and Cooke
1990): in humans telomere length varies between individuals (approximately 5 - 
lOkb in peripheral blood cells) due to differences in the number of hexameric base 
pair sequences (de Lange, et al 1990, Lansdorp, et al 1996), with different strains 
of mice showing a greater degree of variability of between 12 and 80kb (Zijlmans, 
et al 1997). Even among individuals of the same age, considerable variation in 
telomere length of peripheral blood lymphocytes has been demonstrated (Rufer, et 
al 1999) and twin studies suggest that most of this variation is genetically 
determined (Slagboom, et al 1994). A novel locus on chromosome 2 has recently 
been proposed as having a role in the regulation of telomeric length in the mouse 
(Zhu, et al 1998), although no such locus has yet been described in humans. 
There is also variation in telomere length between individual chromosomes, with 
17p having the smallest number of telomere repeats in humans (Martens, et al
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1998). The significance of these interchromosomal variations remains unclear 
however, and the majority of published studies use average telomere length 
measurements for experimental purposes.
1.4.2 The biology of cell senescence
Leonard Hayflick, in a seminal series of experiments performed some 40 years 
ago, was first to suggest the existence of a finite limit to diploid cell division in vitro 
(Hayflick and Moorhead 1961). He utilised human diploid fibroblasts (HDFs) to 
demonstrate irreversible cessation of cell division after 60-80 population doublings 
(the ‘Hayflick limit’ or Mortality 1 (Ml)), with concomitant development of a 
phenotype that he described as “senescent” (‘old or withered’, as opposed to 
quiescence which is generally assumed to be reversible) (Hayflick 1965). 
Consequently it was assumed that all normal cells had an intrinsically limited 
replicative lifespan. The term ‘replicative senescence’ is now used to describe 
these observations.
Despite a state of cell-cycle arrest, senescent cells remain metabolically active, 
and may remain viable for years with appropriate attention to supporting culture 
conditions. It is now known that this state is achieved by activation of the p53 and 
retinoblastoma (RB) tumour suppressor pathways (Shay, et al 1991). 
Consequently, the introduction of oncogenes that inhibit these control mechanisms 
-  such as SV40 large T antigen (Ikram, et ai 1994) -  allows cells to undergo 
further cell division (Counter, et ai 1992). However their replicative capacity again 
remains finite, and after a further 20-30 population doublings, the cells enter a 
period of ‘crisis’, characterised by genomic instability and apoptosis (M2). 
Occasional immortalised clones may emerge from this chaotic state (Counter, et ai
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1992), albeit rarely (at a frequency of less than 1 in 10 )^. These in-vitro 
observations have largely been explained in terms of telomere dynamics.
1.4.3 Replicative senescence
The most attractive ‘counting’ mechanism to mediate replicative cell senescence is 
that of telomere shortening. Harley et al showed that HDF telomeres progressively 
shorten in culture (Harley, et al 1990), and it was demonstrated that their 
replicative capacity correlated with absolute telomere length rather than with the 
age of the fibroblast donor (Allsopp, et al 1992). In keeping with these studies is 
the observed accumulation of short telomeres prior to senescence in human 
fibroblast cultures (Martens, et al 2000). In this study, HDFs lost 50 -  150 bps of 
telomere sequence with each division. Telomeres of 1-2Kb or shorter were 
observed immediately prior to senescence and, interestingly, the onset of 
senescence was significantly correlated with the mean telomere length (rather 
than with that of the shortest chromosomes). Telomere shortening is thought to 
induce senescence once some telomeres have become sufficiently short to 
activate a DNA damage signal (Harley 1991). In summary these early studies 
pointed to a tight relationship between telomere length (and hence genomic 
stability), DNA-damage surveillance and repair mechanisms and cell-cycle arrest / 
tumour suppressor pathways. Disruption of such regulatory elements could clearly 
be of importance in the development and evolution of tumours.
A causal link between telomere shortening and replicative senescence was 
ultimately achieved in two ways. Firstly, Bodnar et al demonstrated that human 
retinal pigment epithelial cells and foreskin fibroblasts transfected with hTERT, the 
rate limiting component of telomerase, underwent at least 20 additional population 
doublings (Bodnar, et al 1998). Furthermore transfected cells demonstrated
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telomere stabilisation or even lengthening. Secondly, it was shown that when 
telomerase was inhibited in tefomerase-positive immortal cells, telomere 
shortening followed leading to chromosome-to-chromosome fusions and cell death 
(Hahn, et al 1999b, Zhang, et al 1999). These important observations have been 
confirmed and extended by other groups (Vaziri and Benchimol 1998, Zhu, et al
1999). It has been assumed that replicative senescence also occurs in-vivo, 
although no definitive proof has yet been published. Telomere shortening is 
certainly demonstrable in many somatic cell types, including PBL (Rufer, et al
1999), which demonstrate a rapid loss in the early years of life, with subsequent 
slowing of loss in later years. However there is as yet no conclusive proof that this 
contributes to organismal ageing. Indeed a truly senescent phenotype has not 
been definitively described in-vivo (Severino, et ai 2000) and somatic cells from 
aged donors can be easily made to grow in-vitro (Cristofalo, et al 1998). Ageing is 
clearly therefore, a more complicated process than in-vitro replicative senescence.
Using HDFs in-vitro, von-Zglinicki has demonstrated that the major mechanism of 
telomere loss in this cell-type under specified culture conditions is via induction of 
single strand breaks (von Zglinicki, et al 2000) and oxidative damage (von 
Zglinicki, et al 1995). Telomeric DNA is less well repaired than the rest of the 
genome (and indeed appears 5 to 10-fold more susceptible to oxidative damage in 
the first place (Oikawa and Kawanishi 1999)), thus telomere shortening may 
simply be representative of genomic damage sustained as a whole. Alternatively, 
telomere shortening by whatever means (oxidative damage or replicative loss) 
may be a crucial final common pathway. As DNA damage signals mediate the final 
phenotype of these cells, it is likely therefore that many different stimuli can give 
rise to a senescent-like state, resulting in a stochastic loss of cell viability. It seems 
likely that upregulation of p i6'NK4A jg particular importance with regards 
telomere-independent senescence (Munro, et a /2001), a phenomenon which has
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been termed MO. The term ‘culture shock’ has also been used to define 
replication-independent mechanisms of senescence in-vitro, emphasising the 
need for meticulously controlled cell culture conditions when studying replicative 
senescence.
The straightforward telomere shortening / Hayflick limit relationship has also been 
questioned recently by Blackburn (Blackburn 2000), who has proposed a more 
complex model of replicative senescence (see Section 1.5.3 below). The basis for 
this hypothesis is largely twofold; firstly that the telomere is a complex DNA-protein 
structure, and that telomere sequence length is unlikely to be the primary 
determinant of ‘capping’ ability; and secondly, that telomere length is not always a 
good indicator of cell ageing and viability (Yang, et al 1999). In the latter study 
hTERT transfected human endothelial cells underwent >100 population doublings 
despite exhibiting shorter telomeres than that of a senescent control population. 
Thus it appears that the presence of telomerase is crucial for determining 
replicative capacity, not necessarily because of its telomere-lengthening ability but 
perhaps via a stabilising or capping role.
1.4.4 Replicative senescence as a tumour suppressor mechanism
Extension of initial observations on telomere-limited growth in-vitro to the in-vivo 
situation has led to the hypothesis that telomere shortening and replicative 
senescence may have evolved as a tumour suppressor mechanism, by preventing 
excessive cell division. The multistep nature of carcinogenesis dictates the need 
for multiple mutations (Vogelstein and Kinzler 1993) with extensive population 
doublings after each mutation for a reasonable chance of further events occurring. 
A replicative barrier of approximately 80 doublings has been estimated to limit the
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expansion of the pre-malignant clone, and serve to generate senescent cells 
which contribute to the ageing phenotype. Given the high rates of apoptosis in 
most tumours however, it is difficult to model the number of divisions required to 
generate a clinically significant tumour. However, as 90% of human tumours 
express telomerase, it would appear that telomere stabilisation is of crucial 
importance for their continued growth (Kim, et al 1994). There is a growing 
consensus that telomere shortening represents a barrier to unlimited replicative 
ability, and akin to the checkpoint function of p53, provides a ‘telomere checkpoint’ 
function (Verfaillie, et al 2002). Any such mechanism will likely not act in isolation, 
but in concert with other tumour suppressive checkpoints’ such as immune 
surveillance, cell-cycle arrest and DNA repair. Identifying the relevant importance 
of these mechanisms is likely to prove very difficult, as studies of cultured cells 
have shown.
1.5 Telomere structure and dynamics
1.5.1 The T-loop and other structures within teiomeric DNA
A recent twist in the tale (literally) of telomeric structure came with the discovery 
that mammalian telomeres (including those of human cell lines and normal 
peripheral blood leucocytes) end in a large duplex loop formed by intercalation of 
the 3’ overhang back into the duplex telomeric strands in a TRF2 (a double­
stranded telomere binding protein) mediated process (Griffith, et al 1999). 
Consistent with this finding is the ability of TRF2 to negatively regulate telomere 
length, presumably by facilitating loop formation and preventing telomerase 
access (Smogorzewska, et al 2000). This would appear to be a neat structural 
solution to prevent the ends of chromosomes from being recognised as double
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stranded DNA breaks, with subsequent activation of DNA repair mechanisms or 
apoptosis. These loop structures are termed t-loops (telomere loops), and result in 
the formation of a small displacement loop (D-loop) where the G-strand overhang 
rejoins the duplex (Figure 1-5). An additional consequence of these loop 
structures is to limit the access of telomerase to the telomeric end, which may be 
further hindered by the presence of ‘G-quartet’ structures. These are planar 
tetrameric arrangements of guanine nucleotides within the G-rich strand, which 
can adopt a number of different topologies as visualised by nuclear imaging 
techniques (Aboul-Ela, et at 1992). Given the requirement of the hTR template 
region of telomerase for a linear non-folded DNA primer, it is entirely plausible that 
these structures provide a further control on access of telomerase to the telomere 
(Zahler, et al 1991). It seems likely that reduction of telomere length below a 
critical threshold could disrupt these stabilising structures.
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Figure 1-5 Telomere structure and telomere associated proteins
A schematic illustrating the higher order DNA structure (namely T- and D-loops) of 
the telomere, as well as a putative model of the binding proteins. For additional 
details see text. NBS-MRE11-RAD50 is a DNA-repair complex that binds to 
telomeres, an association mediated at least partly by TRF1 and TRF2 (Wu, et al
2000). Ku is a component of the DNA dependent protein kinase complex (DNA- 
PK) involved in double strand DNA repair (Bailey, et al 1999). The telomerase 
associated proteins dyskerin, TEP1, Stau and L22 are shown to convey the 
potential complexity of the entire telomere-telomerase complex, and are described 
in Section 1.6.9.1. Adapted from Modes etal. (Modes, et al 2002).
1.5.2 Telomere binding proteins
Several telomere-binding proteins (TBPs) have now been characterised as 
important for telomere stability and length regulation. The first to be characterised, 
two related TBPs (TRF1 and TRF2), bind the duplex array of T2AG3 repeat 
sequences via direct interaction with double-stranded DNA (Blanchi, et al 1997)
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(Broccoli, et al 1997). Van Steense! has shown that TRF1 negatively regulates the 
action of telomerase, possibly at the level of individual telomeres, by preventing 
telomerase access. In those studies over expression of TRF1 in human cell lines 
resulted in telomere shortening (van Steensel and de Lange 1997). As regards 
TRF2, a small ubiquitously expressed protein, inhibition of its function in many cell 
types (including primary human lymphocytes) results in loss of the G-rich 
overhang, cell cycle arrest and apoptosis via the ATM / p53-dependent DNA 
damage checkpoint pathway (Karlseder, et al 1999). Indeed TRF2 would appear 
to play such a central role in telomere homeostasis that de Lange has proposed 
that the role of T2AG3 repeats is to provide TRF2 binding sites (de Lange 2002). It 
is likely that some (if not all) of these characteristics of TRF2 are dependent on its 
ability to stabilise the T-loop structure described above, via its binding to the base 
of the loop (Griffith, et al 1999). From these data TRF2 would appear to be a 
major protective factor operating at chromosome ends.
Although much less well characterised than TRF 1 and 2, other TBPs also exist, 
although a full description of these is beyond the scope of this section (Figure 
1-5). Briefly, Pot 1 (protection of telomeres 1), has recently been described in 
humans as a single strand DNA binding protein necessary for protection of 
telomeric ends (Baumann and Cech 2001). Others, such as TIN2, TANK1 and 
hRAPI have profound effects on telomere length when over expressed (Kim, et al 
1999, Li, et al 2000a). Recently described associations between DNA repair 
proteins and the telomere are less well understood however. For example the 
DNA repair component DNA-PKc (the catalytic component of the DNA-dependent 
protein kinase complex, a non homologous end-joining, NHEJ, and repair enzyme) 
has been shown to have a role in telomere capping and maintenance, with dual 
DNA-PKc and telomerase knock-out (KO) mice showing greater rates of telomere 
shortening than telomerase KO mice alone (d'Adda di Fagagna, et al 2001,
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Espejel, et al 2002). Intriguingly DNA-PKc is down regulated by BCR-ABL, 
highlighting the potential importance of this association in terms of the telomere 
loss observed in CML (Deutsch, ef a/2001).
Although telomerase is discussed fully in the next section, it is important to 
emphasise that as well as having the ability to ‘reset’ the mitotic clock via telomere 
elongation / stabilisation, it also plays a ‘capping’ role via telomere stabilisation in 
cells with very short telomeres ((Yang, et al 1999), (Zhu, et al 1999) This would 
appear to be independent of its role in telomere elongation and may simply involve 
a telomerase-telomere physical interaction to form a protective cap. In conclusion 
it seems that there are many ways to stabilise a telomere; by analogy there must 
also be many ways to destabilise it.
1.5.3 Telomere structure, function and dynamics: a synthesis
What is now becoming clear is that telomere length per se, although important, 
need not be the sole determinant of its functional state. Three crucial factors 
participate in stabilising the telomere: a minimum number of telomeric repeats, an 
intact G-strand overhang and a complex set of associated telomere binding 
proteins. Elizabeth Blackburn has proposed a model of telomere dynamics in 
which telomeres exist in capped and uncapped states (Blackburn 2000). In this 
model the presence of DNA repair proteins at the telomere is postulated to be 
crucial for the action of telomerase, which involves transient uncapping. In long 
telomeres, with extensive protein binding sites, the chances of the telomere being 
uncapped is low. After successive divisions this possibility becomes more likely 
and, in a stochastic fashion, the telomere may become uncapped. At this stage 
one of three things may happen: telomerase could act transiently at the uncapped
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site, the telomere could undergo homologous replication (and thereby maintain or 
even increase its length), or NHEJ will occur and fuse telomeres (resulting in 
genomic instability at the next cell division). If the cap is not restored via any of 
these mechanisms, the cell can exit the cell-cycle and may undergo apoptosis. 
Crucial to this model is the stochastic nature of the process: indeed such a model 
neatly explains the stochastic nature of cell division in vitro. As Blackburn states: 
“whether a telomere will become uncapped is expressed as a probabilistic function 
influenced by several factors, only one of which is length”.
In experimental terms, the complete determination of the functional state of a 
given telomere may therefore require quantification of multiple proteins, telomeric 
length measurement and visualisation of secondary DNA structure etc. From a 
practical aspect this is difficult (and laborious, particularly where large numbers of 
samples require to be analysed), and the mainstay of assessing telomeric status 
continues to involve measurement of telomere length.
1.6 Telomerase
1.6.1 Background
It is now accepted that the apparent tumour-suppressive role of telomere 
shortening can be circumvented by the presence of telomerase, a 
ribonucleoprotein reverse transcriptase first described by Elizabeth Blackburn and 
Carol Greider in Tetrahymena (Greider and Blackburn 1985). The two crucial 
constituents of telomerase (which together can reconstitute telomerase activity in- 
vitro in a rabbit reticulocyte-lysate model (Weinrich, et al 1997)) consist of a 
catalytic protein subunit known as ^TERT (Greenberg, et ai 1998, Harrington, et al
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1997) and an RNA template molecule of complimentary sequence to the telomeric 
DNA (hTR) (Blasco, eta l 1995, Feng, e ta l 1995, Greider and Blackburn 1989).
While hTR can be detected in most tissues, hTERT is much more restricted in its 
expression (Harrington, et al 1997, Meyerson, et al 1997, Nakamura, et al 1997). 
Introduction of the latter is sufficient to reconstitute telomerase activity and this has 
led to the concept that hTERT is the primary rate-limiting component of 
telomerase. This is however a simplistic view as hTR can also be limiting for 
telomere maintenance in some circumstances (described in detail below). For this 
reason most studies of telomerase regulation have focused on transcriptional 
control of TERT, with comparatively few on regulation of hTR or post-translational 
mechanisms. These are now being seen as increasingly important.
Present in 90% of tumours (Kim, et al 1994), telomerase is thought to confer 
immortality via addition of teiomere repeats, although other non-telomere 
dependent functions of this tightly regulated enzyme are a possibility. A second, 
less well-characterised, telomerase-independent mechanism of telomere 
maintenance known as alternative lengthening of telomeres, or ALT, has also 
been described (Bryan, et al 1995). This mechanism would appear to occur 
infrequently however, being detected most commonly in tumours of mesenchymal 
origin (Bryan, et al 1997). Human ALT cells are rare (thus far seen in a few 
tumours and cell lines only) and are characterised by lack of telomerase activity 
with great heterogeneity in telomere length. The latter is due to recombination 
events involving telomere repeats, the mechanism of telomere maintenance 
operating in these cells. In general terms the overall contribution of ALT to 
malignancy appears small. This is perhaps partially explained by a recent study 
which found ALT tumours from mTERT^' lnk4a/ARf^' mice unable to generate 
métastasés, a property which was restored upon reconstitution of mTERT (Chang,
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et al 2003). Considerable interest in ALT remains however, not least because of it 
being a potential mechanism of resistance to anti-telomerase therapies.
1.6.2 Measurement of telomerase activity
The majority of the studies described in the following sections have utilised the 
telomeric repeat amplification protocol (TRAP assay) to detect enzymatic activity 
in the extracts of the cells or tissue in question. As originally described by Kim 
(Kim, et al 1994) (with subsequent modifications (Kim and Wu 1997)), the TRAP 
assay is based on the ability of telomerase (within the sample extract) to extend a 
DNA primer, with the products subsequently amplified via a PCR step and 
visualised on a polyacrylamide gel. A number of control samples are incorporated: 
a heat -  or RNAse- treated negative control sample (to inactivate the catalytic or 
RNA components respectively), a positive control (an immortal telomerase-positive 
cell line sample) and an internal DNA standard (with flanking sequences for the 
TRAP assay primers, e.g. ITAS) to control for inhibitors of Taq polymerase (which 
can be present in the sample). Although highly sensitive, the technique is at best 
semi-quantitative, as it depends on a PCR step. Additionally it is sensitive to 
protease interference, as it relies on the presence of the intact telomerase 
holoenzyme. Furthermore, many TRAP studies are undoubtedly confounded by 
contaminating telomerase positive cells (eg lymphocytes) in the samples, and pre­
assay homogenisation of the sample precludes localisation of the enzymatic 
activity. As originally described the assay was moderately laborious (and therefore 
expensive) and probably unsuitable for high-throughput screening of clinical 
samples in a diagnostic setting, as had been originally hoped. Further advances
as regards simplicity have resulted in an ELISA based TRAP, which may yet allow
'- a
it to enter a clinical setting.
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Whether telomerase activity in-vitro, as measured by TRAP, actually reflects 
telomere maintenance in-vivo however is open to some considerable doubt; for 
example KO mice deficient in a crucial telomerase component do not display any 
alteration in TRAP activity yet have profound defects in telomere maintenance 
(Hathcock, ef a/2002). This will be discussed in more detail in Chapter 6.
A complementary approach to TRAP is the direct measurement of the hTR or 
hTERT components. hTR (cloned and sequenced prior to hTERT (Feng, et ai
1995)) was initially detected using Northern blotting, although an early report failed 
to show any correlation between hTR levels (expressed both in normal and tumour 
samples) and telomerase activity in immortalised cells and tumours (Avilion, et ai
1996). Such studies were partly responsible for the (still) often repeated and 
misleading term ‘ubiquitous expression of hTR', thereby implying that it is not 
regulated in any particularly relevant manner. As detailed below, interest in this 
molecule as a regulatory element of telomerase activity, and as a mediator of 
human disease, has been rekindled of late. Other means of detecting hTR include 
in-situ hybridisation (Soder, et al 1997a) and RT- and Q-RT-PCR (Takahashi, ef al
2000). hTERT, the apparent rate-limiting component of the telomerase 
holoenzyme, is generally accepted to be a surrogate marker of telomerase activity; 
levels of hTERT are generally correlated with TRAP activity (Kilian, et al 1997, 
Meyerson, et al 1997, Nakamura, ef al 1997) and hTERT transfection confers 
telomerase activity to telomerase negative cells (which express hTR, see below). 
hTERT measurement by sensitive and accurate Q-RT-PCR is therefore 
particularly useful in addition to the semi-quantitative TRAP assay.
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1.6.3 Cellular immortalisation and telomerase
1.6.3.1 Transfection of hTERT into human cell lines
Subsequent to the observation that transfection of hTERT into retinal pigment 
epithelial and foreskin fibroblast human cell lines conferred increased growth in 
culture (Bodnar, et al 1998), extensive phenotypic studies on hTERT immortalised 
fibroblasts have shown that they lack the characteristics of neoplastic cells 
(namely anchorage independent growth, reduced serum requirements and tumour 
formation in nude mice), have a normal karyotype and have intact DNA damage 
checkpoint controls (Ouellette, ef a/2000). Thus up-regulation of telomerase alone 
does not confer oncogenic ability.
Hahn and Weinberg have determined the genetic ‘requirements’ for the creation of 
a human tumour cell in-vitro (Hahn, et al 1999a). In this study, which also 
emphasised the need for tumour cells to overcome Ml and M2 checkpoints, only 
cells expressing hTERT, SV40 large-T antigen and H-rasV12 were truly 
tumourigenic on injection into nude mice. This ‘4-hit’ model therefore incorporates 
loss of p53 and Rb checkpoint functions (via SV40) and growth signals (via an 
activated ras gene) in addition to a telomere maintenance mechanism (hTERT). 
Such a model fits very neatly within the classical hallmarks attributed to cancer in- 
vivo\ namely self-sufficiency in growth signals; loss of suppressor / checkpoint 
functions; avoidance of apoptosis; limitless replication potential; angiogenesis; and 
invasion and metastasis (Hanahan and Weinberg 2000). In terms of leukaemia it is 
likely that the latter two characteristics assume much less importance in disease 
evolution, due to bone marrow origin of the disease and likely circulation of the 
target malignant cell. Telomere maintenance is almost certainly a requirement 
however.
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1.6.3.2 Modulation of telomerase activity in human cell-lines
Using an alternative approach to define the role of telomerase, transfection of 
immortalised human glioblastoma cell lines with a vector expressing antisense 
telomerase RNA was found to induce either apoptosis or differentiation (Kondo, et 
al 1998). More recently, Herbert ef al. demonstrated that oligonucleotide inhibition 
of telomerase immortalised human breast epithelial cells led to progressive 
telomere shortening and apoptosis (Herbert, et al 1999). In addition to 
demonstrating the importance of telomerase in the maintenance of most 
immortalised cell lines, these studies also provide support for telomerase as a 
valid target for anti-cancer strategies.
1.6.3.3 Telomere independent functions of telomerase
As suggested above, there is some evidence that telomerase may have 
proliferative effects on the cell that are independent of its action at the telomere. In 
mice that overexpress mTERT, (in basal kératinocytes within the skin via the 
bovine keratin 5 promotor, while retaining normal telomere length and skin 
histology), there is a twofold increase in the rate of skin wound healing and skin 
tumour development from chemical carcinogenesis (Gonzalez-Suarez, ef a/2001). 
These data imply that telomerase may have direct growth-promoting effects in 
cells with sufficiently long telomeres. These effects can be aggravated when mice 
overexpressing mTERT also lack p53, and in these double-transgenic mice there 
was a significant reduction in lifespan due to a high incidence of neoplastic and 
pre-neoplastic lesions in the affected tissues (Gonzalez-Suarez, ef al 2002). In 
another model, forced cardiac-myocyte expression of mTERT resulted in 
hyperplasia and hypertrophy of the cells (Oh, ef a/2001).
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In-vitro studies of human cells have gone some way to explaining these 
observations. In one study hTERT expressing human mammary epithelial cells 
become resistant to the anti-proliferative effects of TGF-(3 (Stampfer, et al 2001), 
thus gaining a proliferative advantage. More recent work on hTERT transfected 
human cells has implicated hTERT mediated upregulation of epiregulin (a potent 
growth factor) and epidermal growth factor receptor in HDFs and human 
mammary epithelial cells respectively (Lindvall, et al 2003, Smith, et al 2003). 
Furthermore, in rodent neural cells, mTERT expression was seen to behave as a 
cell-protective mechanism by conferring resistance to apoptosis (Fu, et al 2000). 
This has recently been confirmed for hTERT human T-lymphocytes in-vitro, which 
displayed resistance to oxidative stress-induced apoptosis (Luiten, et al 2003). 
Further work to determine the significance of these findings for normal tissue 
homeostasis and cancer biology is required.
Although the signalling and effector mechanisms for these potential additional 
actions of telomerase (and ultimately their in-vivo significance) remain unclear; 
they further support the strategy of targeting telomerase within anti-tumour 
strategies.
1.6.4 The telomerase-negative mouse
The telomerase knock-out (KO) mouse was developed by Blasco et al., with 
telomerase activity confirmed to be completely absent in cells of animals 
homozygous for the null mTR allele (Blasco, et al 1997). Q-FISH techniques 
demonstrated steady telomere shortening, with disappearance of the T2AG3 signal 
on some chromosomes (consistent with shortening of telomeres to a few hundred 
bps long). An increase in end-to-end chromosomal fusions was observed in later 
generations of mice, all of which remained viable for at least the six generations 
studied.
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However, in a subsequent report involving later generation animals, mice 
displayed defective spermatogenesis and infertility, uterine and intestinal villous 
atrophy, impaired mitogenic responses of lymphocytes, ulcerative dermatitis, an 
increased rate of apoptosis and compromised proliferative capacity of cells within 
the haematopoietic system (Lee, et al 1998, Rudolph, et al 1999). The impaired 
germinal centre reaction with B-cell telomere shortening observed in these animals 
after immunisation (wild-type animals demonstrated germinal centre B-cell 
telomere lengthening) also provided support for a telomere-dependent model of 
immune senescence (Herrera, et al 2000). However of particular interest was the 
fact that these telomerase-absent mouse cells could be spontaneously 
immortalised in culture, transformed by oncogenes and (despite their severely 
shortened telomeres) formed tumours in nude mice. Recent studies have also 
shown that the ALT mechanism can maintain, and indeed lengthen, telomeres in 
telomerase KO murine cell lines in some circumstances (Hande, et al 1999) and it 
may be this process which allows immortalisation to take place.
If telomerase is not then required for unlimited cell growth in cell lines derived from 
these mice, it raises questions as to the role of mouse telomerase in vivo where 
activity has been repeatedly demonstrated in mouse tumours (Blasco, et al 1996, 
Broccoli, et al 1996). Indeed there is the possibility that mouse telomerase 
activation is simply a surrogate marker of clonal evolution and proliferation in 
tumour cells, inferring that caution should be exercised when extrapolating these 
data to human biology. Arguing against this however, mTR' '^ mice developed 33% 
fewer skin tumours in response to chemical carcinogens than wild type telomerase 
competent mice, indicating that telomerase does indeed have a role in mouse 
tumourigenesis (Gonzalez-Suarez, e ta l2000).
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it is now apparent that different tissues would appear to respond to lack of 
telomerase in different ways. A thorough study of the phenotypic features of late 
generation telomerase KO mice showed an increased incidence of cytogenetic 
abnormalities and a 4-6 fold increase in spontaneous cancers, at a younger age 
than the wild type mouse (Rudolph, et al 1999). That most of these tumours arose 
in highly proliferative cell types where telomere shortening (and hence 
chromosomal abnormalities) should be most marked (lymphomas and 
teratocarcinomas), is compelling evidence for telomere instability having a direct 
role in tumour formation. That there should be an increased risk of cancer at all, in 
the face of a general reduction in cell viability in these mice, is somewhat 
contradictory. One explanation is that telomerase independent mechanisms 
facilitate long-term tumour growth after the initial period of genetic instability and 
carcinogenesis. Data from S. cerevisiae has confirmed that obtained from mice: 
the mutation rate in the target gene {CAN1) increased 10-100 fold in strains with 
absent telomerase and telomere dysfunction (Hackett, e ta l2001).
These data suggest a biphasic role for telomerase in tumorigenesis: absence in 
the early stages promotes genetic instability and tumour evolution, with 
subsequent upregulation (and/or other mechanism of telomere maintenance) 
allowing clonal expansion and tumour growth. The human disorder dyskeratosis 
congenita (DKC, described below), a hereditary disorder of telomerase function, 
directly supports such a mechanism in humans.
Ultimately the genetic background of a cell with critically short telomeres, 
particularly in relation to its p53 or Rb status, is likely to determine its fate. p53 is 
an extremely efficient tumour suppressor, and DNA damage (for example 
secondary to ionising radiation) results in rapid phosphorylation of Its N terminus 
with stabilisation of the molecule (Shieh, et al 1997), (Siliciano, et al 1997). The
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consequence of this critical regulatory step is either cell cycle arrest (with DNA 
repair) via expression of p21, or apoptosis. Studies using an mTR' ‘^ p53’ '^ mouse 
model have demonstrated a p53-mediated response to critically shortened 
telomeres, with increased frequency of chromosomal fusions (3-fold) and 
transformation in cells lacking both mTR and the p53 checkpoint function (Chin, et 
al 1999). Presumably the latter cells are able to accumulate more genetic damage 
without undergoing cell cycle arrest or apoptosis, increasing the likelihood of a 
‘second hit ‘ .
1.6.5 Patterns of telomerase activity in humans
The initial report of telomerase activity in human tissues (Kim, et al 1994) {i.e. a 
specific association with tumour cells, immortal cells and germ cells, with no 
activity in somatic tissues) has not been borne out by subsequent studies. For 
example, high levels of telomerase activity have been demonstrated in activated 
lymphoid cells (Weng, et al 1996) and proliferating endometrium (Brien, et al 
1997), with low levels present in many other somatic tissues. It appears to be the 
case that such low-level expression results from rare telomerase expressing stem 
or progenitor cells rather than low-level expression in all cells in the specimen 
(Bonatz, et al 1998, Kolquist, et al 1998, Ramirez, et al 1997), although there may 
be more widespread expression in proliferating endometrium (Kyo and I noue 
2002).
Thus many somatic tissues, previously accepted as telomerase negative, have 
been shown to harbour subsets of telomerase competent, presumed progenitor 
cells. This hierarchical tissue model, with regards to telomerase expression and 
regulation, has been best studied in the haemopoietic system, and will be 
discussed in detail in subsequent chapters. In all tissue types however, telomerase 
activity appears to be tightly associated with proliferative status, although how this
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occurs at a regulatory level remains unclear. One practical consequence is that 
many observations of telomerase modulators in-vitro (or of telomerase activity 
between different primary tissues) may be confounded by altered or inherently 
different cell cycle activation status rather than by direct modulation of telomerase 
activity per se. Some of the regulatory elements of telomerase activity, as 
discussed below, also regulate cell proliferation. This view is complicated even 
further if one accepts that telomerase itself may confer proliferative status on a cell 
directly, as discussed above.
Studies of telomerase regulation during cell cycle progression have produced 
conflicting results. Zhu et al. demonstrated upregulation of telomerase activity in 
human tumour cells in S phase, using a series of phase-selective cell cycle 
inhibitors (Zhu, et a! 1996). However a subsequent study, using selected cycling 
cell populations based on DNA content (hence avoiding potentially cytotoxic cell 
cycle modulators), demonstrated no change in telomerase activity during cycle 
progression (Holt, et a! 1997). When cells entered Go however, telomerase was 
repressed. In this study telomerase activity generally correlated with growth rate. 
By analogy, cells that are post-mitotic should therefore not express telomerase; 
indeed rapid down-regulation of activity has been described in several cell lines 
during terminal differentiation (Reichman, et a! 1997, Sharma, et a! 1995). This 
downregulation is apparently mediated by a rapid reduction in hTERT mRNA 
levels, and occurs independently of simple cell cycle arrest as a specific 
component of the differentiation programme (requiring de-novo protein synthesis) 
(Xu, efa/1999).
The implications of these observations are considerable, and are frequently 
overlooked. They would imply that a primary determinant of TRAP activity in a 
tumour or tissue sample is likely to be the proportion of cycling cells (i.e. stem or
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progenitor whether they are normal or malignant) rather than true differences on a 
cell-to-cell basis. Studies on haematological malignancy support this notion; for 
example in early chronic lymphocytic leukaemia (a disorder characterised by slow 
accumulation of mature B-lymphocytes displaying resistance to apoptosis rather 
than increased turnover) TRAP activity is not raised until the disease transforms or 
accelerates (when cell turnover is increased) (Bechter, et al 1998). To determine 
whether there are genuine cell-to-cell or sample-to-sample differences in 
telomerase activity there is at least a requirement for cell-cycle profiling (with 
resolution of Go populations) of the samples under investigation and ideally, 
comparison of sorted cell-cycle phase-specific (eg S-phase) purified populations. 
Such studies can be performed relatively easily upon normal and malignant HSC 
and progenitor cells isolated from PB or BM.
1.6.6 Telomerase deficiency as a cause of human disease
Almost without exception, early studies of telomerase in humans concentrated on 
the patterns, associations, mechanisms and consequences of over expression, 
with the major emphasis on tumourigenesis. It was, therefore, of profound interest 
that an established human congenital disorder, dyskeratosis congenita (DKC), has 
been linked to mutation and / or aberrant expression of the hTR component of 
telomerase.
DKC is an inherited multisystem syndrome characterised by skin abnormalities 
(skin pigmentation, nail dystrophy and leucoplakia), pulmonary complications (a 
reduced diffusion capacity and / or restrictive defect), BM failure (85.5% of patients 
have a cytopaenia of one or more lineages) and a propensity to develop solid 
tumours, myelodysplasia or AML (Dokal 2000). Indeed the probability of BM failure
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is 94% at 40 years of age, although expression of the other phenotypic 
characteristics is very variable. The majority of patients (67%) die from the direct 
consequences of BM failure, with the remainder succumbing to malignancy (Dokal
2000). Laboratory studies of BM from these patients have described a prematurely 
aged BM: namely a reduction in the proliferative potential of progenitor cells plus a 
reduced subplating cloning efficiency (Dokal 2000, Marley, ef al 1999). DKC 
therefore appears to affect proliferative tissues, and could quite feasibly fit the bill 
as a disorder of telomere homeostasis, with its not dissimilar phenotype to late 
generation KO mice.
The X-linked form of the disease is caused by missense mutations in DKC1, the 
gene coding for dyskerin (Heiss, et al 1998), a highly conserved nucleolar protein 
with pseudouridine synthase activity. As well as binding to the H/ACA small 
nucleolar RNAs (snoRNA, responsible for ribosomal RNA processing) (Mitchell, et 
al 1999b), dyskerin also associates with hTR via its H/ACA RNA motif (Mitchell, et 
al 1999a, Mitchell, et al 1999b). It is assumed that mutations affect this interaction. 
In affected males there is a fivefold reduction in levels of hTR RNA, with reduced 
telomerase activity and markedly shorter telomeres in lymphoid cells from these 
individuals (Mitchell, et al 1999b). How dyskerin mediates these effects on hTR 
and telomerase is as yet unknown, however it may be required for telomerase 
RNP assembly or accumulation.
That telomerase dysfunction is the ‘final common pathway’ in this heterogeneous 
disorder has received further support from studies on the autosomal dominant 
form of the disease. Vulliamy et al. have shown that in some affected individuals 
studied there are destabilising mutations in one of the hTR alleles (Vulliamy, et al
2001). However in these patients hTR expression is not reduced (on Northern 
blot) and a ‘dominant negative’ effect of the mutated allele was proposed as the
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mechanism for the significant telomere shortening observed in these patients. 
Unfortunately no TRAP analysis was performed in an attempt to resolve this issue. 
What is of additional interest is whether hTR abnormalities could play a role in 
other disorders with similar bone marrow failure phenotypes, for example severe 
aplastic anaemia (SAA) (Vulliamy, et al 2002). Of 17 SAA patients studied, 2 
patients had hTR mutations not observed in 214 normal controls, and all patients 
demonstrated significant telomere shortening. Ultimately some form of gene 
therapy may be applicable to these individuals.
1.6.7 Telomerase (and telomeres) in tumourigenesis: a synthesis
A complex ‘biphasic’ relationship of telomerase and telomere function in the 
context of tumour evolution and growth has been suggested (Hackett and Greider 
2002), as briefly outlined above. Progressive telomere shortening, observed in 
most tumours studied to date and assumed to be largely replicative (de Lange, et 
al 1990, Hastie, et al 1990), results in telomere loss and genomic instability. Such 
telomere loss may be facilitated by lack of telomerase, as observed in KO mice 
and DKC patients. Conversely, telomerase expression, often implicated as a late 
event during tumour evolution (Chadeneau, et al 1995, Tang, et al 1998) can 
stabilise telomere length (by ‘healing’ short dysfunctional telomeres (Rudolph, et al
2001)) and promote immortality.
This pattern of short telomere length and high telomerase activity is not 
uncommon, particularly in advanced haematological malignancies (Ohyashiki, et al
2002), and it is tempting to speculate that this is due to such sequential telomere 
shortening followed by telomerase upregulation. Several models incorporating a 
biphasic role for telomerase have been proposed in the context of human
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malignancy, including CIVIL (Brummendorf, et al 2000). Such models also imply 
prognostic significance for telomere length and / or telomerase activity, as 
according to this mechanism of tumourigenesis short telomeres and elevated 
telomerase would indicate advanced disease. This has been tested (and shown to 
be the case) for CIVIL (Brummendorf, et al 2000), multiple myeloma (Wu, et al
2003) and myelodysplasia (Ohyashiki, et al 1994). As well as having prognostic 
import, such a model may alter the approach to anti-telomerase therapy. For 
example telomerase inhibitors may be most effective when administered in the 
context of short telomeres and telomerase dependence (i.e. in advanced disease). 
It may also suggest that their use should be approached with caution in early or 
pre-malignant disease, when telomere shortening and genomic instability may be 
promoted. It is probable that such questions will only be answered by appropriate 
animal studies or even at the Phase I/ll stage of clinical trials.
1.6.8 Telomerase in cancer: diagnostic, prognostic and
therapeutic potential
In a large study, Kim determined telomerase activity (as measured by TRAP) to 
have a specificity of 91%, sensitivity of 85%, positive predictive value of 93% and 
negative predictive value of 81% in the diagnosis of malignancy in biopsies from a 
range of tissues (Kim 1997). However these malignancies can, in general, be 
diagnosed accurately by conventional histological techniques, and one could 
argue that telomerase adds little in this context.
Detection of telomerase activity may therefore prove more useful in the screening 
of bodily fluids, e.g. urine or sputum, or fine-needle aspirates (FNA) where 
conventional cytological techniques are more demanding, less sensitive and to a 
degree, subjective. Hiyama et al. undertook a prospective study of telomerase 
activity in FNA samples from suspected breast cancer: the diagnostic accuracy of
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TRAP analysis was significantly higher than conventional cytology (86 vs. 70%, 
p<0.0D1) (Hiyama, et al 2000), TRAP activity of sputum in suspected lung cancer 
had a sensitivity, specificity and diagnostic accuracy of 81.6, 100 and 86.5% 
respectively (Sen, et al 2001). These studies clearly illustrate the genuine clinical 
utility of telomerase detection; however, to our knowledge, these techniques have 
not entered routine clinical practice (at least in the UK).
In the era of intensive chemo- and radiotherapy protocols, improved prognostic 
indices are a prerequisite for administering risk-adapted treatment regimens. 
Numerous reports have dealt with telomerase as a prognostic determinant. In 
colonic adenocarcinoma, levels of telomerase activity are higher with increased 
tumour stage (Chadeneau, et al 1995) and are an independent predictor of 
outcome (Tatsumoto, et al 2000). Similar data has been obtained in non-small cell 
lung cancer (Marchetti, et al 2002) and breast cancer (Clark, et al 1997). In one of 
the most intriguing studies, telomerase negative stage IVS neuroblastomas 
exhibited short telomeres and frequent spontaneous regression, while those with 
high TRAP activity had a poor outcome (Hiyama, et al 1995). Thus telomerase 
may indeed, at least in this context, be a true indicator of biological behaviour and 
clinical outcome. Many reports are inconsistent however, and there are almost 
certainly issues concerning representative tissue sampling and contaminating 
telomerase-positive cells (e.g.lymphocytes).
In-vitro studies of telomerase inhibition in immortalised cell-lines (as described 
above) have provided encouragement for the development of anti-telomerase 
therapies in-vivo. The biology of telomere shortening predicts that after inhibition of 
telomerase there will be a significant lag-time before a critical length is reached, 
and this has been born out by studies demonstrating that timing of cell death is 
related to initial telomere length (Hahn, et al 1999b, Zhang, et al 1999). These
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studies, which used dominant-negative constructs of hTERT, have two important 
implications; in tumours with long telomeres the patient may be dead before crisis 
is reached, and that tumours with short telomeres will be more amenable to 
telomerase inhibition. Importantly, these studies also demonstrated that wild-type 
p53 was not a prerequisite for apoptosis, which given how common loss-of- 
function p53 mutations are in human cancer, is reassuring. Additionally, surveys of 
telomere lengths in cell lines have revealed them to be universally short (5kb or 
so) (Chu, ef al 2000). It will therefore be crucial to determine the appropriate 
clinical setting in which to test anti-telomerase strategies.
The ideal therapeutic approach to telomerase inhibition would involve the use of 
tailored small-molecule inhibitors. The broad range of expression of telomerase in 
human cancer makes it an attractive target for the development of such agents 
(Shay and Baccheti 1997). Crucial to their success will be selectivity or (ideally) 
specificity for tumour cells. This may be achieved because normal stem and 
progenitor cells generally have long telomeres, with low-level telomerase activity. 
Reverse transcriptase inhibitors (such as zidovudine) and nucleoside analogues 
(such as dideoxyguanosine triphosphate) have anti-telomerase properties in 
immortalised cell lines in-vitro (Strahi and Blackburn 1996). An alternative strategy 
targets the substrate (the G-quadruplex telomere structure) of telomerase, with 
several molecules recently described with potent activity in this respect (Harrison, 
et al 1999, Perry, et al 1998).
As with all other anti-cancer agents, concerns already exist over development of 
drug resistance, most likely via selection for ALT tumour cells. That such a 
mechanism may co-exist with telomerase-dependent telomere maintenance in 
human cells has recently been demonstrated, giving credence to concerns about 
resistance via this mechanism (Cerone, ef al 2001). Alternative approaches to
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targeting telomerase that may avoid this potential problem include immunotherapy. 
In a seminal study Vonderheide at al. demonstrated tumour cell lysis by CDS’*" 
cytotoxic T-cells specific for an hTERT peptide (Vonderheide, et al 1999). Phase I 
trials targeting hTERT by this strategy in advanced cancer are currently underway 
in the USA (Vonderheide 2002). In clinical terms therefore, telomerase has not yet 
even begun to fulfill its potential; however there are high hopes that the next 5-10 
years will change this.
1.6.9 Structure of telomerase and regulation of its activity
The importance of telomerase, both in physiological and pathological systems, is 
apparent. In contrast, relatively little is known about the mechanisms regulating the 
expression of telomerase, particularly in primary human cells and during 
tumourigenesis. Given that most somatic cells repress telomerase activity and 
most cancer cells express it, it is logical to assume that it is tightly regulated. An 
understanding of the mechanisms involved is a prerequisite for attempting to 
manipulate telomerase activity successfully. One important, and as yet 
unresolved, issue is whether the emergence of telomerase positive tumour cells 
reflects the phenotype of the originating {i.e. stem or precursor) cell, or if there is a 
sequential breakdown of regulatory events within tumour cells resulting in 
telomerase expression. This section will deal with the current understanding of 
how telomerase activity is regulated, and what may go wrong in disease states.
1.6.9.1 The telomerase ribonucieoprotein complex
Exactly how telomerase acts at the telomere is not fully understood. It is assumed 
that telomerase binds to telomere primer and, using the RNA template of hTR, 
catalyses the addition of single DNA nucleotides to the telomere (Shippen-Lentz 
and Blackburn 1990). Once a complete TTAGGG sequence has been completed.
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telomerase can translocate to the next binding site, and so on. The catalytic 
activity (the ability to elongate sequential telomeres) and processivity (the ability to 
add single nucleotides) would appear to be differentially affected by 
physicochemical conditions (specifically temperature and concentration of and 
substrate) (Sun, et al 1999). However it remains unclear even whether or not 
these reactions require ATP, and detailed information on the kinetics of the 
process are lacking. How (and indeed where) the telomerase ribonucieoprotein 
(RNP) complex is assembled, and what its key components are, is also an area 
that needs further study.
The estimated molecular mass of the telomerase RNP is approximately lOOOkDa 
in unfractionated nuclear extracts (Schnapp, et al 1998), indicating that in-vivo it 
consists of more than simply hTERT plus hTR in combination (Figure 1-5) 
although this is the minimum requirement to reconstitute telomerase activity in- 
vitro (Beattie, et al 1998). In-vitro TRAP activity does not necessarily equate with 
active telomerase and telomere maintenance in-vivo however; the other 
constituents of the telomerase RNP are likely to be crucial to its action.
The molecular chaperones p23 and heat-shock protein (hsp) 90 have recently 
been shown to stably associate with hTERT in-vitro and in mammalian cells 
(Forsythe, et al 2001, Holt, et al 1999). Subsequent to binding hTERT, p23 and 
hsp90 direct assembly with hTR. Consistent with these data is the observation that 
hsp90 inhibitors blocked telomerase activity (presumably by disrupting its 
assembly process). It is also notable that p23 and hsp90 were present in the rabbit 
reticulocyte lysate model that was used to establish the functional significance of 
hTERT and hTR (Forsythe, et al 2001), suggesting that they could be an absolute 
functional requirement. TEP1 (telomerase-associated protein 1) on the other hand 
appears to be of doubtful relevance to telomerase activity (Liu, et al 2000a).
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The human telomerase holoenzyme exists as a functionally co-operative dimer in- 
vivo, containing at least two frans-complementary hTERT molecules (Beattie, et al
2001) and two interdependent hTR molecules (Wenz, et al 2001). hTERT stably 
associates with the RNA template via a small region at its amino terminus (Lai, et 
al 2001). The majority of evidence to date suggests that transcriptional, post- 
transcriptional and post-translational mechanisms of the major telomerase 
components (hTR, and particularly hTERT) all contribute to regulation of 
telomerase activity.
1.6.9.2 hTR: expression, genetics and molecular regulation
In comparison to hTERT (see below) very little is known about regulation of this 
intriguing molecule. Part of the reason for this may be the oft-quoted statement 
describing ‘ubiquitous expression’ of hTR, implying (wrongly) a lack of regulation 
and almost a ‘housekeeping’ presence. Initial reports using RT-PCR detected hTR 
at ‘steady-state’ in many telomerase-negative tissues (Feng, et al 1995), and 
hTERT has been demonstrated as the ‘rate-limiting’ component of telomerase 
activity in most circumstances (Weinrich, et al 1997) leading to it becoming the 
focus of attention. However, studies on lymphocytes demonstrated hTR levels that 
paralleled telomerase activity, with a 5-fold increase upon activation (Weng, et al
1997) indicative of dyanamic regulatory mechanisms in primary cells. Furthermore 
a detailed study of hTR expression during embryogenesis detected hTR at high 
levels in undifferentiated tissues that progressively became undetectable during 
differentiation. In adults, expression was predominantly limited to dividing cells, 
with particularly high levels in the primary spermatocytes and Sertoli cells of the 
testes (Yashima, et al 1998). hTR levels are often increased in immortal human 
cells and tumours, with descriptions of amplification and increased copy number in 
the literature (Soder, et al 1997a). The latter study, using in-situ hybridisation,
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elegantly demonstrated hTR expression within tumours but not in surrounding 
normal tissue, a finding subsequently confirmed by other groups (Heine, et al
1998). These data, in addition to its role in the pathogenesis of DKC, point to hTR 
as a crucial telomerase component.
The gene for hTR has been mapped to chromosome 3 (specifically 3q26) (Soder, 
et al 1997b) and is transcribed by RNA polymerase II, which, after processing at 
its 3' end, results in a mature transcript of 451 nucleotides (Feng, et al 1995). A 
telomerase RNA subunit has now been cloned from more than 25 species, from 
dilates to human. Despite their striking difference in size (in dilates it may only be 
147 nucleotides in length (Greider and Blackburn 1989)) and sequence (hTR and 
mTR share only 65% sequence homology (Blasco, et al 1995, Feng, et al 1995)) 
their common feature is a template sequence complimentary to approximately 1.5 
telomeric repeats. The introduction of mutations to this crucial site results in 
predictable alterations to the telomere sequence with cell senescence as a result 
of telomere dysfunction (Yu, et al 1990). In telomerase negative cells, the half-life 
of hTR is approximately 5 days, and this can be increased some 1 6-fold by the 
presence of hTERT, via both an increase in transcription and (possibly) half-life 
duration (Yi, ef a /1999).
How transcription of hTR is controlled is poorly understood. The elements 
required for hTR promoter activity are contained in a 231 bp region between -272 
bp and -42 bp upstream of the transcription initiation site (Zhao, ef al 1998). The 
hTR gene is sited within CpG islands, and méthylation of the promoter region has 
been demonstrated in some ALT cell lines, which failed to express hTR (Hoare, ef 
al 2001). Interestingly, this region contains consensus sites for the binding of 
haemopoietic transcription factors, such as GATA-1, PU.1 and C/EBP (Hohaus, ef 
al 1995, Scott, ef al 1994, Zon, ef al 1991), which is highly relevant to the
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regulation of telomerase activity in normal haemopoiesis and leukaemia. Binding 
of the transcription factor complex NF-Y (also known as CBF) to the CCAAT 
region of the promoter is essential for hTR promoter activity (Zhao, et al 2000), 
and Sp1 and pRb also activate it. In contrast Sp3 is a potent repressor, raising the 
possibility that altered Sp1/Sp3 ratios regulate overall gene expression. Indeed 
Sp1 also activates hTERT expression (Kyo, et al 2000), and the possibility of a 
common mechanism of transcriptional control cannot be discounted. NF-Y can 
interact with histone acetyltransferase (HAG) enzymes (which antagonise 
chromatin induced repression), and may serve as a means of keeping the 
chromatin open' to allow transcription to occur (Jin and Scotto 1998). 
Considerable work is still required to understand regulation of this intriguing 
molecule.
1.6.9.3 hTERT: genetics and molecular regulation
The hTERT gene is located on chromosome band 5p15.33 (Bryce, ef a/2000) and 
extends over 35kb (with 16 exons and 15 introns (Cong, ef al 1999)). As most 
somatic cells do not express hTERT to any great degree it is largely assumed that 
the primary means of regulating hTERT is at the level of transcription.
1.6.9.3.1 Epigenetic regulation
The subtelomeric location of the hTERT gene has raised the possibility that its 
expression is influenced by telomere position effect (TPE), whereby subtelomeric 
genes undergo reversible silencing. Some evidence for this mechanism exists in 
human cells (Baur, et al 2001) and it would provide a neat ‘feedback’ mechanism 
whereby progressive telomere shortening negated TPE with derepression of 
hTERT. The recently published complete hTERT sequence pinpoints the gene as 
greater than 2Mb away from the telomere however (Leem, ef al 2002), and Cong
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has pointed out that this may be too distant for the TPE to function (Cong, et al 
2002).
CpG islands are target sites for méthylation, a process involved in normal 
development (e.g. X-chromosome inactivation, imprinting and suppression of 
extraneous DNA sequences (Li, et al 1993, Panning and Jaenisch 1998)). The 
méthylation status of cancer cells is markedly different from that of their normal 
counterparts: a general hypomethylated state (Goelz, et al 1985) is interspersed 
with areas of CpG hypermethylation which generally results in preferential 
transcriptional silencing of tumour suppressor genes (Merlo, et al 1995). However 
both transcriptional activators and repressors may be méthylation sensitive as far 
as binding to promoter sequences (which may or may not be methylated). Thus 
promoter méthylation is not a simple matter of an ‘on-off’ switch. The observed 
hypomethylation of the hTERT promoter in somatic cells with hypermethylation in 
cancer cells has been explained as involving a methylation-sensitive 
transcriptional repressor binding site (Devereux, et al 1999). Conversely one 
heavily methylated hTERT-negative fibroblast cell line, SUSM-1, expressed 
hTERT subsequent to treatment with the demethylating agent 5-aza-2'- 
deoxycytidine (Devereux, et al 1999), In-vivo, hTERT promoter méthylation has 
been correlated to low telomerase activity in a subset of B-CLL tumour samples, 
however numbers were small in this study (Bechter, et al 2002). The true 
contribution of méthylation status to hTERT regulation and expression in-vivo thus 
far remains doubtful.
Likely to be of more relevance is the role of chromatin status: addition of 
trichostatin A (TSA), an inhibitor of histone deacetylase (HDAC), induced hTERT 
expression in telomerase-negative human cell lines (Cong and Bacchetti 2000), 
resting T-cells, normal fibroblasts and in cancer cell lines (Hou, et al 2002). It
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should be noted that TSA does not lead to global changes in gene expression, 
with acétylation associated with specific target genes (Struhl 1998). Spl binding 
sites, located at the proximal end of the hTERT promoter, were found to be 
required for the action of TSA (Hou, et al 2002). hTERT promoter histone 
hypoacetylation has been observed to occur during the differentiation of HL60 
cells, concomitant with a reduction in hTERT expression (Xu, et al 2001). 
Importantly, this reduction was prevented by addition of TSA. Supporting the 
existence of this mechanism in-vivo, upregulation of hTERT expression 
subsequent to T-lymphocyte activation has been shown to involve histone 
hyperacetylation (Hou, et al 2002). How chromatin remodeling enzymes are 
recruited and activated at specific promoter sequences and how they interact with 
known transcriptional factors are currently areas of intense research.
1.6.9.3.2 Transcriptional regulation
Transcriptional regulation is thought to be the most important regulatory element 
controlling telomerase activity in cells (Ducrest, et al 2001), although the evidence 
for this is not absolute. The core promoter region is contained between 330bp 
upstream of the transcription initiation site and the second exon (Cong, et al 1999), 
and luciferase-promotor constructs demonstrate inactivity within normal somatic 
cells with increased activity in immortalised cells, consistent with their observed 
telomerase activity (Cong, et al 1999). The core promoter region also contains 
numerous transcription factor-binding sites (Cong, et al 1999), including E-boxes 
and Sp1 binding sites.
Transfection of mammary epithelial cells with C-MYC expressing viral vectors 
resulted in a 50-fold increase in pjER T  mRNA levels (Wang, et al 1998). c-Myc 
expression is a prerequisite for the Gi-S transition, and is deregulated in a large 
number of human tumours. It is, therefore, not unreasonable to postulate that c-
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Myc overexpression is the cause of increased hTERT levels in normal proliferating 
cells and in tumours (Fujimoto and Takahashi 1997). The c-Myc protein binds to 
Max and, as a heterodimer, binds to the E-box sequence in the core promoter 
region of hTERT, activating transcription (Blackwood and Eisenman 1991, Kyo, et 
al 2000). This step is independent of de-novo protein synthesis, and is therefore a 
direct effect (Greenberg, et al 1999). An additional level of control is provided by 
the Mad protein which complexes with Max, competes for E-boxes, and represses 
hTERT transcription (Xu, et al 2001). Kyo et al have shown that c-Myc cooperates 
with the transcription factor Spl (which binds GC boxes) to activate hTERT 
transcription (Kyo, et al 2000). Mutation of these GC-sites absolutely abolished 
hTERT transcriptional activity (Cong and Bacchetti 2000). Oestrogen, via two 
potential oestrogen response elements in the promoter region, can also directly 
upregulate hTERT in hormone responsive tissues (Kyo, et al 1999, Misiti, et al 
2000). This mechanism neatly explains endometrial telomerase activity as 
described above. In the mouse, the highly-expressed and inducible transcription 
factor NF-kB can bind to the promoter region and activate mTERT transcription 
(Yin, et al 2000), and hTERT has recently been described as a downstream target 
of NF-KB in a human myeloma cell line (Akiyama, et al 2002). With regards to 
CML, BGR-ABL has direct effects on both c-Myc (Sawyers, et al 1992) and NF-kB 
(Reuther, et al 1998) leading to speculation that hTERT expression may be 
directly affected in BCR-ABL+ cells.
Repression of hTERT transcription may be an important mechanism in somatic 
cells: fusion of normal cells to immortalised (telomerase positive) cells results in 
telomerase repression (Wright, et al 1996). The transfer of chromosome 3, but not 
others, into human tumour cell lines repressed telomerase activity in a c-Myc 
independent fashion (Cuthbert, et al 1999, Ducrest, et al 2001). This activity has 
been mapped to two small regions that may contain telomerase repressors
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(Tanaka, et al 1998), and which often display loss of heterozygosity or 
homozygous deletion in human cancers (Cuthbert, eta l 1999).
The other major mechanism for suppression of hTERT transcription is via the 
‘classical’ tumour suppressor genes p53, Rb and Wilm’s tumour (WT) 1. By an as 
yet undefined Spl dependent (and p21 independent) mechanism, p53 appears to 
directly repress hTERT expression (Xu, et al 2000). The repressive effects of Rb 
are less well understood, and may be secondary to cell-cycle inhibition (Xu, et al
1997). WT1 on the other hand appears to repress hTERT via direct promoter 
interaction, and may be involved in tissue-specific hTERT repression during 
differentiation (Oh, et al 1999). Again, these observations are attractive in the 
context of tumourigenesis, as they link loss of tumour suppressor function with 
loss of inhibition of hTERT expression, arguably the two most common 
abnormalities in human cancer.
1.6.9.3.3 Alternative splicing
Estimates of the number of human genes with alternately spliced forms range from 
35 to 59% (Consortium 2001, Modrek and Lee 2002) of the 35,000 or so genes in 
the human genome, and it is apparent that this process contributes significantly to 
both the size of the proteome and the resulting phenotypic complexity. Although 
the mechanisms of splicing itself are well documented, its regulatory elements are 
not. Indeed alternative splicing would appear to be subject to tight regulation, both 
in a tissue specific (incorporating activation- and developmental-status specific 
elements) and inducible manner (Lynch and Weiss 2000, Min, et al 1997), thus 
providing a critical regulatory step for post-transcriptional gene expression.
The human hTERT gene has been shown to contain at least 6 alternate splice 
sites; to date 4 insertion and two deletion sites have been identified (Kilian, et al
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1997, Wick, et al 1999). In Kilian et al's original report the most striking variation in 
patterns of splicing to be observed involved the deletions of one or both 36 and 
182bp motifs from the common reverse transcriptase domains A and B {hTERT~a 
and -(3, resulting in inactivity or premature translation termination respectively) 
(Kilian, et al 1997, Lingner, et al 1997) (Figure 5-6). The proximity of these sites 
allowed their simultaneous detection using one set of primers for RT-PCR. In no 
normal or tumour tissue so far studied has telomerase activity been detected in the 
absence of the full-length transcript (Ulaner, et al 1998, Ulaner, et al 2000). 
Additionally, the demonstration that the -a variant is a dominant negative inhibitor 
of telomerase activity has given further support for a regulatory role of alternatively 
spliced products (Colgin, et al 2000, Yi, et al 2000). Various normal tissues 
(colonic crypt and testes), cell lines and primary tumour tissues demonstrate 
marked differences in splicing patterns at these sites (Kilian, et al 1997, Ulaner, et 
a /1998).
It is possible that that splicing may regulate telomerase activity independently of 
transcription: in foetal heart tissue, loss of telomerase activity with gestation 
correlates completely with loss of expression of all hTERT transcripts (implying 
primarily transcriptional control) whereas in kidney it correlates with loss of full- 
length hTERT only, with ongoing expression of (3-deleted hTERT (Ulaner, et al
1998). Conversely in solid tumour cell lines it has been demonstrated that there is 
a near uniform expression of splice variants, with only 5% of total transcripts being 
full-length (Yi, ef a/2001). It is however, likely that the highly selected nature of cell 
lines confounds studies of telomerase expression. Indeed in studies of primary 
human tumours and normal tissues a wide variety of splice variants are 
expressed. Thus heterogeneous patterns (albeit generally exhibiting hTERT-^ 
expression) are observed in both in melanoma (Villa, ef al 2001) and 
neuroblastoma (Krams, ef a/2001), while normal resting B and T lymphocytes fail
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to show any splicing (Liu, et al 1999) with only full-length, functional transcripts 
observed. These patterns strongly support the regulated expression of hTERT 
splice-variant mRNA, leading to the description of splicing as the ‘dimmer switch’ 
for telomerase (Aisner, et al 2002).
1.6.9.3.4 Post-translational regulation
The location and activation status of the telomerase RNP would appear to be 
tightly regulated. The fact that overexpressed hTERT and hTR localise to the 
nucleus would support the hypothesis that assembly occurs there (Harrington, et 
al 1997, Hiyama, et a /2001). Preferential nuclear localisation would appear to be 
dependent on the 14-3-3 protein family, which bind hTERT and appear to prevent 
its nuclear export (Seimiya, et al 2000). Furthermore Yang et al demonstrated 
active nucleolar-nucleoplasmic shuttling of hTERT (Yang, et al 2002), with the 
nucleolar localisation signal residing in the extreme N-terminus of the hTERT 
protein. The release of hTERT from the nucleoli occurs in a synchronised manner, 
with nucleoptasmic hTERT levels enhanced at the expected time of telomere 
replication, namely S phase (Wong, et al 2002). Interestingly in tumour and 
transformed cells, hTERT remains almost completely dissociated from the 
nucleolus and is predominantly nucleoplasmic, suggesting that disruption of 
compartmentalisation is a mechanism operating during tumourigenesis.
Studies on primary human cells have produced similar findings: upon activation of 
T-lymphocytes, hTERT is phosphorylated and shifts into the nucleus, and the 
resulting increased TRAP activity occurs without a concomitant rise in hTERT 
protein levels (Liu, et al 2001). Such regulation of the active telomerase complex’s 
proximity to the telomeres via its compartmentalisation is eminently logical. It is 
also apparent that conventional in-vitro whole-cell TRAP analysis will be ‘blind’ to
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this process, as dramatic shifts in telomerase location may occur with no overall 
change in telomerase activity.
Phosphorylation of hTERT protein by c-ABL in response to ionising radiation, can 
negatively regulate telomerase activity (Kharbanda, et al 2000). c-ABL mediates 
growth arrest and apoptotic responses to DNA damage in normal cells: one may 
speculate that by preventing ‘capping off of broken chromosomes (via the action 
of telomerase), the propagation of cells containing damaged DNA may be avoided. 
It also raises intriguing questions about potential interactions between hTERT and 
BCR-ABL. The latter is largely cytoplasmic, and c-ABL is primarily nuclear: 
constitutive BCR-ABL tyrosine kinase activity may dysregulate cytoplasmic hTERT 
which could have significant effects upon telomere maintenance. Other signalling 
pathways, namely protein kinase 0 (PKC) and phosphatidylinositol 3-kinase 
(PI3K) via Akt kinase, have also been shown to control the phosphorylation and 
activation of hTERT (Kang, et al 1999, Li, et al 1998). These pathways are 
intimately involved in cell proliferation, apoptosis and carcinogenesis and 
promotion of telomerase activity may be crucial to their activity.
In summary, expression of telomerase activity is controlled at multiple levels; 
however by far the majority of these studies have utilised cell lines. It follows that 
the relevance of these observations to primary human cells, particularly the critical 
populations of interest (e.g. stem cells) remain unproven. Furthermore, given the 
apparent complexity of normal regulatory mechanisms, there is enormous scope 
for their disruption in cancer. Acquisition of a single oncogene such as BCR-ABL 
may have complex downstream effects upon telomerase activity, and these 
potential interactions are illustrated in Figure 1-6. As a first step in delineating 
these it is necessary to characterise the expression of the major telomerase 
components and telomerase activity in BCR-ABL'^ primary human HSC.
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Figure 1-6 Potential interactions of BCR-ABL kinase activity with telomerase
The major regulatory pathways governing telomerase activity are illustrated, as are 
potential interactions (numbered 1-7) with BCR-ABL. These are as follows: 1) Via 
alteration of HSC cell cycle regulation (i.e. increased cycling), there may be 
indirect effects upon transcriptional or post-transcriptional regulation; 2) Alteration 
of hTERT mRNA splicing; 3) Altered homeostasis of cytoplasmic pool of hTERT, 
possibly via phosphorylation by the cytoplasmic BCR-ABL kinase; 4) Alteration of 
telomerase transcription via interaction with transcription factors known to act 
downstream of BCR-ABL; 5) Direct interaction with hTERT or 14-3-3 proteins 
altering nuclear-cytoplasmic shuttling; 6) Altered assembly of telomerase 
ribonucieoprotein complex and nuclear-nucleolar sub-localisation; 7) Loss of one 
normal c-ABL allele (as a result of the BCR-ABL transclocation), perhaps with loss 
of cell-cycle inhibition or altered phosphorylation status of telomerase. These 
interactions are entirely speculative, with perturbation of both inhibitory and 
stimulatory pathways.
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1.7 Telomeres and telomerase in normal and malignant 
haemopoiesis: background and aims
Normal HSC express telomerase; however this is not reflected by stable telomere 
length (reviewed in Chapter 3, Results 1), loss of which is detected in total 
nucleated cells and CD34'"CD38'° cells from adult BM as compared to foetal liver 
or cord blood (Vaziri, et al 1994, Yui, at al 1998). Telomerase activity is 
upregulated in CD34^CD38^ (typically cycling) cells, and repressed in the (largely) 
quiescent CD34^CD38'° group and their differentiated progeny (Yui, at al 1998).
Bone Marrow Lymphoid Organ
CD34 + C034C071+ + 0034*0033X013^ +
Myeloid Progenitor Oell(§) (§ )Gran-Mono Progenitor Oell
0034 0038- ++0034X071+ ++Hematopoietic Oommitted OD34+c-kit'’'n^ ++Stem Oell Stem Oell
Erythro-MK Proynitor Oell
( § ) - .  ( * )
0034X038 +0034-0033 +C034*c-lot +0034X071 i"X045RA^w+ (§)
Lymphoid Progenitor Oell
Granulocyte
Monocyte
#
Platelets
«
Lymphocytes 
(T cell/B cell)
(§)
Resting + Activated +++
Thymus
Tcell
(§)
004X08 +++004 008 +++004X08 +++004 008 ++
Lymph nodes/Tonsil 
Tcell
(§)i
Resting +Germinal center ■
Figure 1-7 Patterns of telomerase expression during haemopoiesis
Telomerase activity (illustrated as +++, ++, +, or high, medium and low 
respectively) is associated with cycling progenitor cells (i.e. CD34^ and lineage 
marker*) and lymphocytes. Activity is particularly high in thymic T-cells and 
germinal centre B cells, both areas of extensive lymphocyte activation. Adapted 
from Ohyashiki at al (Ohyashiki, at al 2002).
This apparently tightly regulated and proliferation-associated pattern of expression 
may be mirrored to a degree in haematological malignancies of different lineage
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and maturational status. For example in chronic lymphocytic leukaemia, a disorder 
typified by slow accumulation of relatively mature B-ceils, TRAP activity is low 
(Bechter, et al 1998), most likely as a result of hTERT promoter méthylation 
(Bechter, et al 2002). Progression of the disease to a more aggressive stage was 
however accompanied by a small (but significant) 2-4 fold increase in TRAP 
activity. In contrast, acute leukaemias are more often associated with high TRAP 
activity (from the outset) and short telomeres, and are characterised by the rapid 
accumulation of blast cells with varying degrees of maturation and lineage 
commitment (Ohyashiki, et al 1997a). TRAP activity in these groups falls with 
remission induction therapy (unsurprisingly, as the blast cells are killed) and tends 
to be higher at relapse (Tatematsu, et al 1996). The pattern of these results would 
suggest that telomerase expression In haematological malignancy partly mirrors 
that of the cell or lineage of origin (i.e. mature non-dividing B-cells express low 
activity, whereas the stem / progenitor cell population from which acute 
leukaemias arise have relatively higher activity). How this relationship develops 
during the course of malignant progression is less clear however: for example 
selection pressure exerted by short telomeres may mean that in telomerase-iow 
malignancies, up-regulation of telomerase is selected for.
When HSC are put under conditions of replicative stress in-vivo (such as post 
SOT, see Chapter 3, Results 1), telomere sequence is lost more rapidly. In 
acquired aplastic anaemia (thought to result from immune-mediated damage to 
the HSC and progenitor-cell compartment) significant telomere loss detectable in 
PB granulocytes has been observed (Brummendorf, ef a/2001b). Furthermore, the 
BM failure of dyskeratosis congenita has been convincingly linked to telomere 
shortening secondary to telomerase dysfunction (Dokal 2000). These observations 
have been synthesised with regards haematological neoplasia in a model that 
describes early replication induced telomere shortening, with telomerase activity
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primarily determined by the proportion of cells in the proliferative pool as well as 
the lineage and maturational status of the tumour cells. Disease progression 
thereafter is characterised by the pattern of short telomeres and frequently, 
telomerase upregulation. This model has been partially validated for CML 
(discussed fully in Chapter 4, Results 2), however many questions remain 
unanswered. Such a model should ideally be tested on primary human material, 
with several specific questions in mind; firstly, does the degree of telomere 
shortening at diagnosis have prognostic implications, and how rapidly does it 
progress thereafter; secondly, whether there is any evidence of telomerase 
dysregulation during CP disease that may contribute to the rapidity of telomere 
loss; and thirdly what is the timecourse for telomerase upregulation during disease 
progression?
1.8 Aims
With regards telomere dynamics in CML,
1. To establish and validate the technique of flow-FISH for telomere length 
measurement
2. To establish the ‘normal’ age-related range of telomere length in our local 
population
3. To determine whether the degree of PBL telomere shortening at diagnosis 
of CML is of prognostic significance
4. To determine the rate at which telomere shortening occurs during 
progression of the disease
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With regards telomerase expression in CML;
1. To establish and validate the technique of quantitative RT-PCR for 
detection and measurement of hTERT and hTR expression
2. To determine the expression patterns in CML PBL during disease 
progression (including hTERT splice variants) and determine any 
relationship to telomere shortening and BP lineage
3. To determine the expression patterns in CML CD34* cells vs. normal
These questions will be dealt with in turn, within the relevant Results Chapters.
Each Chapter begins with a short, focused introduction to the data and culminates
in a brief discussion.
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2. Materials and Methods
2.1 Cell handling and culture
2.7.1 Red cell !ysis
Red blood cells in whole peripheral blood samples or leucapheresis aliquots were 
lysed with ammonium chloride solution (0.083%, Sigma, Poole, Dorset, UK) at 
37°C for 10 minutes (at a 15:1 NH4CI to PB ratio), which was repeated at least 
twice to ensure complete red cell lysis for flow-FISH. Nucleated cells were 
recovered by centrifugation (250g for 10 minutes) and resuspended in PBS 
(Sigma)/0.1% BSA (Calbiochem, Nottingham, UK) for flow-FISH or PBS/2% PCS 
(Calbiochem).
2.1.2 Cell counting
All cell counts were performed on a Coulter MD18 Analyzer (Beckmann Coulter, 
Fullerton, CA), which utilised 12pl of sample.
2.1.3 Viability assessment
In most instances viability was assessed using Trypan Blue (Sigma) exclusion. 
Briefly 40pl of 1:10 Trypan Blue was added to lOpI of cell suspension and 8pl 
transferred to a haemocytometer. 200 cells were counted, with blue-staining cells 
counted as non-viable. For pure populations i.e. ex-vivo expanded T-cells and 
CD34* selected cells, viability assessment using propidium iodide (PI, Sigma) 
staining and FACS analysis was performed (see below). PI was added (after the 
appropriate fluorescent surface antibody had been washed off) as the final stage 
of cell staining at a concentration of Ipg/ml in PBS. After spinning at 250g for 10
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minutes cells were resuspended in PBS prior to FACS analysis. PI stained cells 
were analysed in FL3, and the positively stained fraction {i.e. non-viable) gated out 
of subsequent analysis.
2.1.4 Freezing cells
CD34^ selected cells, control T-celi acute lymphoblastic leukaemia (T-ALL) cells 
for flow-FISH and aliquots of expanded celMines were frozen down for subsequent 
use where appropriate. Briefly an appropriate cell number was aliquoted into a 
Nunc cryotube (Fisher Scientific, Loughborough, UK) and resuspended in 10% 
DMSO (Quest Biomedical, Solihull, UK)/ALBA (4.5% albumin solution, SNBTS, 
Edinburgh, UK) solution. Cryotubes were cooled steadily in isopropyl alcohol at -  
80°C in a cryofreezer container (Fisher Scientific) before being transferred to liquid 
nitrogen for storage. For TRAP analysis a dry cell pellet was immediately frozen at 
-80°C.
2.1.5 Recovering cells from frozen
Cells were cryopreserved in liquid nitrogen. Extreme care was taken to ensure 
successful thawing, particularly when a high proportion of granulocytes was 
anticipated. Cells were removed from liquid nitrogen and immediately thawed at 
37°C in a water bath until all ice crystals had disappeared. One 15ml sterile tube 
(Greiner Bio-One, Longwood, Florida, USA) was used for each sample, and 
thawing solution added dropwise (i.e. very slowly) initially (2.5mM MgCl2 (Sigma), 
lOU/ml pulmozyme (Roche Products Ltd, Welwyn Garden City, UK) and 1% 
human serum albumin (SNBTS) in Calcium and Magnesium free D-PBS (Sigma)). 
Importantly, this was performed at room temperature (RT) to facilitate the action of 
the enzyme pulmozyme. Once 15mls of this solution had been added, cells were
Chapter 2, 74
spun at 250g for 10 minutes. Cells were then washed in PBS/2% PCS, counted 
and checked for viability.
2.1.6 r-ce// culture
T-celts were expanded ex-vivo from CML patients as a source of Ph‘ cells on 
which to perform telomere length measurements by flow-FISH. It has previously 
been shown that this population of cells is indeed Ph" (Brummendorf, et al 2000). 
2.5x10® unmanipulated fresh PBL (from CML PB specimens) were cultured in 2mls 
RPMI 1640 supplemented with 10% FBS, 2% L-glutamine (Sigma), 2% penicillin- 
streptomycin (Sigma), 50 U/ml recombinant human IL-2 (Pepro Tech, Rocky Hill, 
NJ, USA) and 1.0 pg/ml phytohaemagglutinin (PHA, Sigma). Adequate T-cell 
numbers (>1x10®) were achieved after 8-10 days of incubation, at a purity of >85% 
of viable cells.
2.1.7 C ell-lines
Cell lines were obtained from previously cryopreserved stored aliquots at our 
institution or as a gift from Dr Junia Melo (Hammersmith Hospital, UK), They were 
maintained in suspension culture in RPMI 1640 medium (Sigma) supplemented 
with 10% FCS. Cells were maintained in 25cm^ tissue culture flasks (Corning Life 
Sciences, Koolhovenlaan, Netherlands). On reaching an approximate cell density 
of 1x10®/ml, they were passaged and re-cultured at 1x10^ / ml.
2.1.8 Primary human PBL
All material was collected with the approval of the Local Research and Ethics 
Committee and with written informed patient consent where appropriate. Fresh 
PBL from 55 normal healthy subjects over a wide age range (Median age 39,
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range 0-99 years) were obtained from discarded routine or voluntary blood 
samples (n=43) and discarded umbilical cord blood (UCB) samples (n=12). All 
CML PBL samples were obtained from patients with 100% Ph^ metaphases on 
their diagnostic or most recent marrow assessment, apart from in 10 patients who 
had achieved a complete cytogenetic response (CCR, /.e.100% Ph"). Stage of 
disease was determined according to the WHO Classification of Tumours 
(Vardiman, ef a/2001). Table 2-1 and
Table 2-2). Diagnostic samples were obtained prospectively from a total of 32 
consecutive patients (median age 54 years, range 33-75, 19 male and 13 female) 
prior to commencement of therapy in all cases apart from 2, who had each 
received hydroxyurea for 2 and 5 days respectively. Hasford prognostic score was 
calculated online at www.pharmacoepi.de/cmlscore.html. All patients at diagnosis 
were in CP apart from 2 who displayed cytogenetic evolution (+8 and +Ph 
respectively, both high-risk score) and were AP as per WHO criteria. Additionally, 
24 patients in early CP (<2 years since diagnosis), 12 in established CP (estCP, 
>2 years since diagnosis), 15 in AP and 17 in BP were sampled. An additional 4 
BP samples archived in TRIzol® (Life Technologies, Paisley UK) were made 
available for analysis of hTERT expression. All cells were analysed fresh 
whenever possible: however the use of paired CP and BP specimens from the 
same patient required analysis of cryopreserved material in 5/7 instances.
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The Diagnosis of CML-AP may be made when one or more of the following are present:
-Blasts 10-19% of WBCs in peripheral blood and/or nucleated bone marrow cells 
-Peripheral blood basophils ^ 20%
-Persistent thrombocytopaenia (<100 x 10®/L) unrelated to therapy, or persistent thrombocytosis 
(>1000 X 10®/L) unresponsive to therapy
-Increasing spleen size and increasing WBC unresponsive to therapy- 
-Cytogenetic evidence of clonal evolution
Table 2-1 Definition of AP CML as per WHO criteria
The Diagnosis of CML-BP may be made when one or more of the following are present:
-Blasts 2:20% of WBCs in peripheral blood and/or nucleated bone marrow cells
-Extramedullary blast proliferation
-Large foci or clusters of blasts in the bone marrow
Table 2-2 Definition of BP CML as per WHO criteria.
2.1.9 Selection of CD34* cells
All cell samples were obtained either from CML patients at diagnosis (n=16), on 
progression to BP (n=3), from normal allogeneic donors (mobilised with 
recombinant human granulocyte colony stimulating factor, or rHu-G-CSF, n=2) or 
from patients with 'non-stem' cell haematological malignancies (non-Hodgkin’s 
lymphoma or multiple myeloma, n=14) mobilised with rHu-G-CSF subsequent to 
chemotherapy. As part of their initial clinical management, CML patients were 
leucapheresed using a Cobe Spectra continuous flow blood separator (Cobe
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Laboratories, Quedgeley, UK) to reduce the peripheral WBC count and to obtain 
CD34^ cells for potential later use in an autologous grafting procedure. From each 
of these leucapheresis products (and after appropriate consent was obtained) a 
sample was taken for subsequent enrichment of CD34^ cells. All samples were 
processed within 24 hours of collection. Populations, enriched for CD34^ cells, 
were obtained using either the Isolex® Immunomagnetic Cell Selection System 
(Baxter, Deerfield, IL, USA) or the StemSep™ Negative Selection System 
(Stemcell Technologies, Vancouver, Canada, both techniques performed by Dr 
Michael Alcorn or Mrs Linda Richmond according to manufacturers’ instructions). 
With the Isolex® System, CD34^ cells are positively selected. With the Stem Sep™ 
System, lineage-marker positive cells are removed, thus providing a population of 
cells enriched for CD34^ cells. To obtain samples with >90% purity of CD34^ cells, 
these pre-enriched samples were thawed and further selected using the MACS 
system (Miltenyi Biotec, Auburn, CA, USA) where necessary, according to the 
manufacturers instructions. The LS column size was used, allowing selection of up 
to 10® cell positively labelled with MACS microbeads, from up to 2x10® total cells. 
The cells were washed once in PBS/2% FCS and resuspended in 2mM EDTA 
buffer (300pl per 10® cells. Sigma). Prior to magnetic labelling, lOOpI of FcR 
Blocking Reagent per 10® total cells was added. lOOpI of CD34 MicroBeads per 
10® total cells were added and incubated at 6°C for 30 minutes. Cells were washed 
in 2mM EDTA and resuspended at 2x10® cells/ml (maximum) in buffer before 
being filtered through pre-wetted (2mM EDTA) 30pm pre-separation filters directly 
onto a pre-prepared LS column in a midi-MACS magnet (all Miltenyi Biotech). After 
washing cells through (3x3ml of EDTA buffer), cells were eluted, and if resultant 
cell purity demanded it (based on target of >90% CD34^ cells on FACS), selected 
for again. An aliquot of approx 5x10^ cells was used for FACS analysis to 
determine purity.
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2.1.10 CD34* cell culture
Upon recovery from liquid nitrogen, CD34^ cells were washed once in PBS/2% 
FCS (Sigma and Calbiochem respectively) and cultured in 35mm suspension 
dishes (Corning Life Sciences, Bucks, UK) at a concentration of 2x10®/ml for 3 
days (at 37°C and in 5% CO2) in strictly defined medium. This consisted of 
Iscove’s modified Dulbecco medium (Sigma), supplemented with a serum 
substitute (BIT, Stem Cell Technologies), 1% penicillin/streptomycin (Sigma), 1% 
L-glutamine (Sigma), and 2-mercapto-ethanol (Gibco, Paisley, UK) and
40pg/ml LDL (Sigma). This was supplemented with rFlu-1 L-3 (50pg/ml, Novartis, 
Basel, Switzerland), rFlu-lL-6 (50pg/ml, Cangene, Mississauga, ON, Canada), rHu- 
SCF (50pg/ml, Terry Fox Laboratory, Vancouver, BC, Canada), rFlu-Flt-3 ligand 
(50pg/ml, Immunex Corporation, Seattle, WA) and rFiu-G-CSF (10pg/ml, Chugai 
Pharma, London, UK). Cells were harvested on day 3 and washed in PBS/2% 
FCS prior to analysis.
2.2 Flow -  cytometry techniques
2.2.1 F lo w - FISH
For measurement of telomere lengths in PBL, flow-FISFI was established in our 
laboratory, as previously described (Brummendorf, ef a/2000), (Rufer, et al 1999). 
This technique allows measurement of fluorescence in whole cells hybridised to a 
specific telomeric fluorescein Isothiocyanate (FITC)-labelled peptide nucleic acid 
(PNA) probe. The PNA probe preferentially hybridises to target DNA in conditions 
of low-ionic strength and is extremely stable. In addition, the reasonably preserved
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cell morphology at the end of the procedure allows subpopulations of cells to be 
discriminated on forward scatter (FSC) vs. side scatter (SSC) on a flow cytometer. 
In almost every case this was performed on fresh PBL, within 48 hours of 
sampling and with appropriate storage (i.e. 4°C) during this period. The 48 hour 
limit was strictly observed: early experience indicated a rapid loss of cell viability 
after this point. Five valuable paired CP and BP samples (i.e. from the same 
patient both at diagnosis and on disease progression) were analysed from frozen. 
Red cell lysis of PB samples was repeated at least twice until complete (to avoid 
potential quenching of the relatively weak FITC signal of the telomere probe by 
haemoglobin) prior to resuspension in PBS/0.1% BSA. Three x 10® viable cells 
were added to each of 4 Eppendorf tubes (Eppendorf, Cambridge, UK) containing 
SOOpl PBS/0.1% BSA and spun briefly at 13000 rpm in a microfuge (Eppendorf). 
Stock PNA probe (of sequence FITC-OO-CCC-TAA-CCC-TAA, Applied 
Biosystems, Framingham, MA) was dissolved in ultra pure formamide (Gibco 
BRL): double distilled water (ddHgO, 1:1) to give a final concentration of Ipg/pl and 
then aliquoted and stored at -20°C in the dark. When required each aliquot was 
resuspended in 640pl of 1:100 TE buffer (Sigma), to a final concentration of 
30pg/ml. Cells were resuspended in 300pl hybridisation buffer in duplicate either 
with telomere probe (20mM Tris pH 7.1 (Sigma), 1% BSA, 70% ultra pure de­
ionised formamide, 0.3pg/ml PNA FITC telomere probe in ddHaO) or without 
(20mM Tris pH 7.1, 1% BSA, 70% ultra pure de-ionised formamide). The ultra 
pure formamide was deionised using AG 501-X8 mixed-bed resin (Bio-Rad 
Laboratories, Hemel-Hempstead, UK). After careful resuspension of cells in the 
hybridisation mix (using a yellow tip with vigorous pipetting to ensure a single cell 
suspension) the tubes were transferred immediately to the thermomixer (CLF- 
Schutron, Emersacker, Germany, preset at 80°C) for a 10-minute dénaturation 
step. The samples were removed and allowed to re-anneal for 2 hours in the dark
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at RT. 1ml of wash buffer #1 was added to each tube (20mM Tris pH 7.1, 0.1% 
BSA, 70% formamide, 0.1% Tween 20 (Sigma) in ddH20) which were vortexed 
and spun at 850g for 7 minutes. This was repeated x 1. Two washes with buffer #2 
were then performed (0.1% BSA, 0.1% Tween in PBS). The cell pellet was 
resuspended in 300pl PI/RNAse (Roche, Welwyn Garden City, UK) solution 
(0.06pg/ml PI, 1,000 U/ml RNAse T1, 0.1% BSA in PBS). Cells were stored in RT 
(in dark) for 4 hours (or overnight at 4°C) before FACS analysis.
Flow- cytometric analysis was performed on a Becton Dickinson FACScan with 
linear-scale measurement of green (FL1) fluorescence and calculation of telomere 
fluorescence (stained-unstained) in molecular equivalent of soluble fiuorochrome 
units (MESF). The MESF unit is defined as “the stoichiometric unit for the number 
of fiuorochrome molecules in solution required to produce the same fluorescence 
intensity as that measured on the labelled particle” (Henderson, et al 1998). 
MESF units are consistent for any given fiuorochrome, and may be compared 
across standards and samples. Where possible, separate lymphocyte and 
granulocyte gates were set (normal volunteers, UCB and established CP samples) 
on the 2N (based on PI staining) population. This was not always possible with 
diagnostic and advanced disease samples; therefore total leucocytes were gated 
on. BP samples almost always had a discernible blast population (based on low 
SSC), and gates were set appropriately. Compensation for day-to-day shifts in 
linearity and laser intensity of the flow cytometer was achieved using a FITC- 
labelled fluorescent bead standard (Quantum™ 24 Premixed, Bangs Laboratories, 
Fishers, IN, USA). At the beginning of each experiment, the fluorescence signals 
from calibration beads suspended in PBS/0.1 % BSA were acquired. The beads 
consist of 4 standard fluorescent (FITC) populations ranging from 3,0000 to 
50,000 MESF (molecules of equivalent soluble fiuorochrome) as well as a 
population of non-fluorescent beads. In FL1 (linear), voltage and amplification
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were set in such a way so as to give a ‘spread’ of signal from the control beads up 
to channel 800 approximately (Figure 2-1). Identical FL1 settings were used for 
analysis of telomere length to allow calculation of the telomere fluorescence signal 
(mean FL1 channel stained -  mean FL1 channel unstained) in kMESF. The 
equation used was Telp (MESF) = (Ts-Tu)/Gcai, where Telp is telomere 
fluorescence, Is  and Tu are mean channel in FL1 for stained and unstained 
telomere fluorescence channel number respectively, and Gcai is the gradient of the 
calibration curve.
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Figure 2-1 Flow-cytometry fluorescence calibration using a fluorescent bead 
standard.
A bead suspension was gated on (R1), and analysed in FL1 (linear). The 
unlabelled beads (marker 1, M l) and 3 of 4 fluorescent standards (M2-M4) are 
shown in the FL1 channel. Mean channel readings were recorded and tabulated to 
obtain the calibration curve (MESF vs FLI mean channel). This was used to 
calculate telomere fluorescence in MESF units (see text), and to allow 
comparisons between different experiments.
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In general, all values for telomere length are reported in kMESF units. To estimate 
telomere length in bps we used the equation as published by Rufer et al: base 
pairs (bp) = MESF units x 0.02604 x 0.019 x lO^, which roughly equates to 1 
kMESF = 0.5 kb. This was derived from a comparative study of flow-FISH and 
Southern blotting for telomere length in normal lymphocytes (Rufer, et a! 1998), 
and subsequently confirmed as valid for granulocytes (Rufer, et a /1999).
In all experiments identical aliquots of T-ALL cells were included to analyse inter- 
experimental variation in flow-FISH results and allow comparison of samples from 
the same individual at different time-points. In all experiments at least 10"^  events 
were collected.
2.2.2 High resolution ceil-cycie analysis
Telomerase activity appears inextricably linked to the cell-cycle status of the 
population of interest, although this is not fully understood. For analysis and 
interpretation of telomerase activity or expression in CD34^ selected populations 
(both CML and non-CML) it was therefore necessary to resolve the cycle status of 
the cells. This was done using the method of Jordan et al (Jordan, et ai 1996), 
which combines 7-amino-actinomycin D (7AAD, Sigma) staining of DNA (in FL3) 
with that of the nuclear activation antigen Ki67 (FLI, BD Biosciences, Oxford, UK). 
Importantly, for interpretation of telomerase activity, this technique allows 
discrimination between Go and Gi phases of the cell cycle.
1x10® Cells were washed in PBS/FCS (2%) before being resuspended and fixed in 
PBS/0.4% formaldehyde (Sigma). After 30 minutes on ice an equal volume of 
PBS/0.2% Triton X-100 (Sigma) was added, and the cells incubated at 4®C 
overnight. Cells were washed once and resuspended in 1ml PBS/2% FCS. This 
aliquot was split and either 20pl of Ki67 FITC labelled antibody, or appropriate
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isotype control, was added to each sample. Cells were washed as before and 
resuspended (by vigorous pipetting through a yellow tip to ensure a single cell 
suspension) in PBS/2% FCS/7-AAD (1 pg/ml) before being incubated at 4®C 
overnight. FACS analysis was performed on a Becton Dickinson FACScan, with 
log-linear analysis on FLI (Ki67) and linear analysis on FL3 (7-AAD). To 
distinguish cells from aggregates and debris the cell population was gated on 
using FSC vs. FL3. This gate was analysed in FL1 vs. FL3 and the relative 
percentages in each stage of the cell cycle calculated. In all experiments at least 
10'^  events were collected.
2.2.3 Staining and analysis of specific leucocyte sub-populations
Enumeration of ex-vivo expanded T-cells, CD34^ cells and CD45RO and CD45RA 
lymphocyte subset was performed as required using appropriate antibodies (CD3- 
PE or FITC, CD34^- PE or FITC, CD45RO-PE and CD45RA-FITC respectively, all 
from BD Biosciences) according to the manufacturer's recommendations. In 
general live populations were gated on using PI staining (1 pg/ml) to discriminate 
dead cells. Flow-cytometer compensation was set as necessary and isotype 
controls used as appropriate.
2.2.4 FACS sorting of specific leucocyte sub-populations
Mr Charlie Pearson or Mrs Susan Graham performed FACS sorting of CD34^, 
CD3^, CD19^ and CD15^ subpopulations using a Becton Dickinson FACSvantage 
instrument. Briefly, viable cells were sorted (using a PI negative gate), before 
setting gates appropriately on the positive stained cells of interest with reference to 
an isotype-control stained population.
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2.3 Molecular techniques
2.3.1 RNA and DNA preparation
RNA was prepared from samples aliquoted in TRIzol®. Between 1 and 10x10® 
cells of interest were stored in 1ml of TRIzol® at -80°C until required. Fewer than 
1x10® cells were stored in 0.5ml TRIzol®. For RNA extraction 200pl of chloroform 
(Sigma) per 1ml TRIzol® was added and shaken vigorously for 10-15 seconds. 
Samples were microfuged at 11,000rpm (5 minutes) after standing at RT for 5 
minutes. The supernatant was transferred carefully to a fresh Eppendorf tube and 
kept on ice. An equal volume of iso-propyl alcohol (Sigma) was added, inverted to 
mix and left at RT for 10 minutes. Centrifugation at 11,000 rpm (5 minutes) 
revealed a pellet of RNA. The supernatant was poured off and 70% alcohol added 
(to a volume equivalent to the original volume of TRIzol®), vortexed and spun at 
7,500 rpm for 5 minutes. The supernatant was removed and the samples allowed 
to dry (30 -GO minutes at RT). Depending on anticipated yield of RNA either 10 or 
20pl of diethyl pyrocarbonate (DEPC)-treated H2O (Gibco BRL) was added at this 
stage before being heated at 55®C for 10 minutes (to help the RNA go into 
solution). Standard precautions were taken to minimise RNAse mediated sample 
degradation i.e. use of gloves, solutions made up with DEPC-H2O and sterile 
RNAse free plastics.
2.3.2 Quantitation of nucleic acids
This was done spectrophotometrically using a GeneQuant pro RNA/DNA 
Calculator (Biochrom, Cambridge, UK) according to the manufacturer’s 
instructions. Absorbance at 260nm quantifies nucleic acids, and together with 
absorbance at 230 and 280 can determine purity (via 260/230 and 260/280 ratios)
Chapter 2, 85
that is compromised largely by protein contamination. RNA and DNA 
concentrations were differentially (and automatically) calculated using a correction 
factor for differing base composition. Pure DNA and RNA preparations have 
expected ratios of ^ 1.8 and 2.0 respectively, and absorbencies should be ^ 0.05 
for accurate measurement. Briefly, Ip l of sample was diluted in 500pl of DEPC 
H2O and transferred to a quartz cuvette for analysis. The instrument displayed 
appropriate absorbencies, calculated ratios and quantitated the nucleic acid in 
question. For quantitative RT-PCR on the LightCycler, RNA was further diluted to 
a working concentration of 50-100ng/pl. RNA and DNA were stored at ~80°C until 
required.
2.3.3 DNAse treatment of RNA samples
The Ambion DNA-free™ Kit (Ambion UK, Huntingdon, UK) was used to remove 
contaminating DNA prior to Q-RT-PCR for hTR (see below) according to the 
manufacturer’s instructions. Briefly, RNA samples were diluted to 50-100 ng/pl, 
and DNAse added with incubation at 37°C for 1 hour. Using the inactivation ‘slurry’ 
provided in the kit, the DNAse was inactivated, spun down (to pellet the slurry) and 
the supernatant aliquoted into a fresh 1.5ml tube for later analysis. Typically this 
process resulted in < 0.1% contaminating DNA.
2.3.4 Synthesis of cDNA and GAPDH RT-PCR
cDNA was synthesized from 1pg of total RNA using the Abgene Reverse-iT™ 1®^ 
Strand Synthesis Kit (Abgene, Epsom, UK) according to the manufacturer’s 
instructions. The integrity of generated cDNA was assessed by performing PCR 
for GAPDH as a housekeeping gene with the Taq PCR Core Kit (Qiagen, Crawley, 
UK) and using the primers 5’-TGAAGGTCGGAGTCAACGGATTTGGT-3’ (forward, 
Clontech, Palo Alto, CA, USA) and 5’-CATGTGGGCCATGAGGTCCACCAC-3’
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(reverse) to generate a 983bp product. Settings used were: 94°C for 45 sec, 60°C 
for 45 sec, 72°C for 2 minutes (all repeated for 30 cycles) then 72°C for 10 minutes
2.3.5 RT-PCR for hTERT altered splicing mRNA products
To analyse the relative expression of the alternatively spliced mRNA products, a 
single set of primers was used within a single PCR reaction, to allow calculation of 
relative amounts of each product. Primers, as previously described (Kilian, et al 
1997), were used to generate a 457 bp product containing the A and B reverse 
transcriptase motifs, and therefore able to detect the a and (3 deletions when 
present (Figure 5-6). Splice variant products were amplified from Ip l cDNA using 
the hT2164F (5’-GCCTGAGCTGTACTTTGTCAA-3’) and hT2620R (5’-
CGCAAACAGCTTGTTCTCCATGTC-3 ) primers (Clontech). The Taq PCR Core 
kit was used with Hot-StarTaq reverse transcriptase (Qiagen). We used the 
following cycles: 94°C for 15 mins, followed by 40 cycles of 95°C for 30s, 64°C for 
45s, 72®C for 45s, and finally 72®C for 5 mins. PCR products were separated and 
quantitated on an Agilent 2100 Bioanalyser using a DNA 1000 LabChip™ (Agilent 
Technologies, Palo Alto, CA, see below).
2.3.6 Visualisation and quantification of PCR products
In place of conventional slab gel electrophoresis we analysed PCR products using 
the Agilent 2100 Bioanalyzer and the DNA 7500 LabChip™ kit. This system allows 
rapid chip-based separation of nucleic acids within micro-fabricated channels and 
automates detection, sizing and quantitation to allow digital data evaluation and 
analysis. Data can be displayed either as a gel-like image or an electropherogram 
plot. Fragments are detected by fluorescence within the 670 to 700nm wavelength 
range. To prepare a chip for sample loading, a gel-dye mix (pre filtered through a 
spin-filter) was injected under pressure into the loading well on a chip. Each
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sample well (up to 12 can be analysed in each chip) was loaded with a marker 
(upper and lower) in buffer solution, followed by the sample of interest {i.e. RT- 
PCR products). A standard DNA sizing ladder in an additional well allowed 
accurate sizing of detected fragments. Chip-analysis on the instrument is 
automated, and was generally complete within 30 minutes. PCR product 
concentrations were calculated in ng/pl, and sized in bps.
2.3.7 Quantitative RT-PCR for hTR and hTERT
Measurement of telomerase activity by the TRAP assay is at best semi- 
quantitative. It is also limited by the requirement for enzymatically active 
telomerase in the sample with the associated problem of enzymatic instability 
during storage. The assay itself may generate non-specific amplification products 
or be inhibited by PCR inhibitors within the sample itself (Kim and Wu 1997). 
These limitations are effectively overcome by quantifying the expression of the two 
major components of the telomerase complex (hTR and hTERT) using the 
LightCycler instrument (Roche Diagnostics Ltd). Both these reactions were carried 
out using the relevant LightCycler kits (the LightCycler TetoTAGGG hTR and 
hTERT Quantification Kits respectively, Roche Diagnostics Ltd) and rely on the 
same principles of detection, namely a one-step RT-PCR in glass capillaries. The 
target sequence was reverse transcribed using commercially supplied primers, 
and the amplicon detected using a specific pair of hybridisation probes. These 
consist of a pair of oligonucleotides that hybridise to an internal sequence of the 
amplified fragment during the annealing phase of the amplification cycle. One 
probe is labelled at the 5’-end with LightCycler-Red 640 and the other at the 3’ end 
with fluorescein. After hybridisation to the target DNA the two probes come into 
close proximity to each other. This results in fluorescence resonance energy 
transfer (FRET) between the two fluorophores. During FRET, fluorescein, the
Chapter 2, 88
donor fluorophore, is excited by the LightCycler instrument light source and part of 
the excitation energy is transferred to the red (acceptor) fluorophore. The 
instrument then measures the emitted fluorescence of LightCycler-Red 640. 
Quantification is achieved by measuring the point at which the detected 
fluorescence crosses the detection threshold (the ‘crossing point’), this being 
inversely proportional to the amount of target present. An absolute number of 
transcripts can be assigned to this point by incorporating a series of standard 
dilutions of RNA template (Figure 2-2). Correction for loading of RNA and PCR 
efficiency is achieved by a separate (although within the same PCR run) one step 
quantitative RT-PCR reaction for porphobilinogen deaminase (PBGD), a 
housekeeping gene. This acts as a reference for relative quantification, and is 
used in both kits; only when >10® PBGD transcripts were detected was the sample 
deemed suitable for inclusion in the final data set. All PCR reactions were run with 
a positive and negative control (for both hTERT or hTR and PBGD).
The assay was performed according to the manufacturer’s instructions, using 
either RNA or cDNA. Briefly the appropriate quantities of master mix (MM, n+1) 
were made; 2pl of hTERT reaction mix, 0.1 pi of reverse transcriptase, 2pl of 
hTERT or PBGD detection mix and 13.9pl of PCR-grade HgO were added per 
sample (total 18pl). These were stored briefly on ice and protected from light until 
required. The RNA of interest was diluted (with PCR-grade H2O) to a final 
concentration of lOOng/pl. After addition of 18 pi of the appropriate master mix to 
each capillary, 2 pi of the sample RNA {i.e. 200ng) was added to each. A typical 
run for hTERT included 5 standards (hTERT template of a known copy number), 2 
positive controls (hTERT and PBGD respectively, provided in the kit), 2 negative 
controls (PCR-grade H2O), and up to 11 samples of interest (with separate hTERT 
and PBGD reactions for each). The instrument settings used were: 60°C for 10 
minutes then 90°C for 30 sec (once only), followed by 95°C for 1 sec, 60°C for 10
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sec and 72°C for 10 sec (repeated for 40 cycles) then 40°C for 60 sec. Amounts of 
hTERT and hTR transcripts were expressed as a percentage relative to that of 
PBGD ([hTERT or hTR transcript copy number / PBGD transcript copy number] x 
100). Use of the same housekeeping gene and identical PGR conditions in both 
the hTR and hTERT assays permitted direct comparison of transcript levels of 
each gene in the same sample.
The hTERT kit utilises a primer / probe set that detects only (3-sequence 
containing transcripts (see Figure 5-6). (It should be noted that sequences of the 
primers and probes were not made available by Roche and repeated attempts to 
sequence the final product were unsuccessful). The hTR gene is intron-less and 
so requires incorporation of minus-RT controls to exclude amplification of 
contaminating DNA. Only samples that demonstrated <0.1% levels of DNA 
contamination (as calculated by [-RT control hTR transcript number / +RT hTR 
transcript number] x 100) were included for analysis.
Chapter 2, 90
I
II§
u.
Cycle Number
RNA
Standard
Number of 
transcripts
Crossing point 
(cycle number)
- standard 1 8 .8x105 21.12
- Standard 2 1.0 X 105 24.22
- Standard 3 8 .4x103 27.93
- Standard 4 9.1 x1Q2 31.27
Standard 5 7.0x101 35.35
B
II R =  -1.0 error = 0.04
Log Concentration
Figure 2-2 Generation of LightCycler standard curve for hTERT Q-RT-PCR
5 known standard concentrations of hTERT RNA template are included with each 
PGR run. The increase in sample fluorescence during the PCR reaction is 
visualised as a curve (A) that generates a ‘crossing point', at which the 
fluorescence becomes detectable (arrow on Standard 1 curve). This is 
proportional to the amount of starting template and can be plotted to obtain a 
standard curve (B). Crossing points for ‘unknowns’ can therefore be converted into 
absolute numbers of transcripts.
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2.3.8 FISH for the BCR-ABL translocatlon
To confirm that the selected populations of CD34^ cells from CML patients were 
clonal in origin (i.e. BCR-ABL positive) we performed dual dolour FISH on an 
appropriately fixed aliquot. Cells were fixed according to a standard protocol. After 
washing in PBS, 1 x 10® cells were spun at 450g at RT and resuspended in 
prewarmed (37°C) hypotonic solution (0.075M KCI, Sigma), mixed gently and 
allowed to stand for 10 minutes at RT. Cells were spun at 450g, resuspended in 
2ml of freshly prepared fixative (methanol: acetic acid, 3:1, Sigma) and incubated 
at RT for 5 minutes. After a further spin cells were suspended in 10ml fixative. This 
step was repeated twice. Cells were transferred to an Eppendorf and resuspended 
in 1ml fixative (to a final density of approximately 1x10® cells / ml) and stored at -  
20°C until required. Mrs Elaine Allan (SNBTS) performed FISH staining and 
scoring of cells. FISH staining was performed using the Vysis LSI BCR-ABL Dual 
Colour Translocation Probe (Vysis, Richmond, UK) according to the 
manufacturer’s instructions and imaged an epi-fluorescence microscope with a 
100-watt mercury lamp with appropriate single band pass filters (including DAP I 
(Sigma) for the counterstain).
2.3.9 Telomere repeat amplification protocol (TRAP)
Telomerase activity of PBL and CD34^ selected samples was peformed (with 
assistance from Aileen Monaghan, Beatson Institute) using a modification of the 
telomeric repeat amplification protocol described by Kim et al (Kim, et al 1994). 
Dry cell pellets (10®-10® cells) were stored at -80®C until required, whereupon they 
were lysed with NP-40/NaDOC lysis buffer (Calbiochem). Protein concentrations 
were measured, and lOpL of appropriately diluted extracts (containing 1 and 0.1 pg 
protein extract of each sample) was added to 40pL reaction buffer (50pM dNTPs, 
Ipg telomerase substrate (TS) primer [5’-AATCCGTCGAGCAGAGTT-3’]
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(Clontech), 20mM Tris/HCI pH 8.3, 1.5mM MgCb, 63mM KCI, 1mM EGTA, 
0.1 mg/ml bovine serum albumin, 2U Taq DNA polymerase (Invitrogen) and lug 
alternative complementary (ACX) primer [5’-
GCGCGGCTTACCCTTACCCTTACCCTAACC-3’]). Samples were incubated at 
room temperature for 30min and then heat inactivated for lOmin at 85°C. 
Telomerase elongated product in samples was amplified: 90sec at 90°C then 31 
cycles of 94°C for 30sec, 50°C for 30sec, 72°C for 90sec. An aliquot of each 
sample was heat-treated (lOmin, 85°C) before assaying to serve as a negative 
control. An internal telomerase assay standard (ITAS, 15 attogram), was included 
in the PCR buffer. For qualitative analyses, 5pL PCR product was analysed on a 
12% non-denaturing polyacrylamide gel. Gels were stained for 20min with IX  
SYBR Green (Invitrogen) and visualised on a UV transilluminator. Samples were 
scored as positive when compared to the GLC4 telomerase positive cell extract 
included as standard in each assay. Limit of detection was 100 GLC4 cell 
equivalents. All samples were assayed blind and experiments were performed in 
duplicate. For semi-quantitative analyses, IpL of PCR product was analysed on 
the Agilent Bioanalyser, using a DNA 500 Chip (Figure 6-2). The concentrations 
(ng/pl) of the first six 6-bp incremental bands were added together (as previously 
described (Hamad, et al 2002)) and expressed as a percentage of 10,000 GLC4 
cell equivalents. The first peak detected was 50bp in length, and consisted of the 
primers plus one telomere repeat (Figure 2-3). This was therefore excluded from 
analysis and the next 6 peaks analysed. All samples were assayed blind.
TS primer 
S' AATCCGTCGAGCAGAGTTIAG
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GGTT AGGGTT 3’
CCAA TCCCATTCCCATTCCCATTCGGCGCG S' 
ACX primer
Figure 2-3 TRAP primers constitute the first detectable peak (SObp) on 
analysis
The TS primer is 18bp in length, and the reverse (ACX) primer is 30bp. Together 
with a single telomere repeat plus a degree of primer overlap, the overall length of 
the product is 50 bp. Consequently this peak was excluded from analysis, with the 
subsequent 6 6bp-incremental peaks quantitated.
2.3.10 Statistics
All statistical tests were two-sided. Comparisons between groups of continuous 
variables were performed using the Mann-Whitney U or Kruskall Wallace tests. 
Paired sample analysis was performed using the Wilcoxon signed rank test. 
ANOVA was used to determine the significance of regression analyses. GB-Stat 
Statistical Software for Windows (Dynamic Microsystems, Silver Spring, MD) was 
used throughout, and significance was assumed for p values < 0.05.
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3. Results 1
3.1 Establishment and validation of flow-FISH
3.1.1 Introduction
Conventional telomere length measurement by Southern blot analysis utilises 
restriction enzymes which cleave internal (but not telomeric) sequences, plus a 
telomere-sequence specific probe [®^P-(CCCTAA)s], and generates a smear of 
DNA fragments called terminal restriction fragments (TRF). Thereafter 
densitometry scanning of each lane allows determination of the amount of 
telomeric DNA and the mean TRF length (Harley, et al 1990). The actual length of 
the telomere sequences is some 2-5kb less than the TRFs as a result of the 
upstream location of the restriction enzyme sites (Harley 1991, Hultdin, et al 
1998), and there is also data to suggest that the position of these sites vary 
considerably between individuals (Brown, et al 1990). Incorporation of sub- 
telomeric sequences in Southern TRF analysis will reduce the ability of this 
technique to resolve small, yet potentially significant, differences in telomere 
length (Rufer, et a /1998).
Fluorescent in-situ hybridisation techniques (FISH) allow measurement of the 
telomere sequences per se, via binding of a fluorescent PNA probe. Such probes 
contain an uncharged glycine backbone (rather than the charged backbones of 
oligonucleotide probes) (Egholm, et al 1993). They hybridise to the target DNA 
sequences under low-ionic strength conditions that do not favour the reannealing 
of the target strands. Therefore, under the hybridisation conditions used in the 
flow-FISH protocol, PNA-DNA interactions (as opposed to DNA-DNA or DNA- 
RNA) are selected for. The heat treatment of the cells (at 80°C in the presence of
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formamide and PNA probe) allows for simultaneous dénaturation of DNA, and 
fixing of the cells.
Flow-cytometric methods of detection measure average telomere length in test cell 
populations (flow-FISH), while digital-imaging techniques can measure individual 
telomeres in metaphase preparations, so-called quantitative-FISH (0-FISH) 
(Poon, et al 1999, Rufer, et al 1998). However, the Q-FISH technique is labour 
intensive and time consuming, and as it measures cells in metaphase, may select 
for those with longer telomeres {i.e. those still able to divide) in populations 
nearing senescence or crisis. Flow-FISH only requires 3x10® cells per sample, as 
opposed to the 10® - 10  ^required for Southern blotting. Although the latter two 
techniques offer a mean telomere length for any given cell population, the 
distribution patterns of the hybridisation signal can allow inferences to be made on 
the distribution of telomere length in the sample. For these reasons we elected to 
use flow-FISH as a high throughput technique which could give a telomere length 
measurement within 30 hours.
The initial aim of our study was to establish flow-FISH in the UK, and validate the 
technique with a collaborative laboratory in Tubingen (Germany). These data are 
discussed in this chapter. Additionally, the measurement of age-related telomere 
decline in a healthy local population served as a baseline for later analysis of CML 
patient material, while further validating our dataset with published normal ranges 
of telomere length. Of further interest was whether we could model the increased 
rate of telomere loss observed for lymphocytes, as previously published, as being 
consistent with a shift from naïve to memory cells.
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3.1.2 Measurement of telomere length in a 2N population using 
flow-FISH
The incorporation of PI staining of DNA allows gating on a 2N population of cells. 
This avoids skewing of the signal by doublets, cells in S phase (synthesising 
telomere sequences), G2 or M phases (4N), and also allows exclusion of cells with 
a sub-2N DNA content {i.e. apoptotic cells). 2N cells were therefore gated on first 
(R1, in FL3 vs. FSC). Analysis of R1 by histogram plot in the FL3 channel 
confirmed the existence of a single (G0/G1) peak (Figure 3-1). Despite the 
dénaturation and fixation steps involved in the procedure, the FSC/SSC properties 
of the 2N cells were remarkably well preserved allowing separate gating on distinct 
populations {i.e. lymphocytes and granulocytes, Figure 3-2). Analysis of the FL1 
histograms consistently demonstrated a greater heterogeneity in the lymphocyte 
gate (as shown by the larger CV, or wider histogram plot) as compared to 
granulocytes. This has been noted previously, and is assumed to be due to the 
more complex replicative history of the lymphocyte population (Rufer, et al 1999). 
In keeping with this was the increased lymphocyte (but not granulocyte) CV with 
age (Figure 3-4). To confirm the rationale for excluding the putative 4N population, 
separate gating on the latter gave a telomere signal almost 2-fold greater than the 
2N equivalent, as would be expected from the duplicated telomere sequences 
(Figure 3-3).
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Figure 3-1 Flow-FISH analysis of T-ALL cells
This pure (95%) population of T-ALL blasts served as a control for all flow-FISH 
experiments. Panels A-D represent the sequential gates used for standard flow- 
FISH analyses. 2N cells (A and C) in FL-3 (PI) were analysed by FSC/SSC to 
confirm a monomorphic population (B). The specific telomere fluorescence of cells 
(Telp) was calculated by subtracting the mean background fluorescence of cells 
hybridised without a PNA probe (Tu, open histogram, panel D) from the mean 
fluorescence obtained with probe (Ts, shaded histogram, panel D). A correction 
factor of 4 was applied to the mean FL1 channel number to correct for analysis of 
FL1 on a scale of 1-1000. Therefore for this example, Telp is calculated by (Ts-Tu) 
X 4/Gcai: i.e. (72.3 -  17.5) x 4 / 0.0217 = 10.1 kMESF, where Gcai is the gradient of 
the slope obtained from the calibration beads for this experiment (see 2.2.1).
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Figure 3-2 Flow-FISH analysis of normal PBL
Nucleated cells (after lysis of red cells) were analysed from a normal 20-year old 
donor. Analysis of the 2N population (R1, A) in FSC/SSC (B) allowed resolution of 
the lymphocyte and granulocyte populations, which could be gated on separately 
(C and D). The validity of these gates for their respective populations has been 
established by Rufer et al, using purified lymphocytes and granulocytes (Rufer, et 
a! 1999). Note that granulocytes have a higher degree of auto-fluorescence than 
lymphocytes (a consistently observed feature). To estimate the telomere length in 
bp, the equation bp = MESF units x 0.02604 x 0.019 x 10  ^was used as previously 
described (Rufer, et a! 1999). By this method lymphocytes had a telomere length 
of 6.8 kbp, and granulocytes 6.7 kbp. The CV for lymphocytes (with probe) was 
greater than for the granulocyte population (19.4 vs. 15.5 respectively, shaded 
histograms).
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Figure 3-3 Telomere signal in 2N vs. 4N populations.
To further confirm the validity of using a 2N gate an actively dividing population of 
cells was analysed; in this case ex-vivo expanded T-cells at day 6 of culture (see 
Methods). It has been shown that DNA content is proportional to chromosome 
(and hence telomere) number (Mandahl, et al 1993). The 2N (G0/G1), S and G2/M 
(4N) populations can be broadly identified from histogram analysis of FL3 and/or 
FL3 vs. FSC (A, B and D). Telomere fluorescence for the 4N population was 
almost double that for 2N cells, as would be expected (C and E). The slightly lower 
than expected value is probably due to inclusion of S-phase cells in R2.
3.1.3 Intra- and inter-experimental variation
To further validate the technique in our hands, several aliquots of T-ALL control 
cells were analysed sequentially in Dr Tim Brummendorfs laboratory in 
Tuebingen, Germany. Their results (mean±SD, 9.7±0.5 kMESF, n=5) compared 
closely with those obtained in our laboratory (10.5±1.7 kMESF, n=62). The
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resulting CV of 17% is in keeping with published results (Brummendorf, et a /2000, 
Rufer, et al 1999, Rufer, et al 1998). Variation in identical samples stained within 
the same run was greatly reduced (mean 6.9±0.28 kMESF, CV 4%, n=8). In 
practical terms several steps were taken to reduce the effect of variation on the 
final data. Firstly, wherever possible, a range of telomere lengths were included in 
each run, i.e. by incorporating a range of ages (from 0-99) for normal controls, or a 
range of CML stages (/.e CP, AP and BP). Secondly, where direct comparisons 
were being made between serial telomere measurements within the same patient, 
a correction factor was applied based on the control cell fluorescence (see 
Chapter 4). Thirdly, meticulous attention to experimental conditions, reagents etc. 
was maintained to reduce variation in results. Fourthly, all samples were analysed 
in duplicate (both stained and unstained) and mean fluorescence used throughout. 
Fifthly, both our batches of probe (used sequentially over a two-year period) were 
compared to an aliquot from the German laboratory (the reference probe) to 
ensure comparable fluorescence intensity.
Probe used Mean Lymphs(±SD, kMESF) Mean Grans (±SD, kMESF)
Reference Probe 11.2+0.7 12.5+0.6
Batch 1 Probe 12.5+0.2 13.8±0.1
Batch 2 Probe 11.9±0.6 13.3+0.7
Table 3-1 Comparison of telomere fluorescence between different batches of 
PNA probe
To ensure uniformity of fluorescence between batches of PNA probe, we 
compared telomere fluorescence using PBL from the same individual. This table 
illustrates a direct comparison of all three lots of probe used within all flow-FISH 
experiments. These were compared within a single run, each in duplicate. It 
should be noted that the relationship between the lymphocyte and granulocyte 
telomere fluorescence remains constant.
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3.1.4 Normal age-related telomere loss
A total of 55 normal volunteer samples were collected from discarded umbilical 
cord blood bottles (UCB, n=12) and otherwise healthy volunteers across a broad 
age range (median age 39, range 0 - 9 9  years). Flow-FISH was performed on 
unfractionated PBL, and granulocyte and lymphocyte telomere fluorescence 
measured as described above (Figure 3-4).
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Figure 3-4 Telomere shortening occurs with age
A representative example of telomere fluorescence at extremes of age. As 
determined by the flow cytometry software there was a progressive increase in CV 
for lymphoc^e fluorescence with age (16.4, 19.4 and 27.1 in this series 
respectively) which was not evident in the granulocyte population (17.0, 15.5 and 
16.5 respectively). This is in keeping with a more diverse replicative history in the 
lymphocyte population, as a result of repeated clonal expansion.
Simple linear regression analysis gave the equations y = -0.0686x + 16.398 (R  ^=
0.46, p<0.0001) for granulocytes and y = -0.0969x + 16.93 (R  ^= 0.68, p<0.0001) 
for lymphocytes, giving approximate annual rates of loss of telomere sequence of 
34 and 48bps respectively (in keeping with previous estimates (Rufer, et al 1999), 
Figure 3-5). Lansdorp’s group have recently described a cubic curve as the best
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fit’ for age related telomere length decline in normal PBL (Verfaillie, et al 2002). 
For our data a quartic relationship further improved the fit (albeit slightly). The 
respective equations were; y = (-5 x 10*° )^ x + (0.0003 x x^)- (0.0896 x x) + 
16.598 for granulocytes (R  ^= 0.46, p<0.0001) and y = (-9 x 10'°®) xx^ + (0.0017 x 
x )^ -  (0.1804 X x) + 17.529 for lymphocytes (R  ^0.7, p<0.0001).
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Figure 3-5 Flow-FISH analysis of normal individuals
The top panel (A) describes age-related telomere loss in a linear fashion, and the 
bottom (B) using a quartic relationship (see text). Telomere loss in the lymphocyte 
population (open circles, dotted line) was more rapid with age than that of 
granulocytes (open squares, solid line). This is most likely due to shorter 
telomeres in the memory lymphocyte population (as compared to naïve) which 
predominates with age.
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3.1.5 Age-related increase in naïve vs. memory lymphocyte 
subpopuiations accounts for more rapid lymphocyte 
telomere shortening
To confirm the shift from a predominantly naïve lymphocyte population to that of a 
memory one (with shorter telomeres (Rufer, et al 1998)) we analysed a subgroup 
of the normal individuals described above for expression of CD45RA vs CD45RO 
by flow-cytometry. CD45RA is present on CD4* T lymphocytes, CD8^ T 
lymphocytes and on essentially all B and NK lymphocytes. CD45RA is expressed 
on naïve T lymphocytes and antigen density rapidly decreases upon activation. 
Conversely, CD45RO (present on T lymphocytes, monocytes, macrophages and 
granulocytes) is upregulated upon activation and its presence most likely defines a 
primed population of memory T lymphocytes. Dual staining of unfractionated PBL 
(n=46) with CD45RO and CD45RA allowed relative quantitation of memory and 
naïve cells within the lymphocyte population (Figure 3-6). There was a 
progressive age-related shift from a naïve to a memory phenotype (Figure 3-7).
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Figure 3-6 FACS analysis of memory vs naïve lymphocytes
The lymphocyte population was identified easily using SSC vs. FSC (A). After 
setting appropriate quadrants using the isotype control (B), CD3-PE and CD4- 
FITC staining allowed discrimination of the major lymphocyte sub-populations (C)
i.e. CD4^ T cells (UR), CD4' T Cells (CD3^CD8^ cells, UL) and presumed B and 
NK cells (LL). R1 was therefore used to determine the relative frequencies of 
CD45RA (FITC) and CD45RO (PE) lymphocyte populations over a range of ages 
(n=46). A representative series of different ages is shown (E-G) in comparison to 
the isotype control (D). A shift from a predominantly naive (CD45RA) to memory 
(CD45RO) population was observed.
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Figure 3-7 A proportional shift from naïve to memory lymphocytes occurs 
with age
PBL from 46 normal volunteers were studied for relative proportions of naïve 
(CD45RA, open squares, R^=0.41, p<0.001) and memory (CD45RO, open circles, 
R^=0.58, p<0.001) lymphocytes. A progressive loss of naïve phenotype (with a 
proportional gain in memory phenotype) was observed with age, as would be 
expected. The equations of the lines were y = -0.3373x + 60.319 (naïve) and y = 
0.4274X + 21.692 (memory).
The proportional shift in naïve to memory phenotype was striking, consistent with 
the mutually exclusive expression of either CD45RA or CD45RO (but not both 
together). Taken together, these datasets {i.e. the rate of lymphocyte telomere 
loss in normal individuals with age, and the rate of conversion from a naïve to 
memory lymphocyte phenotype) allowed us to estimate the degree of telomere 
loss expected from the observed age-related conversion to a memory phenotype, 
and allowed comparison to the increased age-related telomere loss measured in 
normal lymphocytes (approximately 14bps per year. Figure 3-5). Such a model 
relies on several assumptions, as follows; that the previous flow-FISH estimate for 
memory vs. naïve T-cell telomere shortening (2.5kb)(Rufer, at al 1998) is a 
constant and is applicable to our data; and that the T-cell phenotype shift is
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relevant to total lymphocyte telomere measurements (i.e. exclusion of B and NK 
cells from the immunophenotyping has little effect on the sample as a whole). 
Given the predominance of T-cells in the peripheral blood of normal individuals 
(>80%), the latter assumption would appear reasonable. With these assumptions 
in mind, a mathematical model of phenotype-shift (i.e. naïve to memory) related 
telomere loss was derived (Equation 1).
1. A =
A
3. A =
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Equation 1 Mathematical modelling of increased telomere loss in 
lymphocytes as a result of a proportional rise in memory cells
Steps 1-9 of the method used to derive the degree of shortening due to naïve- 
memory conversion of lymphocytes with age are shown. The mean contribution of 
naïve (N, the percentage naïve cells at either time point) vs. memory (M, the 
percentage memory cells at either time point) cells to telomere length at age 0 (to) 
is derived as value A, while at age 90 (ti, the upper age from Figure 3-7) it Is 
represented by B. x represents the mean lymphocyte telomere length at the 
respective time points, with y being the excess telomere length observed in naïve 
lymphocytes (in this case it is accepted as 2.5 kbps as per Rufer et al. (Rufer, et ai 
1998)). The value of x is cancelled out in steps 5/6, and therefore the derived 
value of immunophenotype-shift mediated telomere loss is independent of starting 
telomere length.
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By these means, we calculated that the progressive shift from naïve to memory 
lymphocytes accounted for an additional 11.1 bps telomere sequence loss per 
year. This is extremely close to the measured value of 14bps per year (Figure 
3-5), and suggests that this excess loss (as compared to granulocytes) is almost 
entirely due to naïve T-cell expansion and conversion to a memory phenotype 
(with shorter telomere sequence) rather than extra progenitor cell divisions.
3.1.6 Discussion
We successfully established flow-FISH in our laboratory, and validated it against 
results obtained in a partner laboratory and against published normal population 
values for telomere fluorescence. By incorporating an identical aliquot of control 
cells in every run we obtained a CV of 17% for all our experiments over a time 
period of 20 months, which is similar to that obtained by other groups. This 
degree of inter-experimental variation is almost certainly related to the multiple 
manual steps involved in the technique. In keeping with this was our observation 
that samples analysed within the same run exhibited considerably less variation in 
staining intensity. It has been shown recently that hybridisation does not proceed 
to saturation under the originally published experimental conditions (Baerlocher, et 
al 2002) and this has led Lansdorp’s laboratory to further (and meticulously) refine 
the technique (Baerlocher, et ai 2002) with particular attention to optimization of 
the dénaturation conditions (15 minutes at 87°C). This has greatly reduced the 
inter-experimental variation in staining intensity (Baerlocher, personal 
communication). These modifications are being incorporated into our current 
protocol and will improve the reproducibility and accuracy of flow-FISH in the 
future.
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The haematopoietic stem cell (HSC) has the daunting task of generating 10^  ^ -  
10^  ^mature blood cells on a daily basis, and although the mechanisms that control 
stem-cell fate are far from clear, some intriguing observations concerning 
telomeres have been made. CD34'"CD38'° selected cells in culture lose 
approximately 40 bps per population doubling and, in keeping with a 
corresponding lifelong telomere loss in-vivo, nucleated cells from foetal liver and 
UCB have significantly longer telomeres than those from adult BM (Vaziri, et al 
1994). These data are in keeping with the fact that HSC are not immortal; there is 
eventual loss of repopulating ability of murine bone marrow following serial 
transplantation (Harrison and Astle 1982). Such observations support the 
existence of a telomere checkpoint in-vivo, and are consistent with the ability of 
foetal liver and UCB HSC to generate significantly more progeny that their adult 
equivalent (Lansdorp, et al 1993). HSC and progenitor cell telomere loss is 
detectable in their peripheral blood leucocyte (PBL) progeny: Rufer et a!., in a 
study of over 500 normal individuals of all ages, detected telomere shortening in 
PB granulocytes and lymphocytes of 39 and 59 bp per year respectively (Rufer, et 
al 1999). A much greater increase (1000 -  3000 bp/yr) was observed in the first 
two years of birth. If one assumes that the number of divisions between HSC and 
mature progeny are identical throughout life, and that telomere loss is replication- 
induced and constant with each division, then PBL telomere length can be used to 
measure the replicative history of HSC (Verfaillie, et al 2002). These data would 
predict that the average HSC divides every 1 - 2  years (based on loss of 50 -10 0  
bps per division) after the age of 2 years or so, which is consistent with data 
derived from mathematical modelling of the mutation rate in red cells (Vickers, et 
al 2000). Our data also support this, and our mean rates of granulocyte and 
lymphocyte telomere loss are comparable with those of Rufer et al. Interestingly, 
recent data from Lansdorp’s group suggests a further acceleration of telomere loss
■
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after the age of 60 years or so (Verfaillie, ef al 2002), and our data was also (albeit 
marginally) best described by a more complex (in this case quartic) regression 
line, pointing to a late acceleration of telomere loss. It should be emphasised 
however that our study was not designed to look for age-related shifts in telomere 
dynamics, and that Lansdorp’s sample-set included an excess of individuals at 
extremes of age. The reasons for more rapid telomere shortening in the elderly are 
not clear but could be as a result of replicative stress within a diminishing HSC 
pool, or the consequences of reduced DNA repair efficiency and / or antioxidant 
defence mechanisms.
From these data it is apparent that telomerase is unable to prevent telomere 
shortening in the HSC compartment. Telomerase activity is detectable in HSC: it is 
expressed at low level in steady-state CD34^ cells, is highest in the CD34V38^ 
subpopulation (which contains proliferating progenitor cells), up regulates in 
response to multiple cytokine stimulation in-vitro within 48 hours (peaking at day 7 
and declining to baseline after 3-4 weeks) and correlates with cell cycle status 
(Engelhardt, et al 1997). Despite telomerase activity, telomeres shortened by 1 -  2 
kbp over the 4 week culture period (albeit at a slower rate during the period of 
telomerase expression, with an overall loss of 73 bps per division). Telomerase 
activity was low in the quiescent CD34V38" population, and could also be down 
modulated with TGF-^. Therefore, despite these cells being telomerase 
competent, telomere loss still occurs. Thus in-vitro telomerase activity perse is not 
adequate to maintain telomere length and is therefore not synonymous with 
telomere maintenance.
The consequences of this can be detected after BM or HSC transplantation: 
Notaro et al first demonstrated significant telomere shortening, of the order of 79- 
1446 bps, in the peripheral blood granulocytes of alloSCT recipients as compared
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with their donors (Notaro, et al 1997). Assuming that telomere shortening is 
directly proportional to the number of cell divisions, the observed inverse 
correlation between the number of mononuclear cells received and the degree of 
telomere shortening was interpreted as reflecting the additional cell divisions 
required to achieve haemopoietic reconstitution. Brummendorf et al. have 
convincingly demonstrated that the initially rapid telomere loss post transplant (an 
average of approximately Ikb) occurs over the first year, with a more gradual loss 
(comparable to the normal rate) thereafter (Brummendorf, et ai 2001a). The results 
of studies in children post alloSCT are similar, demonstrating telomere shortening 
equivalent to approximately 15 years of ageing (Wynn, et a /1998).
As to the potential pathological significance of such post transplant telomere 
shortening in disease, little is known. It must be remembered that late failure of a 
successful graft is extremely rare, and some individuals in these studies had no 
demonstrable telomere loss post transplant Early onset of clonal haemopoietic 
disorders could be predicted, in an analogous fashion to that of aplastic anaemia, 
where telomere shortening correlated with chromosomal abnormalities and clonal 
disorders have been described (Ball, et al 1998). Further study, for example on the 
role of telomere shortening in dysplastic states observed post autologous SCT, is 
required although clearly there will be many confounding variables such as the 
mutagenic effects of treatment. Its significance may only eventually be realised 
with the ex-vivo manipulation of stem cells, such as that used in gene therapy or 
UCB transplant protocols, where a small number of stem cells are required to fully 
reconstitute an adult marrow. Clearly the passage of time, as well as further 
study, is needed.
Interestingly, in wild-type mice serially transplanted with transgenic hTERT- 
expressing BM or HSC (c-Kit '^, Sca-1^', Thy1.l'°, Lin"^^) no telomere shortening
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was observed, even after 4 serial transplants (Allsopp, et al 2003b). This was in 
comparison to the wild-type transplanted animals, where they lost approximately 
40% of the serially transplanted donor telomeric DNA. However, it was not 
possible to transplant beyond a fourth attempt; therefore telomere maintenance 
did not extend replicative capacity. The authors suggested that this may reflect the 
influence of telomere independent senescence mechanisms, due to repeated HSC 
handling and cell-stress, akin to the telomere independent ‘culture-shock’ 
observed in-vitro. This has major potential implications for tissue engineering and 
ex-vivo cell expansion etc. Simply over expressing hTERT may not permit 
unlimited cell expansion, and it is likely that meticulous attention to cell culture 
conditions etc will be required to avoid inducing cell senescence via other routes.
In addition to HSC determined telomere loss, mature lymphocytes must undergo 
massive clonal expansion in response to antigenic stimulation, and consequently 
memory CD4^ and CD8^ cells have significantly shorter telomere sequences than 
naive (Rufer, et al 1998), (Weng, et al 1995),. These additional replications have 
been assumed to explain the more rapid telomere loss in lymphocytes, in parallel 
with a shift from naive to memory cells with age. Our mathematical model of 
immunophenotype-related telomere shortening supports this notion, and the 
calculated increased loss (11.1bps per year) was remarkably close to the 
measured increase over and above that of granulocytes (14 bps per year). Again 
this underscores the principle that telomere loss remains significant, even in 
telomerase competent cells. The potential sequelae of lymphocyte telomere loss, 
primarily immunosenescence, have been discussed extensively in the literature 
and are beyond the scope of this section (Globerson and Effros 2000). However 
such a mechanism could explain the inefficiency of immune surveillance post BM- 
or HSC-transplant (as suggested by the progressive increase in risk of solid
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tumours) as well as loss of immune function in the elderly. Again these in-vivo 
effects may be exaggerated by future ex-vivo manipulation of such cells.
In summary, telomere length measurement can offer unique insights into cell 
turnover and ageing, and flow-FISH is particularly applicable to the study of 
haematological cell types. We therefore studied, in detail, the telomere dynamics 
of the archetypal HSC malignancy CML.
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4. Results 2
4.1 Telomere dynamics at diagnosis and during 
progression of chronic myeloid leukaemia
4.1.1 Introduction
CML offers an interesting and valuable model in which to study telomere dynamics 
during tumour progression, as the degree of telomere shortening is likely to reflect 
Ph^ HSC turnover. Although there is evidence of lymphohaemopoietic progenitor 
involvement, circulating T lymphocytes are not typically involved in the malignant 
clone (Brummendorf, et al 2000, Haferlach, et al 1997, Jonas, et al 1992).
Several reports have documented increased PBL telomere shortening in CML 
(Table 4-1), and have attributed varying degrees of prognostic significance to the 
degree of telomere loss observed. In 1997 Iwama et al. reported that increased 
telomere loss in CP CML (as compared to normal controls) predicted for increased 
likelihood of BP within the study time period and also that those patients with 
telomeres within the normal range had a higher incidence of cytogenetic 
responses to interferon-alpha (IFN) (Iwama, et al 1998). Boultwood et al. 
demonstrated that increased age-adjusted telomere loss was predictive for time to 
AP (but not BP) (Boultwood, et al 2000) and more recently Brummendorf has 
shown that CP patients developing BP within 2 years of sampling had significantly 
shorter PBL telomeres than those who progressed after 2 years (Brummendorf, et 
al 2000). The degree of telomere shortening at diagnosis therefore warrants 
further investigation as a prognostic indicator. What was consistently observed 
within these studies was that mean telomere length in CP CML was shorter than in
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normal age-matched individuals, and that further telomere shortening was 
observed with disease progression.
study TechniqueUsed
Normal
Controls CP CML
AP or BP 
CML Reference
1 Southern 8.7kb, n=34 6.4kb, n=34 4.1 kb*, n=12, BP a
2 Southern 9.7kb, n=75 6.0kb, n=59 ND b
3 Southern lO.Okb, n=33 6.1 kb, n=33 4.5kb*, n=21, BP c
4
5
Southern
Flow-FISH
Not given
13.2kMESF,
n=147
19 pts in normal 
range (mean 
7.8kb), 25 
patients below 
(mean 5.2kb) 
H.OkMESF, 
n=96
ND
9.5kMESF*, 
n=14, AP&BP
d
e
6 Southern 7.8kb, n=108 5.6kb, n=7 4.7kb, n=12, BP f
Table 4-1 Telomere length in CIVIL.
This table summarises the data presented in 6 studies of telomere length 
published to date. All demonstrated significantly shorter telomeres in CP CML as 
compared to the normal control cohort. Additionally, 3 out of 4 (studies 1, 3 & 5) 
showed further (and significant) shortening with disease progression. The 
prognostic relevance of these data within their respective study is described in the 
text. *, significantly shorter than CP; a, (Boultwood, et al 1999); b, (Boultwood, et 
a /2000); c, (Ohyashiki, e ta l 1997b); d, (Iwama, e ta l 1998); e, (Brummendorf, et al 
2000); f, (Engelhardt, e ta l2000).
These observations have led Lansdorp’s group to suggest that telomere attrition, 
eventually leading to genetic instability and clonal evolution, could play a role in 
progression of CML (Figure 4-1).
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Figure 4-1 A mode! of telomere and telomerase dynamics during 
progression of CML
Clonal expansion subsequent to acquisition of BCR-ABL in the HSC compartment 
results in progressive telomere loss, detectable in myeloid progeny in the 
peripheral blood. The malignant population is driven through the ‘Hayflick Limit’ 
(M1) and proceeds to early cell crisis (M2) and clonal evolution. Telomerase 
cannot prevent telomere loss during CP, and its regulation during this period 
remains poorly characterised. In contrast, BP exhibits upregulated telomerase and 
short (but stable) telomere length. Using Ph" T cells as an internal control for 
somatic cell telomere length, the degree of telomere loss can be measured on an 
individual basis (‘Delta-Tel’) thereby correcting for genetic and age related 
variation in telomere sequence length.
In this chapter we aimed to further define the prognostic significance of telomere 
shortening at diagnosis, measure rates of telomere attrition and to determine the 
dynamics of telomere length changes over time in responding and non-responding 
imatinib mesylate treated groups.
4.1.2 Telomere length in CML PBL is representative of the BCR- 
ABL* CD34* compartment
In the studies described in Table 4-1 it was assumed that telomere length in CML 
PBL was representative of the Ph^ HSC compartment. To establish that this was a 
valid assumption we performed flow-FISH upon freshly selected cell populations 
(Figure 4-2) and unfractionated PBL from 2 patients at time of diagnosis of CML
Chapter 4, 117
(Figure 4-3). To confirm that the CD34^ cells were part of the CML clone, FISH 
was performed for BCR-ABL (98% and 95.6% BCR-ABL positive for patients A 
and B respectively).
m' ' ■ im
FSC FL1
CD34
CD15 GDI 9
FL1
Figure 4-2 FACS sorting of selected populations of cells from CML PBL
CD34^ (PE), CD15^ (FITC), CD3^ (PE) and CD19^ (FITC) labelled cells were 
selected at high purity (>95%) from leucapheresis material. PI staining with 
analysis in FL3 was used to gate on live cells (A, R1), and gates were then set on 
the populations of interest (C and D) with reference to the isotype control (B). 
Flow-FISH was performed immediately on the freshly selected cells.
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Figure 4-3 Flow-FISH measurement of selected subpopulations from CML 
patients at diagnosis
The mature B cell (CD19*) population displayed by far the longest telomeres 
(approximately 2.0 kb longer than circulating T cells), consistent with a recent 
observation (Martens, et al 2002). Samples were analysed in duplicate and mean 
values are displayed with SD bars. In patient B insufficient cells were obtained 
from the CDS / CD19 sort for analysis. Note the broken y-axes.
Telomere fluorescence of CD34^ cells was directly comparable to that of whole 
PBL or the CD15^ mature myeloid population in both patients A and B, in keeping 
with a previous study which also reported no significant difference between the 
populations (4.8kb and 4.4kb for BM CD34^ cells and PB MNCs respectively in 
CML) (Engelhardt, ef a/2000).
4.1.3 Telomere shortening occurs during progression of CML
PBL telomeres at all stages of CML were significantly shorter than that of a cohort 
of normal individuals approximately matched for age (Table 4-2 and Figure 4-4). 
Additionally, BP telomeres were significantly shorter than those of early CP. The 
latter observation was confirmed after correction for age related loss: Age adjusted 
differences in telomere length (CML PBL, blast or granulocytetei -  calculated
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normal granulocytetei) were calculated for CML patients at different stages of 
disease using the expected normal granulocyte values as a reference (from the 
equation of the quartic regression line, Figure 3-5B). To establish whether any 
residual age-related influence on telomere length remained in CML, telomere 
fluorescence was plotted against age for each of the CML cohorts (Figure 4-5). 
Interestingly, preservation of age related decline was observed for all stages 
(although this did not reach statistical significance for early CP or AP), which was 
most marked with myeloid BP. The relatively limited age-range of the patients (as 
compared to the normal cohort) and the fact that this corresponded to the ‘flat’ part 
of the quartic regression line for the normal population inevitably hampered the 
ability to detect statistically significant correlations for these groups. The strong 
correlation for the myeloid BP samples was unexpected, and may point to 
inefficient telomere maintenance mechanisms in advanced age when faced with 
significant replicative stress.
Cohort n Median age in years (range)
Median  
duration of 
CML in months  
(range)
PBL Telom ere  
length  
kMESF (+SD)
Age-related  
degree of 
telom ere  
shortening  
kM ESF (±SD)
P values  
vs N adults I 
vs CP CML < 
2yrs
UCB 12 0 - 16.4 (±2.3) - -
N adults* 35 57(24 -81) - 12.5 (±2.3) - -
CP < 2  
years 54 54 (24 -  77) 0 ( 0 -  22) 10.5 (±3.1) -2.2 (±3.0) <0.01 / -
CP > 2  
years 12 55.5 (45 -  70) 50 (25 -  84) 10.2 (±2.3) -2.3 (±2.6) < 0.01 /N S
AP 15 63 (41 -  75) 63 (41 -  75) 9.3 (±2.5) -2.8 (±2.4) <0.001 / NS
BP 17 61 (37 -  75) 61 (3 7 -7 5 ) 6.1 (±2.9) -6.2 (±2.9) <0.0001 / <0.0001
Table 4-2 Flow-FISH results from cohorts of normal individuals and CML 
patients
*35 patients from the total cohort of 55 normal individuals were selected to mirror 
the age range and distribution of the CML cohorts. N adults, normal adults.
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Figure 4-4 Telomere length and age-related degree of telomere shortening In 
normal volunteers and at different stages of CML
The top section of the chart shows PBL telomere length with median and 
percentile ranges shown (black bars 10 -  90%, open box 25 -  75%). The lower 
section illustrates mean age corrected differences in telomere length from that of 
granulocytes in the normal population (bars represent standard error). 35 patients 
from the total cohort of 55 normal individuals were selected to mirror the age range 
and distribution of the CML cohorts. All stages of CML had significantly shorter 
telomeres than the normal adult group (see text and Table 4-2). In addition BP 
demonstrated further shortening in comparison to CP of duration less than 2 years 
(p < 0.0001). As in previous studies a wide range of telomere lengths were noted, 
limiting the ability to define small but significant differences between groups. N 
adults, normal adults (age matched): UCB, umbilical cord blood; Tel, telomere 
length.
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Figure 4-5 Age-related telomere fluorescence from different stages of CML
Telomere fluorescence from early CP, AP and myeloid BP (only 4 lymphoid BP 
samples were studied and are therefore not shown) from the cohorts described in 
Table 4-2 were plotted against age (open triangles, CML samples; open squares, 
normal granulocytes). A trend towards an age related decline in telomere length 
was observed with early CP and AP (R =0.05, p=0.1 and R^=0.04, p=0.5 
respectively), but was highly significant and most marked in myeloid BP (R^=0.68,
p<0.01).
As in previous studies, there was a large variation in telomere length between 
patients, particularly in CP. This is almost certainly attributable to a combination of 
genetic factors, disease heterogeneity and technical variation, indicating that large 
numbers of patients would be required to demonstrate small differences between 
groups (i.e. different disease stages and prognostic sub-groups at diagnosis). To 
allow us to interpret such inter-individual differences we used expanded T-cells as 
an internal control for normal (i.e. Ph ) telomere length (Figure 4-6). Delta-tel was 
calculated from (T Celltei -  PBL or granulocytetei) in kMESF, and provided a 
measure of the CML-related degree of telomere shortening within an individual 
patient. Although lymphocytes and granulocytes shorten at different rates (a 
potential confounding factor for interpretation of delta-tel values), the relationship
â
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between the two populations is relatively constant over the age range of our CML 
cohort (Figure 3-5 B). A trend towards shorter telomeres in AP patients compared 
to CP in the cohort group was confirmed by measurement of delta-tel in 9 CP and 
7 AP patients (0.8 ± 1.8 and 3.4 ±1.9 kMESF respectively, mean ± SD, p<0.05. 
Figure 4-7), which demonstrated significantly greater shortening in the AP group. 
T cell expansion in adequate numbers from representative BP samples was only 
successful in one case (shown separately in Figure 4-8), presumably because of 
the advanced nature of the leukaemic process with either established or incipient 
bone marrow failure.
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Figure 4-6 Ex-vivo expansion of T-cells.
Whole PBL from CML patients were cultured for 7-10 days in the presence of IL-2 
and PHA. When adequate numbers of T-cell clones were visible, the culture was 
harvested and analysed by FACS for T-cell purity. Viable cells were identified by 
PI staining (R2, B), and CD3-FITC negative (C, isotype control) and positive (D) 
stained populations used to determine T-cell purity. In this representative example 
93% of the viable cells were T-cells.
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Figure 4-7 Degree of telomere shortening in CP and AP CIVIL using patient T 
cells as an internal control of Ph telomere length
To correct for age related and genetic variation in telomere length, delta-tel was 
calculated (see text). Significantly shorter telomeres were detected in the myeloid 
compartment of AP patients (mean values plus SE bars) as compared to early CP 
(p<0.05, see text). T, T cell compartment telomere length; M, myeloid 
compartment telomere length.
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Figure 4-8 Serial measurement of delta-tel in patient progressing from CP to 
BP
This patient demonstrated an additional 1.4kMESF telomere loss on progression 
to BP: in comparison to the normal rate of granulocyte telomere loss this 
represents an approximately 20-fold increase in rate.
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To determine if individual patients undergo telomere shortening during progression 
of their disease from CP to BP we analysed paired samples from 7 individuals. All 
patients had the CP sample taken at diagnosis (apart from 1 who was sampled 
after 22 months of CP), with a median time to repeat sampling at onset of BP of 49 
months (range 6 -  75). Where possible (in the case of frozen paired samples, n=5) 
these samples were analysed within the same staining run, otherwise a correction 
factor was applied (n=2) derived from the control cell fluorescence (Equation 2).
Corrected sampletei= [Mean control T-ALL celltei/measured control celltei] x 
sampletei
Where tel is telomere fluorescence (kMESF)
Equation 2 Correction for variation in fluorescence intensity between 
experiments
Mean telomere length of CP and BP samples was 9.1 ± 1.9 and 6.0 ± 2.0 kMESF 
respectively, and paired analysis of samples demonstrated significantly shorter 
telomere sequence in BP samples (p<0.05). The mean degree of shortening was 
therefore calculated as 3.1 ± 2.8 kMESF, or 0.75 kMESF per year, approximately 
10 X  the rate of normal.
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Figure 4-9 Telomere shortening in paired CP and BP samples from individual 
patients
Telomere shortening was observed in BP as compared to their respective CP 
sample in 6 out of 7 samples analysed. A mean decrease of 3.1 ±2.8 kMESF was 
observed with disease progression (p<0.05).
4,1 A  The degree of telomere shortening at diagnosis correlates 
with prognostic score
Brummendorf et al. demonstrated that short telomeres in CP predicted for time to 
disease progression. To investigate this relationship further we prospectively 
measured telomere length in 32 newly diagnosed patients and correlated PBL 
telomere length with their Hasford prognostic score. There was no significant 
difference in PBL telomere length between the high-risk (HR), intermedlate-rlsk 
(IR) and low-risk (LR) prognostic groupings (Kruskall-Wallace test, p=0.38), 
although there was a trend to shorter telomeres with increased risk score (LR 
10.1+2.5, IR 9.2+3.8, HR 8.4±2.5 kMESF, mean+SD, Figure 4-10). Delta-tel was 
calculated for these patients using ex~vivo expanded T-cells from 32 consecutive 
newly diagnosed patients. The mean delta-tel for all patients was 2.1 ± 2.8 
kMESF. High-risk Hasford score (n=12) patients had significantly greater mean 
delta-tel values (3.4 ± 2.8 kMESF, mean ± SD) than low-risk score (n=8) patients
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(0.6 ± 2.2 kMESF, p<0.05), with intermediate risk (n=12) patients having values 
falling between these extremes (1.3 ±1.4 kMESF, Figure 4-11). There was no 
significant difference in T-cell telomere length between the prognostic groups after 
a correction for age-related shortening was made (p=0.5, Kruskall-Wallace test).
n«8 n»12 n»12
Hasford risk group
Figure 4-10 Mean PBL telomere fluorescence for patients at diagnosis
Telomere length was measured on whole PBL from 32 CML patients at diagnosis. 
Although there was a trend to shorter telomere for the high-risk (HR) group, this 
was not statistically significant (Kruskall-Wallace test p=0.38). IR, intermediate- 
risk; LR, low-risk. Histogram bars represent the mean for each group, with 
standard error bars.
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Figure 4-11 Delta -  tel values at diagnosis correlate with prognostic score in 
CML
32 consecutively diagnosed CML patients had delta-tel measured and correlated 
against conventional Hasford prognostic risk groups (mean values plus SE bars). 
High-risk patients had significantly greater telomere shortening at diagnosis than 
low-risk (p<0.05). LR, low-risk; IR, intermediate- risk; HR, high-risk.
4.7.5 Telomere dynamics in CCR vs non-responders to imatinib 
therapy
To determine the rate of telomere shortening in individual patients, it was 
necessary to select those who, despite treatment, remained 100% Ph"^  as 
determined by BM cytogenetics. This then allowed for the valid assumption that all 
myeloid PBL were clonal in origin. The spectacular success of imatinib therapy in 
inducing complete cytogenetic responses (CCR, i.e. 100%Ph) allowed us to 
directly compare the telomere dynamics between persistently 100% Ph^ patients 
and those attaining 100% Ph' status over time. All patients who obtained a CCR
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were in CP (n=10, median duration of disease 11.5 months, range 0 ~ 54) and of 
those who remained 100% Ph^ (n=11, median duration of disease 40 months, 
range 0 -  84) 8 were in CP and 3 in AP. CP and AP patients were treated with 
400mg and 600mg / day of imatinib mesylate respectively, as part of the Novartis 
UK Expanded Access Programme, at our institution. Follow-up sampling on CCR 
and non-responders was performed after a median period of 6 months (range 4 -  
9) and 8 months (range 2 - 1 4 )  respectively. To correct for variation in staining 
between experiments separated by time in the same patients, a correction factor 
was applied based on the control cell kMESF values (Equation 2). Those 
achieving a CCR demonstrated a mean increase in telomere signal of 2.4 ± 2.0 
kMESF, consistent with the re-establishment of primarily Ph” haemopoiesis 
(Figure 4-12). After correction for age, patients went from 2.3 ± 1.6 kMESF below 
to 0.6 ± 1.2 kMESF above that expected for normal granulocytes. In contrast, 
those patients who remained 100% Ph^ underwent a mean telomere loss of 0.9 ± 
2.3 kMESF, a rate of loss that is approximately 20 times that of the granulocyte 
compartment in cross -  sectional data from normal individuals.
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Figure 4-12 Telomere dynamics over time in cytogenetic responders and 
non-responders to imatinib therapy
To calculate relative rates of telomere loss, 11 patients who remained 100% Ph+ 
despite imatinib therapy had follow -up telomere measurements performed (see 
text). These patients (100% Ph*) showed a mean rate of telomere shortening of 
approximately 20 x the rate expected from cross-sectional data from normal 
volunteers. Conversely, and as expected, the restoration of polyclonal 
haemopoiesis (0% Ph*) resulted in an increase in mean telomere length. 
Histogram bars represent the mean change, with standard error bars shown. Tel, 
telomere length.
4.1.6 Discussion
In this chapter we have determined the degree, rate and potential prognostic 
significance of telomere shortening in CML. Using several methods (comparison of 
cohorts at different disease stages, age-corrected comparisons, measurement of 
delta-tel incorporating a benign control population of presumably normal telomere 
length, and repeat sampling of responding, non-responding and progressing 
patients) we have established that the degree of telomere shortening has
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prognostic significance at diagnosis, and proceeds rapidly with progression of 
disease. Models of telomere dynamics in CML suggest that significant telomere 
loss at diagnosis could lead to early progression of disease, as a result of telomere 
dysfunction and genetic instability (cell crisis. Figure 4-1). Consistent with this, our 
data have shown that delta-tel correlates to a significant degree with the Hasford 
risk score. It should be emphasised that risk definition is not simply a reflection of 
an early or late diagnosis: in an important study involving 83 patients with pre­
diagnostic blood counts (up to 36 months before CML was diagnosed), the length 
of the diagnostic latency was independent of the calculated prognostic score 
(ICSG CML 1987). Such scores would seem therefore to be true indicators of 
disease 'aggressiveness', rather than simply reflecting the time taken to diagnose 
the illness, and consequently the remaining survival.
The lack of any age-corrected difference in expanded T-cell telomere length 
between the prognostic groups argues against any predisposing influence of 
normal telomere length in disease evolution. Features of high-risk disease in the 
Hasford scoring system {i.e. large spleen size, high blast, basophil, eosinophil and 
platelet count, and advanced age(Hasford, et al 1998)) may reflect the size and/or 
rate of growth of the Ph* clone with greater degrees of telomere loss arising as a 
consequence. One drawback of this score is that it was based on cohorts of 
patients treated with IFN, and treatment options for CML have now changed. The 
introduction of the selective BCR-ABL tyrosine-kinase inhibitor imatinib mesylate 
(IM) has resulted in high cytogenetic response rates in CP disease (Druker, et ai 
2001b), but much less so in AP and BP (Druker, et ai 2001a) where additional 
mutations co-exist with BCR-ABL. Delta-tel could be of value as a surrogate 
marker for advanced disease and could be predictive of response to IM. 
Unfortunately the variety of treatments administered to our cohort of newly
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diagnosed patients did not permit this analysis. As recently shown, cytogenetic 
and molecular responses achieved with IM therapy are associated with a 
normalization of previously shortened telomere length, arguing against a pre­
existing telomere length deficit in normal hemopoietic cells from patients with CML 
at the time of malignant transformation (Brummendorf, et al 2003). Our current 
data support this view, with a return to 0.6 kMESF above baseline for age in 
patients achieving CCR. Sequential measurements to establish the rate of 
telomeric attrition in individual patients may further increase the value of this 
assay, as rates of shortening appear to vary widely between patients, and allow 
estimation of time to crisis and disease progression. With recent improvements to 
the technique by Lansdorp’s group increasing reproducibility (Baerlocher, et al 
2002) we would advocate validation of delta-tel measurements as a prognostic 
indicator within a large prospective clinical trial.
Telomeric attrition in PBL is generally assumed to result almost entirely from 
replicative loss, and as such may be used as a marker for stem cell turnover. That 
the Ph* HSC compartment is cycling more rapidly than their Ph' counterparts, 
thereby explaining the greater telomere loss, is suggested by two main 
observations. Firstly, ^H-thymidine suicide assays (specifically toxic for S-phase 
cells) demonstrate normal PB and BM colony forming cells (CFCs) to be largely 
quiescent, whereas those from CML are predominantly in cycle (Eaves and Eaves 
1987). Secondly, cell cycle analysis of GD34* cells from normal donors and CML 
patients has shown a greater percentage actively cycling in the latter group 
(Holyoake, et al 1999a). Our data from normal volunteers are in keeping with 
normal HSC dividing every 1-2 years (assuming a loss of 50 -  100bps per 
division) (Rufer, et al 1999). We have also confirmed previous estimates of a 
mean Ikb loss at time of presentation of CML (Brummendorf, et al 2000),
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suggestive of an extra 10-20 HSC divisions at the time of presentation. With our 
additional data, a more detailed model of telomere dynamics at diagnosis and 
during progression of CML is proposed (Figure 4-13).
Diagnosis
BP BP
Cllnlast asoase wHhOccult tttsease i
stem cell 
acquires 
ber-abi
Time from acquisition of Ph* stem cell 
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Figure 4-13 Updated model of telomere dynamics over time in CML
Our data allow the proposal of a more detailed model of telomere shortening, 
allowing for certain assumptions (see text). Based on data from the atomic bomb 
survivors in Hiroshima, there is a mean latent period of 6-7 years from (presumed) 
acquisition of BCR-ABL before clinical presentation (Ichimaru, et al 1981). 
Although low-risk patients display a rate of telomere loss during this period only 
slightly greater than that of normal (approximately 300bps), high-risk patients have 
lost a mean of 3.4 kMESF (approximately 1.7kb) at the time of diagnosis (giving a 
rate of loss some 14-fold greater than normal). Our data also indicate telomeric 
shortening after diagnosis at a rate of 10 - 20 times that of normal PBL, pointing to 
a biphasic or accelerating rate of loss before onset of BP. The latter is 
characterised by loss of some 40% of telomere sequence compared with that at 
diagnosis.
BP patients exhibit an age-corrected mean telomere loss of 6.2kMESF (3.Ikb), 
indicating at least 30 -  GO additional CML HSC doublings. However, all such 
models require a number of assumptions, as follows: the only mechanism of 
telomere loss is replicative; the amount lost remains constant with each cell 
division and is similar in CML and normal individuals; the number of divisions
Chapter 4, 133
required to produce the progeny (in which telomere length is measured) remains 
constant; and finally, and possibly most importantly, HSC and progenitor 
telomerase activity remains unchanged throughout the course of the disease and 
is similar in CML patients and in normal individuals. A paucity of data on 
mechanisms of telomere loss in CML and telomerase expression in the HSC 
compartment currently allows such assumptions to be made. Alternative 
mechanisms of telomere loss require to be considered however. It is known that 
telomere repeat sequences are highly susceptible to damage from reactive oxygen 
species (ROS) (Oikawa and Kawanishi 1999), which can cause telomere 
shortening in human diploid fibroblasts in vitro (von Zglinicki, et a /2000). Sattler et 
al have recently demonstrated a marked increase in ROS activity in a tetracycline 
dependent BCR-ABL expressing cell line (Sattler, et ai 2000). These data, 
together with the recently described BCR-ABL mediated down-regulation of the 
DNA repair complex DNA-PKcs (Deutsch, et ai 2001), may predict a mechanism 
of telomeric DNA damage by ROS, ineffective repair and potential sequence loss. 
Thus telomeric sequence loss in CML could be a surrogate indicator of DNA 
damage and repair inefficiency. It is also possible that telomere attrition could be 
facilitated by telomerase dysfunction. Such a mechanism is most likely responsible 
for the bone marrow failure and increased incidence of cancer observed in the 
human disorder DKG (1.6.6), where acquisition of oncogenic mutations are 
thought to be secondary to critical telomere loss. It is therefore of importance to 
characterise the expression of the major telomere components in CML, given the 
rapid rate of telomere attrition.
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5. Results 3
5.1 Altered hTERT expression during the progression of 
CML
5.1.1 introduction
If one is to accept the hypothesis that telomere shortening has evolved primarily 
as a tumour suppressor mechanism, logic dictates that tumours must circumvent 
this obstacle to achieve immortality. The majority (>90%) do so by expressing 
telomerase at levels well above those of normal somatic tissue (Kim, et al 1994). 
In addition, one may also expect telomerase to be upregulated relatively late in 
tumour development, when selection pressure for telomerase expressing cells {i.e. 
critically short telomeres) is exerted. Whether this involves a selective outgrowth of 
high-telomerase activity cells (such as a malignant stem-cell compartment) that 
has been present from early tumourigenesis, or involves telomerase upregulation 
(via additional mutations) in a telomerase competent population, is unknown. CML 
is relatively easy to study in this regard; early and late serial samples from 
evolving disease are easily obtainable, and clinical and pathological staging 
indices are well established.
Broccoli et a/., in the first study to use the TRAP assay to study CML, failed to 
demonstrate any increase in telomerase activity in samples from CP or early AP 
CML when compared to that of normal PBL (Broccoli, et al 1995). Many of the 
CML samples (BM MNCs) actually had lower activity than the respective purified 
normal cell sub-populations (granulocytes, lymphocytes and monocytes). Indeed 
prior to these data, normal PBL were considered to be telomerase-negative, and it 
was only following improvements in TRAP sensitivity that such activity could be
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demonstrated. Interestingly, the telomerase activity levels from de~novo acute 
leukaemias were significantly higher than from CP CML; however numbers in this 
early study were small, and conclusions were therefore limited. Progression from 
CP to BP disease was associated with a statistically significant (5-6 fold) increase 
in telomerase activity in a small study which also demonstrated a huge variation in 
BP telomerase activity in BM MNCs (Ohyashiki, et al 1997c). Highly variable 
telomerase activity in BP has also been confirmed recently, although only a small 
non-significant increase in BP BM (as compared to CP) was demonstrated 
(Verstovsek, et al 2003a). The authors did however suggest that relatively ‘high’ 
levels in CP were associated with shorter survival, although no comparative data 
from normal BM were presented. A 2-fold increase in telomerase activity was 
observed by Engelhardt et a i on progression from CP CML to AP or BP, in CD34^ 
selected populations of cells (Engelhardt, et al 2000). This study was flawed 
however, in not confirming that the CP CD34^ cells were BCR-ABL positive (Ph' 
CD34^ cells are commonly found in diagnostic, particularly BM, specimens). From 
these studies it is apparent that there is considerable heterogeneity in telomerase 
activity in CML (particularly in BP disease), with a possible trend to increased 
levels with disease progression. As the major determinant of telomerase is thought 
to be hTERT, it is therefore of considerable interest to quantitate the expression 
profile of this gene in CML, including its alternatively spliced isoforms. Additionally, 
the dramatic rates of telomere shortening described in the previous chapter raise 
several questions about the progression of CML;
1. As hTERT expression is a major determinant for telomerase activity, is it 
upregulated during the progression of CML?
2. Do splicing patterns of hTERT mRNA alter with disease progression?
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3. Can quantitation of hTERT expression in CML PBL be used as a marker to 
define disease progression?
These questions will be addressed in this chapter.
5.7.2 Quantitation of mRNA using the LightCycler™
instrument
A commercially available kit was used to quantitate hTERT from total RNA, which 
utilised PBGD as a housekeeping gene to correct for RNA loading (Figure 5-1). It 
should be emphasised that the probes and primers in the LightCycler™ hTERT kit 
are designed so as not to detect the (3-deleted altered splice variant 
(Manufacturer’s Data Sheet, Roche Diagnostics). Although the a-deleted form may 
still be detected, this forms only a very small part of the overall hTERT mRNA 
splice-pattern (typically less than 1-2% and often zero, see later), and the assay 
may be considered as detecting full-length transcripts {i.e. +a+(3) only.
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Figure 5-1 Quantitation of hTERT mRNA using the LightCycler™
A representative set of data for 3 samples (x, y and z) obtained from a single Q- 
RT-PGR run is shown. Panel A shows the sigmoid detection curves generated for 
hTERT. A series of RNA standards were run in parallel (B), allowing generation of 
a standard curve (0). The crossing points (cycle number at which fluorescence is 
above background) obtained from the samples in A were used to determine the 
transcript concentration from 0 and D. These steps were performed by the system 
software. Simultaneous measurement of PBGD allowed normalisation for RNA 
loading, and calculation of hTERT expression as a percentage of PBGD 
expression was performed as in D.
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Figure 5-2 hTERT mRNA expression in a range of cell lines and normal 
tissues.
Expression of hTERT mRNA from ALT and CML cell lines and cDNA from normal 
spleen and testes was measured. cDNA can be easily used in the assay in place 
of RNA by omitting RT (and correspondingly increasing the H2O) in the master mix. 
A range of CML lines was analysed, and the other samples were done in 
duplicate. The values obtained were: ALT, 0.04% and 0.06%; spleen 1.1% and 
1.3%; testes 6.2% and 6.7%; KY01 33.3%, LAMA84 62.7%, K562 21.9%, EM2 
22.1%, KU812 17.1%, BV173 34.7%, T0M1 20.2%, ALL-MIK 33.8%. Mean values 
are shown with standard error bars.
To assess the dynamic range of the assay we measured hTERT expression in a 
range of samples (ALT cell lines, which do not express telomerase, normal spleen 
tissue, normal testes and a range of CML cell lines. Figure 5-2). As predicted 
hTERT mRNA was low / undetectable in the ALT cell lines, with the highest mean 
activity (approximately 30%) in the CML cell lines. Testes, a telomerase-high 
normal tissue had a mean hTERT/PBGD ratio of 6.4%. The inter- and intra- 
experimental reproducibility of the assay was studied by analysing duplicate 
samples (Table 5-1).
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Sample Result 1 (hTERT/PBGD)%
Result 2 
(hTERT/PBGD)% Mean SD CV (%)
1 23.3 20.3 21.8 2.1 9.7
2 4.0 5.7 4.8 1.2 24.8
3 4.6 6.1 5.4 1.1 19.8
4 3.2 2.3 2.8 0.6 23.1
5 11.5 8.2 9.8 2.3 23.7
6 3.4 3.6 3.5 0.1 4.0
7 6.8 4.8 5.8 1.4 24.4
8 2.8 2.0 2.4 0.6 23.6
9 7.3 7.8 7.6 0.4 4.7
mean 1.1 17.5
B
Sample Result 1 (hTERT/PBGD)%
Result 2 
(hTERT/PBGD)% Mean SD CV (%)
1 43.1 43.8 43.4 0.5 1.1
2 12.1 12.3 12.2 0.1 1.2
3 3.3 3.5 3.4 0.1 4.2
mean 0.3 2.2
Table 5-1 Reproducibility of Q-RT-PCR for hTERT over a range of values
Intra-run variation in paired analyses of identical samples (B) was considerably 
less than that observed between runs (A). The relatively low dynamic range of 
results is inevitable, due to the use of a ubiquitous and highly expressed 
housekeeping gene (PBGD) with which to compare a relatively rarely expressed 
transcript (hTERT). Although inter-run variation was within acceptable limits, 
wherever possible a range of different cohorts or, when required, paired samples, 
were run in each PCR run to minimise this effect. The highly reproducible intra-run 
data meant that analysis of samples in duplicate was not required.
5.1.3 PBL hTERT expression Is increased with advanced CML
To determine whether hTERT was upregulated in CML PBL (thereby validating Q- 
RT-PCR for hTERT mRNA as a marker of disease progression) we analysed total 
RNA extracted from over 70 samples, including normal individuals and CML 
patients at various stages of disease (see Section 2.1.8, Table 5-2 and Figure 
5-3. The data from all CML patients is tabulated in Appendix 1). Whole PBL were 
used both to avoid enriching for lymphocytes via a Ficoll-Hypaque step (thereby
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confounding the analysis with telomerase expressing normal cells), and to 
determine the possible clinical utility of the assay (where minimal sample handling 
and high throughput are important). Normal allogeneic donors were included 
because of their high ‘left-shifted’ (immature) granulocyte count (n=3, total WCC 
was between 20-30 x 10®/L after 5 days of rHu-G-CSF), thereby bearing a 
resemblance to the mixed immature / mature myeloid picture typical of CP CML. 
Transcripts were detected in all samples apart from 6 (3 CML at diagnosis, and 3 
in established CP). There was no significant increase in hTERT transcripts in CP 
CML as compared to normal PBL. AP and BP demonstrated mean hTERT 
transcript levels significantly above those of normal PBL (but not, interestingly, CP 
CML at diagnosis); however the range of expression was extremely wide 
(particularly when BP was considered as a group). The >100 fold variation in 
hTERT expression in BP was not simply due to sampling differences (blast counts 
varied from 30%- 80%), although these may have had a minor influence. Indeed 7 
of the BP specimens had hTERT levels on or below the mean level for normal 
PBL. All of these 7 samples were of myeloid lineage and, interestingly, all 3 BP 
samples that had hTERT levels similar to those of cell lines {i.e. >20%) were 
lymphoid on immunophenotype analysis (data from routine clinical analysis, and 
therefore not shown).
These data prompted separate analysis of the BP subgroups, with lymphoid BP 
exhibiting significantly greater hTERT expression (Figure 5-4). Only a small 
number of paired CP and BP RNA samples were available for analysis: recovery 
of good quality RNA suitable for Q-RT-PCR was rarely achieved from archived 
PBL CP samples due to the poor recovery of neutrophils from frozen (with release 
of nucleases etc). The dramatic increase in hTERT expression on progression 
from CP or AP to BP in both lymphoid BP samples (as compared to myeloid,
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Figure 5-5) show that increased hTERT expression is not an inherent property of 
these samples during CP, and is a genuine characteristic of the BP phenotype.
Category n Mean Median SD Range
P value vs 
Normal PBL/CML Dlag
(hTERT/PBGD)%
Normal PBL 8 1.3 1.1 1.2 0.3-3.8 NA/ NA
Alio Don 3 0.4 0.5 0.3 0.1 -0.7 NA/NA
CML Diagnosis 18 3.4 3 2.6 0 -7 .5 0.1 / NA
CML estCP 7 1.4 0.2 2 0 -5 .2 0.4 / 0.07
CML AP 13 6 5.4 4.5 0.7-16 0.009*/0.09
CML BP (all) 21 7 3.3 9.1 0.2 - 34.4 0.03*/0.4
CML BP (Myeloid) 15 3.4 1.9 3.3 0.2-10.5 0.17/1.0
CML BP (Lymphoid) 6 17.4 17.4 12.6 4 - 34.4 0.002* / 0.009*
Table 5-2 Summary statistics for hTERT expression in normal and CML PBL
Descriptive statistics and p-values (Mann-Whitney U-test) are shown for each of 
the cohorts studied. A wide range of values was apparent, most marked for BP 
samples. Considerable overlap with normal values was seen for all CML cohorts 
apart from lymphoid BP. Alio Don, allogeneic donor; estCP, established CP; SD, 
standard deviation; * statistically significant p-value.
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Figure 5-3 hTERT expression in normal and CML PBL
A histogram depiction of the data in Table 5-2 Histogram bars represent mean 
values with standard error bars. PBGD, porphobilinogen deaminase.
Myeloid BP 
n=15
Lymphoid BP 
n=6
Figure 5-4 hTERT expression in myeloid vs lymphoid BP.
hTERT expression was significantly increased in lymphoid BP (p<0.01). Bars 
represent mean values.
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Figure 5-5 hTERT expression in paired CP or AP and BP specimens
On progression to BP, all 4 samples showed an increase in hTERT expression. 
The myeloid BP samples (broken lines) increased from 1.9% and 2.2% (both CP) 
to 6.2% and 4.0% respectively. The lymphoid BP specimens (solid lines) 
increased from 1.5% and 7.6% (both AP) to 23.8% and 34.4% respectively. The 
latter levels were similar to those detected in CML BP cell lines (Figure 5-2).
5.1.4 Resolution of alternatively spliced hTERT mRNA by RT-PCR
Altered splicing of hTERT mRNA is a recently described post-transcriptional 
regulatory mechanism of telomerase activity (Section 1.6.9.3.3). As the Q-RT-PCR 
assay only detected full-length hTERT mRNA, we performed RT-PCR with a 
single set of primers to detect the commonly expressed alternatively spliced 
mRNA species (Figure 5-6).
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hT2164F hT2620R
182 bp36 bp
+ a + p (457 bp)
- a + p (421 bp) 
+ a - p (275 bp)
- a - p (239 bp)
PCR
products
Figure 5-6 The reverse transcriptase domain of hTERT mRNA with 
alternative splicing sites and respective PCR products
1, 2 and A-E represent the conserved RT motifs. The position of deletions a and p 
are illustrated (as originally described by Kilian et al (Kilian, et ai 1997)), flanked by 
primers hT2164F and hT2620R. The potential PCR products from the alternative 
splice combinations are shown, with the full-length product (+a+p) extending from 
base 2164 to 2620 (457 bp). Loss of the a domain (-a) removes a 36 bp sequence 
from the A motif, with the translated protein appearing to confer dominant negative 
hTERT activity (Colgin, et ai 2000). Splicing of the p site causes a 182 bp deletion, 
resulting in translation of a non-functional truncated protein (Ulaner, et al 2000). 
Domains 1 and 2 are hTERT specific and A-D are common to all reverse 
transcriptases (Lingner, eta l 1997).
By utilising a single PCR and single primer set, the relative quantities of each of 
the mRNA species could be measured. This was achieved by resolving the PCR 
products on a DNA 1000 chip in the Agilent Bioanalyser and expressing the 
relative amounts of each of the 4 potential mRNA variants as a percentage of total 
transcripts (Figure 5.7).
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Figure 5-7 Eiectropherogram analysis of alternatively spliced hTERT mRNA 
RT-PCR products.
A single set of primers was utilised to amplify the 4 potential alternatively spliced 
hTERT mRNA products. These were analysed on the Agilent Bioanalyzer 
instrument, and quantitated in jL/g//jl. Incorporation of a DNA ladder (A) facilitates 
automatic sizing of each peak, the concentration of which is then determined 
automatically. The relative percentages of each product were then calculated. A 
CML CD34* selected sample exhibiting all 4 potential splice products is illustrated 
(B), with concentrations (and relative percentages of all transcripts) as follows; 
+£7+yff 4.0 jL/g/jul (16.5%), -a+yff 0.5 jjg/jjl (2.1%), +a-jS 19.3 //g//yl (79.8%) and -a-/3 
0.4 /jg//jl (1.7%). RT-PCR for the housekeeping gene GAPDH (22.3 /jg//jl) is 
shown in (C). Sizes (in bps) of each of the relevant peaks are indicated and a ‘gel’ 
like image is shown for comparison in each of the right-hand panels. LM, lower 
marker; UM upper marker.
As a control for cDNA quality and quantity, GAPDH RT-PCR was performed on all 
samples that undenA/ent splice-variant PCR (Figure 5.7). A satisfactory control 
PCR was determined by a clearly visible GAPDH band of 983bp, with a 
concentration of >5.0 jjg//jl.
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5.7.5 Only fulNength (+a+P) hTERT mRNA Is associated with 
telomerase activity
Previous reports have determined that telomerase activity is generally only 
detected in the presence of full length (+a+p) transcripts. We sought to confirm 
these observations in our CML samples. Several samples (all PBL), found to be 
negative for +a+p transcripts were selected for TRAP analysis, and compared to 
those positive for +a+j3 (PBL and CD34^ CML cells). All 4 samples which were 
negative on TRAP assay failed to express +a+(3 by RT-PCR, while the 4 samples 
which did express +a+|3 were positive by TRAP (Table 5-3 and Figure 5-8). The 
TRAP-negative samples were also low / negative for +a+p as quantitated by the 
LightCycler (0%, 0.03%, 1.2% and 2.5% respectively). This illustrates the greater 
sensitivity of the LightCycler platform, and illustrates that low-level expression of 
+a+{3 hTERT does not necessarily translate into TRAP activity as detected by this 
assay. This observation may also imply post-translational mechanisms of 
telomerase control in this cell population.
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Figure 5-8 TRAP analysis of selected CML samples.
TRAP was performed as described and 5pl of product was run on a 12% non- 
denaturing polyacrylamide gel. 6 samples and respective controls are illustrated. 3 
lanes were run for each sample (Ipg and 0.1 pg protein lysate, and 0.1 pg heat 
inactivated lysate respectively, from left to right). Control 1 represents 1000 GLC4 
cell equivalent preparation with a heat treated control, and Control 2 is a 1000 and 
100 GLC4 cell equivalent preparation from left to right respectively). CML samples 
A-F are described in the table below (Table 5-3). The ITAS band (at approximately 
150bp) is illustrated. It can be seen that in lane 1 of sample A no ITAS is visible, 
and the processivity of the enzyme appears to be weak. Lane 2 of sample A 
however (at a 1:10 dilution) has resulted in a diluting out of the TRAP inhibitors, 
and a distinct ITAS band. Thus the processivity of the assay was indeed being 
masked in lane 1. Conversely sample C has no telomeric repeat laddering, but the 
ITAS control is clearly visible. This is a true negative result. It is harder to visualise 
the ITAS in the strongly positive samples (i.e. D and F) because the telomeric 
repeats have sequestered the reaction mix reagents and there is less available for 
ITAS amplification.
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Sample Type UPN hTERT/PBGD(% )
%
+a+3 TRAP
A 34^ - 3.3 17.8 +
B 34* - 3.6 24.1 +
C PBL 13 2.5 0 -
D 34* - 3.6 25.4 +
E PBL 6 0 0 -
F 34* - 16 36.4 +
G PBL 3 4.9 ND +
H PBL 12 0.03 0 -
1 PBL 9 1.2 0 -
Table 5-3 Comparison of TRAP vs. hTERT RT- and Q-RT-PGR in selected 
CIVIL CD34* and PBL samples
9 CML samples were selected based on the presence or absence of +a+p as 
determined by RT-PCR and LightCycler and analysed for telomerase activity by 
TRAP. There was a clear correlation between presence / absence of +a+p 
transcripts as measured by RT-PCR and TRAP activity. For this illustration 
samples are independently named A-l, and the relevant UPN is given for data 
shown in Appendix 1. The CD34^ data is described in full in the next chapter, the 
samples having been used as +o+p positive controls in this case.
5.1.6 Patterns of alternatively spliced hTERT mRNA in CML PBL
To determine if splicing patterns were disease-stage specific, and as an initial step 
in investigating the potential significance of alternative splicing for hTERT 
regulation in CML, we performed RT-PCR for splice variants on 53 PBL samples 
from all stages of CML (Appendix 1). Striking heterogeneity of expression was 
evident, particularly in the BP samples and especially with regard to full-length 
(+a+P) functional hTERT expression. The non-functional, p-deleted (+o-P) variant 
was the most frequently expressed, and to the greatest degree in all but 1/16 
diagnostic samples and 3/17 BP samples which expressed greater levels of +a+p
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than +Q-P). This is in keeping with published results for normal tissues, solid 
tumours and cell lines ((Ulaner, et al 2000, Yi, et al 2001)), where the p-deleted 
(and non-functional) variant is most commonly expressed. In comparison to a 
range of cell lines (described in Figure 5-2), 7/8 (87.5%) of which expressed all 
transcripts, only 12.5% and 29% of diagnostic CP and BP samples respectively 
expressed all. No estCP or AP samples expressed the full range of transcripts. 
The percentage of samples expressing full-length +o+p transcripts, and the 
degree to which they expressed it (as a percentage of total hTERT transcripts) is 
illustrated in Figure 5-9 and Figure 5-10 respectively. It can be seen that BP is 
associated with a greater proportion of samples expressing a greater percentage 
of unspliced full length +a+(3 hTERT mRNA.
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Figure 5-9 Proportion of samples expressing +a+p transcripts at different 
disease stages
Disease progression was associated with near universal expression of full-length 
(+0+P) transcripts, in addition to 100% of the cell lines described in Figure 5-2.
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Figure 5-10 Percentage of total hTERT transcripts which are full-length 
(+0+P)
BP disease was associated with an approximately 3-fold (statistically significant) 
increase in the mean percentage of full-length transcripts. However, as illustrated 
by the SD bars, the range of expression was large. The relevant results for the 
leukaemia cell lines were 18.8±6.8 (mean±SD). The increase in BP full-length 
transcript expression was at the expense of P-deleted variant (+a-p), which 
underwent a significant fall in mean expression levels (from 82.4±19.0 to 
63.6±24.2%, p=0.02). Complete expression data was only available for 4 lymphoid 
BP samples, therefore a valid comparison between myeloid and lymphoid BP was 
not possible.
Two possible ways in which an absolute increase of full-length (+a+p) functional 
hTERT mRNA may occur are via a proportional increase in the total number of all 
hTERT transcripts, or via a shift in splicing patterns leading to an increase in the 
overall proportion of full-length (+a+P) functional hTERT mRNA. While the former 
mechanism does not necessitate a shift in splicing patterns, the latter clearly does. 
To determine whether a shift away from splicing (thereby increasing levels of full- 
length hTERT) influenced overall +a+p hTERT levels (as determined by 
LightCycler), we correlated the percentage of unspliced hTERT transcripts with the 
LightCycler data (Figure 5-11). Somewhat surprisingly (given the heterogeneous 
nature of PBL specimens, and the inherent difficulty in comparing different PCR 
techniques) a significant correlation was seen, at least suggesting that shifting 
splicing patterns may influence overall hTERT activity in this setting.
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Figure 5-11 Correlation of % +a+p transcripts (by RT-PCR) with Q-RT-PCR 
measurement in all CML stages
A significant correlation was observed between these two parameters (R^=0.25, 
p=0.0002), implying that splicing control may play a part in regulating overall 
funcüonal hTERT levels in CML.
So far, these data do not reveal any differences in total {i.e. all potential splice 
variants) quantity of hTERT transcripts detectable at any given stage of disease, 
or in cell lines for that matter. By combining the two data sets for any given sample 
(LightCycler quantitation and RT-PCR for spliced mRNA) a complete picture of 
hTERT gene expression can be estimated by the equation:
Total Transcripts (as % of PBGD) = {100/ % +a+p of all transcripts} x {(+a+p I 
PBGD)x100>
Equation 3 Estimation of total hTERT transcript expression
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The limitations of this approach (other than the results are an estimate) are that 
samples failing to express full-length transcripts (either by RT-PCR and / or Q-RT- 
PCR) cannot be included in the analyses, thereby potentially skewing the data. 
With these reservations in mind however, the comparison of total transcript 
quantities between the disease stages is of interest
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Figure 5-12 Estimated total hTERT transcript expression
Using Q-RT-PCR and RT-PCR data (defining the quantity of +a+p hTERT relative 
to PBGD and the percentage +o+p hTERT of total transcripts respectively), the 
total expression level of all hTERT mRNA variants was estimated as a percentage 
of PBGD expression. Due to the limitations of the calculation (see text), only 4 
diagnostic CP and 2 est CP samples could be included, and are illustrated for 
completeness. There were no significant differences in hTERT expression 
between diag CP, AP or BP. The cell lines exhibited greatly increased expression 
however (p=0.009 and 0.0008 vs. AP and BP respectively).
Total hTERT transcripts were in significantly greater abundance in cell-lines than 
primary human CML samples. Indeed there were no statistically significant 
differences between any of the material from the different disease stages, where 
numbers permitted adequate analysis (namely CP at diagnosis, AP and BP).
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5.1.7 Discussion
We have demonstrated Q-RT-PCR for hTERT to be a reproducible technique, 
which is considerably more sensitive than RT-PCR. A wide dynamic range of 
hTERT expression was evident, and this correlated broadly with the published 
range of telomerase activity (by TRAP) within these samples; namely high in 
tumour or leukaemia cell lines, moderate in HSC populations and testes, low or 
undetectable in PBL and absent in ALT cell lines. Additionally, only full length 
hTERT transcripts (+a+P) were detected by Q-RT-PCR, and we have established 
that such transcripts are a prerequisite for detectable TRAP activity.
Several aspects of +a+p hTERT expression in CML samples from different 
disease stages are of interest. Firstly, CML PBL samples at diagnosis had 
comparable expression levels to normal PBL. This is not surprising: despite their 
clonal nature CML PBL cells are in various stages of myeloid terminal 
differentiation and such cell types are not typically associated with significant 
telomerase activity. Secondly, despite consisting of at least 30% blasts (by 
definition), the BP samples (as a whole) failed to show a significant mean increase 
in hTERT expression over CP PBL, and demonstrated a large range of values. 
However, LBP samples had significantly greater hTERT expression than MBP. 
This observation suggests that hTERT ‘competent’ cell types {i.e. B-lymphoid cells 
in this case) have an inherent ability to upregulate hTERT expression in a similar 
fashion to their normal counterparts, and that this may facilitate high expression 
during disease progression. Thirdly, despite no significant increase in mean 
absolute +a+p hTERT levels, disease progression was associated with a shift in 
splicing patterns; BP samples exhibited significantly less splicing (primarily of the 
+a-(3 variety), with a proportional increase in unspliced full-length +a+(3 transcripts. 
Indeed a weak (but statistically significant on AN OVA analysis) correlation was
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demonstrated between overall +a+p hTERT levels detected by the LightCycler, 
and the proportion of +a+p transcripts of total. This raises the intriguing possibility 
that subtle changes in splicing of hTERT mRNA may be involved in determining 
functional +a+p transcript levels, and hence telomerase activity.
Accumulation of a particular mRNA species is a function of 3 cellular processes; 
namely transcription rate, mRNA half-life and alternate splicing activity. If one 
assumes that hTERT mRNA half-life remains constant during disease progression, 
then our attempt to quantify expression of all hTERT transcripts suggests that 
transcriptional rate does not change during CML progression, and that even BP 
samples have much lower (approximately 7-fold) expression than equivalent cell 
lines. However, as described above, within this picture of unchanging' expression 
there exists a shift towards preferential expression of +a+ p transcripts in the BP 
samples.
For the reasons outlined in Section 5.1.3, these experiments were performed upon 
PBL from various stages of CML. From our data it is clear that hTERT 
measurement in PBL per se would not be helpful in determining disease 
progression: overlap between disease stages is considerable and it appears to 
offer no additional advantage beyond conventional classification of disease stage. 
However it remains possible that a rising hTERT level (from baseline at diagnosis) 
may herald disease progression. The rarity of paired samples in our study made 
this difficult to determine however. Almost certainly, the major confounding factor 
with utilising PBL material is the cell mix involved, with changes in hTERT 
expression reflecting alterations in relative proportions of cell types. Thus BP 
samples are likely to express more hTERT as a consequence of them containing 
large numbers of CD34^ cells, rather than as a consequence of a more subtle shift 
at the molecular level causing a change in gene expression. Indeed the marked
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heterogeneity of hTERT expression patterns illustrated in Appendix 1 (particularly 
in BP) are likely to be due, in large part, to heterogeneity of cell content. 
Additionally there is marked disease heterogeneity from both clinical and 
laboratory points of view. Although recent advances have been made in 
determining the molecular nature of this (particularly with deletions of the 
derivative chromosome 9 (Huntly, et al 2001)) much still needs to be learned. 
From this aspect it is therefore not surprising that inconsistent patterns of 
telomerase expression are detected; it is their significance that needs to be 
determined. To further define the nature of such changes, CP and BP CD34'*' cells 
require to be studied.
Our data would indicate that upregulated expression of hTERT is a rare event 
during progression of CML (the implications of this will be covered in the final 
discussion) that is largely dependent on cell-background {i.e. lymphoid or myeloid) 
and is consistent with published data showing non-significant increases in TRAP 
activity upon entry into BP (Verstovsek, et al 2003a). This is despite the detection 
of marked telomere shortening in BP samples (see previous chapter). As far as we 
are aware, no previous attempts have been made to sub classify BP samples with 
regards TRAP activity, and it is possible that the findings of such studies reflect 
different proportions of BP phenotypes {I.e. MBP, LBP or mixed lineage). This 
observation also raises questions regarding telomere maintenance during CP 
disease and upon progression to BP. Many studies performed upon solid tumour 
material demonstrate increased TRAP activity in the specimens, in comparison to 
surrounding normal tissue and earlier stage of tumourigenesis, and this is 
generally accompanied by increased hTERT expression.
In summary, despite the considerable telomere shortening observed during 
progression of CML from CP to BP, increased expression of functional hTERT
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transcripts (at least compared to CP PBL) is apparently not a prerequisite for MBP 
disease. This raises the intriguing possibility that CML is primarily a disorder of 
telomere shortening, and does not conform to conventional models of 
telomere/telomerase dynamics in tumourigenesis. To answer this question more 
definitively it is necessary to perform more detailed studies of telomerase 
component expression on CD34^-selected cell populations.
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6. Results 4
6.1 Expression of telomerase components and 
telomerase activity In CP CML and non-CML CD34* 
cells
The finding, albeit inconsistently, of elevated in-vitro telomerase activity in CP CML 
CD34^ cells (Engelhardt, et a! 2000, Ohyashiki, eta! 1997c) presents something of 
a paradox: the rapid rate of telomere loss observed by ourselves and others would 
suggest that in-vivo it is unable to prevent telomere loss. If one accepts that the 
conventional TRAP assay is representative of telomerase activity in-vivo it is 
therefore difficult to explain the rapidity of telomere loss observed at this early 
stage of the disease.
Detection of TRAP activity however does not always reflect ability to maintain 
telomeres (Ouellette, et a! 1999) and this is corroborated in-vivo with the 
observation that telomerase-competent HSC continually lose telomere length. 
Indeed mTR haploinsufficient mice (mTR'^^) have defective telomere elongation 
yet fail to demonstrate any reduction in telomerase activity by TRAP (Hathcock, et 
a! 2002). Additionally, mTERT^^ and mTERT'^^ ES cells have no detectable 
differences by TRAP (Liu, et ai 2000b), despite greatly increased telomere loss in 
the former. These authors suggested that differences in dosage of the main 
telomerase components, while limiting in-vivo, were not reflected in-vitro by TRAP.
It is therefore conceivable that undetected telomerase dysfunction in the CML 
HSC compartment could contribute to the observed rate of telomere loss. The 
precedent for such a mechanism has already been set, in the form of the inherited 
disorder dyskeratosis congenita (see section 1.6.6). Not only is the phenotype of
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these individuals similar to mTR"^ " mice (in that it affects primarily tissues with a 
high turnover) (Blasco, et a! 1997, Lee, et al 1998), but it is associated with 
dramatic telomere shortening and an increase in cancer incidence. The latter is 
thought to be due to the genetic instability resulting from critical telomere 
shortening and thus provides direct support for the hypothesis that telomeres, 
while normally limiting for tumourigenesis in-vivo, may promote clonal evolution 
and tumourigenesis when dysfunctional. One crucial aspect of this model remains 
unexplained however; namely the mechanism of telomere maintenance in tumour 
cells with constitutionally impaired telomerase function. The most obvious 
explanation is that these tumours depend upon the ALT mechanism; however 
there is, to our knowledge little evidence as yet to support this model. It is also 
conceivable that such cells (given the intense selection pressure exerted by short 
telomeres plus a genetically unstable background) may acquire additional means 
with which to upregulate telomerase. Admittedly DKC is rare: however the 
association of short telomeres and genetic instability is not, and has been 
observed in many solid tumours and leukaemias. It therefore is an intriguing 
prospect that clonal evolution, at least in some tumours, may be propagated by the 
telomere shortening induced by early telomerase dysfunction.
The aim of this chapter was therefore to comprehensively characterise and 
quantitate expression of the major telomerase components and telomerase activity 
in purified normal and BCR-ABL-positive candidate stem ("CD34 )^ cells.
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6.1.1 Peripheral blood BCR-ABC CD34* cells demonstrate 
increased cell cycle activity
CP CML is associated with marked telomere shortening detectable in PBL, 
therefore we measured relative cell-cycle activity in a pure progenitor cell/HSC 
(CD34^ selected) population. Additionally, as TRAP activity is reduced or absent in 
Go populations, such data also allow correlation of differences in TRAP activity 
with the cell cycle status of the cell sample. Because of the requirement to resolve 
the Go population we utilised the high-resolution cell cycle analysis method as 
described by Jordan et al. (Jordan, et al 1996). Resolution of Go vs. Gi and 
S/G2/M (Figure 6-1) demonstrated significantly fewer CML CD34^ cells in stage Go 
and correspondingly greater numbers in S/G2/M (Table 6-1), as compared to non- 
CML. This is in keeping with the increased cell cycling observed in CML 
progenitors using other methodologies (reviewed in (Holyoake, ef a/2002)).
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Figure 6-1 High-resolution cell-cycle analysis of CD34* cells
A representative CML CD34* sample is shown. The addition of FITC labelled Ki67 
anübody (a cell cycle activation antigen that is expressed in early Gi) to 7-AAD 
(detected in channel FL3) allowed discrimination of Go vs. Gi. Gating on the 2N/4N 
intact cell population (A) does not allow discrimination of Gq/Gi on FL-3 analysis 
alone (B). KI67 expression (channel FI-1) resolved these two populations however 
(D), as compared to the isotype control (0).
Samples
(number)
% CD34 
(median, 
range)
% BCR- 
ABL pos 
(median, 
range)
% in Go 
(meanlSD)
% in Gi 
(meantSD)
% in S/G2/M 
(meanlSD)
CML (16) 94.1 (88.9- 98.1)
96.3 (86.5- 
99.4) 5.8±4.4* 79.6±5.4 11.8±4.4‘ *
Non-CML
(14)
94.1 (88.0- 
99.0%) NA 15.0±8.r 74.9±8.7 5.1 ±4.2**
Table 6-1 CD34* cell purity and cell-cycle status
High purity CD34^ cells were selected and subsets used for all the experiments in 
this chapter. CML patients were chosen with high percentages of BCR-ABL- 
positive cells in the CD34^ population (one patient was excluded because this was 
low at 26%). Significant differences in percentages of cells were observed 
between the Go and S/G2/M compartments for the two populations (but not 
between Gi). * and **, p<0.05; SD, standard deviation; NA, not applicable.
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6,1.2 In-vitro telomerase activity, as measured by TRAP, is 
increased in the BCR-ABL^ CD34* compartment and 
correlates with ceii-cycie profile
It is conventional to assess telomerase activity semi-quantitatively by using the 
TRAP assay. The methods used for the quantification step are numerous; we 
utilised the Agilent Bioanalyser with a DNA-500 Chip to resolve the 6-bp 
incremental peaks (Figure 6-2). For all samples the first 6 such peaks were added 
together (in ng/pl) to generate an 'area under the curve’ as previously described 
(Hamad, et al 2002). This was then expressed as a percentage of the activity 
observed from a 10,000 GLC-4 equivalent cell preparation.
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Figure 6-2 Quantitation of TRAP activity using the Agilent Bioanalyzer
Analysis of TRAP products was performed on the Agilent as described in the text 
(a non-CML CD34* sample is illustrated). The first peak, which consisted of the 
primers plus one telomere repeat, was excluded (Figure 2-3). The next 6 peaks 
(as shown) had sizes of 56, 62, 68, 74, 80 and 86 bps respectively, and the 
respective concentrations were 0.13, 0.07, 0.03, 0.02, 0.03 and 0.03 ng/yul. The 
sum of these products (0.31 ng///l) was expressed as a percentage of the sum of 
10"^  GLC4 cell activity (0.91 ng/>L/l), which in this case was 34.0%.
All CD34'’ samples expressed TRAP activity, with higher levels (some 1.5-fold) 
detectable in CML (n=16) as compared to non-CML (n=8) cell populations (94.8 ± 
22.1% vs. 64.6 ± 21.3% respectively, mean percentage activity of 10"^  GLC4 cells 
± SD, p=0.004). This activity correlated significantly with the cell-cycle profile of the 
samples however, with samples containing a greater proportion of Go cells {i.e. the 
non-CML samples) having the lowest TRAP activity. Conversely there was a trend
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towards samples with greater numbers in S/G2/M (i.e. primarily CML) having 
greater TRAP activity. This would suggest that the relatively small differences in 
TRAP between these populations are primarily a reflection of cell-cycle status, and 
may not reflect any genuine cell-to-cell increase in telomerase activity in CML. 
However only studies looking at sorted cell-cycle stage specific populations would 
be able to resolve this issue.
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Figure 6-3 TRAP activity in CML vs. non-CML CD34* cells
A small (1.5-fold) but statistically significant increase in TRAP activity was 
observed for the CML samples. Activity was expressed as a percentage of that 
seen in 10,000 GLC-4 cells.
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Figure 6-4 TRAP activity correlates with cell-cycle profile of CD34* cells
TRAP activity was seen to correlate inversely with the percentage of CD34^ cells 
in Go, as might have been expected (adjusted r^  0.17, p=0.02). This relationship 
was only observed when all samples (CML and non-CML) were analysed together, 
presumably as this increased the dynamic range of measurements. Conversely a 
trend towards higher TRAP levels was observed with increasing numbers of cell in 
S/G2/M (adjusted 0.11, p=0.06). No correlation was observed with Gi (adjusted 
1^ 0.005, p=0.3). ■, CML samples; □, non-CML samples.
6.1.3 Full length functional (+a+P) hTERT mRNA expression is not 
increased in BCR-ABC CD34* celis
Interestingly, despite their leukaemic origin, increased cycling status and TRAP 
activity, the CML CD34'^ cells did not demonstrate a significant increase in +a+p 
hTERT expression (Figure 6-5, p=0.08) as measured by Q-RT-PCR. A trend 
towards higher levels in the CML samples was largely the result of two samples 
which exhibited markedly higher +a+P hTERT expression than the remainder; 
however there were no obvious differences in their clinical parameters (e.g. on 
review of their diagnostic data they were definitely in CP). Comparison of the 
median level for both groups confirmed this; at 3.6% and 3.2% for CML and non- 
CML respectively. No correlation (either positive or negative) was observed 
between +o+p hTERT expression and TRAP activity or percentage of cells in each
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of the cell cycle stages for CML, non-CML or combined samples. However, Q-RT- 
PCR on the LightCycler quantitated full-length (+a+(3) hTERT mRNA only; it is 
known that alternative splicing may play a role in regulation of hTERT expression 
and that other hTERT transcripts may be present, some of which may have a 
regulatory role.
non-C M L 34C M L 34
Figure 6-5 +a+p hTERT mRNA expression by Q-RT-PCR in primary CD34* 
cells
Total RNA from CML vs. non-CML CD34^ cells was analysed for expression of 
+0+P (full-length functional) hTERT. Although there was a trend towards higher 
levels of +a+(3 hTERT in the CML samples, this did not reach statistical 
significance (p=0.08) and was skewed by two samples exhibiting high levels; 
median values for the two groups were similar (see text).
6.1.4 Altered hTERT mRNA splicing profiles in BCR-ABL~positive 
and negative CD34^ ceils
Two possible ways in which an absolute increase of full-length (+a+P) functional 
hTERT mRNA may occur are via a proportional increase in the total number of all 
hTERT transcripts, or via a shift in splicing patterns leading to an increase in the
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overall proportion of full-length (+a+P) functional hTERT mRNA. While the former 
mechanism does not necessitate a shift in splicing patterns, the latter clearly does.
As described previously, RT-PCR for hTERT splice variant expression was 
analysed on the Agilent, and the percentage of each transcript (of total) calculated. 
By combining these data with quantitative (LightCycler) analysis of full-length +a+p 
hTERT expression, a complete expression profile of the hTERT gene can be 
derived Figure 6-6. As +a+p hTERT mRNA is quantitated against the PBGD gene 
with the LightCycler system, and its percentage (of total transcripts) is determined 
by splice-variant RT-PCR, a quantitative estimate of total hTERT transcripts {i.e. 
all spliced isoforms) can be made (as illustrated by histogram height in Figure 
6-6). This was comparable for both CML and non-CML cells. As has been 
previously described, the +a-p variant (P-deleted) was expressed to the greatest 
degree by far, although all samples also expressed the functional +a+p transcript. 
The percentage of all transcripts which were full-length (+o+p) was significantly 
greater for the CML samples (p=0.001), at the expense of the p-deleted (+a-p), 
which was significantly reduced (p=0.004). Interestingly, the percentage of +a+p 
hTERT (of all transcripts) as determined by splice variant RT-PCR displayed a 
highly significant correlation on a sample-to-sample basis with the absolute levels 
(as measured by Q-RT-PCR) for both CML and non-CML samples (Figure 5). 
This suggests that subtle shifts in splicing patterns determine overall +a+p hTERT 
expression in the CD34^ population, rather than the simple on/off +a+p expression 
demonstrated in some previous studies.
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Figure 6-6 Total hTERT expression In CML and non-CML CD34* cells
By combining data from +o+p hTERT Q-RT-PCR and splice variant RT-PCR (see 
text), a complete picture of steady state hTERT expression could be constructed 
(A). Total transcript levels (as indicated by histogram height) were similar for CML 
and non-CML CD34^ cells, however full length +o+(3 transcripts constituted a 
significantly grater proportion of these (as indicated by numbers to the right of the 
bars) in the CML samples (p=0.001). When results generated by the two PCR 
techniques were compared, a significant correlation was observed between +o+p 
hTERT/PBGD and the percentage of +a+p hTERT mRNA as determined by splice 
variant RT-PCR (B & 0).
6.1,5 5~fold lower levels of hTR expression are observed in CP 
BCR'ABC CD34* cells
The other major component of telomerase, hTR, is also tightly regulated in the 
haemopoietic system (Weng, et al 1997), and many studies have shown it to be 
upregulated in tumours (Soder, et a! 1998, Soder, et a! 1997a). We performed Q- 
RT-PCR for hTR on CML vs. non-CML CD34^ selected cells (Figure 6-7).
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Interestingly, the mean hTR level in CML CD34'" cells was some five-fold lower 
than that for non-CML. Together, hTERT and hTR are the minimal requirements 
for reconstituting TA activity in-vitro] it may therefore, be of functional relevance if 
the ratio between these molecules is altered significantly. The use of the same 
housekeeping gene for quantitation as that for hTERT {i.e. PBGD, with the same 
primers, probes and PCR conditions), allowed direct comparison of the relative 
(mean) hTERT/hTR expression ratio. This was approximately 1:10  ^ for hTERT: 
hTR in BCR-ABL* CD34* cells (1:179), and 1:10  ^for non-CML cells (1:991, Figure 
6-13). A 1:10  ^ hTERT:hTR ratio has previously been described for tumour cell 
lines (Yi, at al 2001). No correlation (either positive or negative) was observed 
between hTR expression and TRAP activity or percentage of cells in each of the 
cell cycle stages for CML, non-CML or combined samples
V) =0.002
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Figure 6-7 Reduced hTR expression in CML CD34* cells
Q-RT-PCR was performed for hTR, using identical PCR conditions (and the same 
housekeeping gene) as for hTERT. A significant (p=0.002) reduction in hTR 
expression was observed for the CML samples. Note that the y-axis is on a 
logarithmic scale.
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6.1.6 Dysregulated expression of telomerase components 
following cell-cycle activation of BCR-ABL* CD34* cells
To assess whether expression of hTERT and hTR was altered under conditions of 
increased replicative stress, we cultured CD34^ cells in a defined medium with a 5- 
growth factor cocktail. Cells were harvested at day 3 for two reasons: firstly a 
previous study (looking at TA by TRAP) demonstrated increased TA in CD34^ 
cells beginning at day 3 (Engelhardt, et al 2000), and secondly pilot studies in our 
laboratory with this cocktail showed rapid loss of CD34-positivity after this time 
point concomitant with differentiation. In general the CD34^ percentage at time of 
harvest was adequate for direct analysis (1 non-CML sample had a CD34^ count 
of 52% however and required a further MACS purification step to increase this to 
>85%). The median CD34^ cell purity at analysis at day 3 was 88.9% (range 84- 
90.7%) and 74.3% (69-87.2%) for CML and non-CML specimens respectively. 
Cell-cycle profiles showed a similar degree of cell-cycle activation at day 3 of 
culture (Table 6.2), although there was considerably greater expansion of CML 
CD34^ cells as might be expected. Conversely non-CML cells, again 
unsurprisingly, had not expanded by day 3, and indeed had actually decreased in 
number. This was almost certainly due to differentiation and early death of non- 
viable cells. Despite these differences CML CD34^ cells showed a mean 30% 
reduction in hTERT levels while the non-CML samples increased by 117% 
(p=0.02). Interestingly, at day 3, the mean percentage of unspliced +a+p hTERT in 
the CML samples fell by a similar degree (27.7%) in the CML samples (from 
27.2+4.9% to 19.6+2.5%, mean+SD) but showed little change in the non-CML 
cells (from 19.5+1.6% to 18.2+0.8%, mean+SD). The latter observation indicates 
that the splicing pattern is not simply PCR artefact related to absolute +a+p 
hTERT levels (which increased in the non-CML samples on culture), and is further 
evidence of a regulatory role for splicing. The increase inCD34^ cells, although it
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cannot be proven with these data, most likely represented increased hTERT 
transcription.
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Figure 6-8 Increased cycling of CD34+ cells subsequent to short term cell 
culture
At least 2x10® CD34^ cells were cultured in defined serum-free medium for three 
days. To confirm comparable cell cycle activation profiles between CML and non- 
CML samples cell cycle analysis was performed at day 0 and day 3. Almost all Go 
cell had entered the cell cycle by day 3.
CD34*
Fold-expansion 
(total cells)
day 3 cell culture results
Fold-expansion %CD34* of total 
(CD34* cells) (meaniSD)
Cell Cycle Analysis
%Gq %Gi 
(meaniSD) (meantSD)
“/oGj/S/M
(meaniSD)
CML (n=4) 2.6±0.7* 2.8±1.0* 87.8±2,9* 0.410.2* 50.916.7 46.516 9
Non-CML (n=4) 0.7±0.2 0.6±0.2 68.3±9.5 1.110.4 36.7112.0 52.015.7
Table 6-2 CD34* cell expansion and cell cycle status at day 3 of culture
Day 0 
hTERT/PBGD% 
(mean±SD)
hTERT expression
Day 0 
hTFt/PBGD% 
(meaniSD)
hTR expression
Day 3 
hTFt/PBGD% 
(meaniSD)
% Change 
(meaniSD)
CML (n=4) 5.8±3.6 2.5±1.6 -30±44.6 8701320 386.5189.2 -48.1130.5
Non-CML (n=4) 4.6±5.1 7.9±3.6 +117,1176 219211539.3 1689.011690.3 -36.5130.4
Table 6-3 Expression of telomerase components at baseline and day 3 of 
culture
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6.1.7 Patterns of telomerase component expression with 
progression to BP
Chapter 5 detailed the changes in expression of telomerase components in PBL 
during CML progression. Interpretation of these data were however limited by the 
degree to which the PBL reflected changes at the HSC/progenitor CML cell level. 
To address this issue we compared expression of hTERT and hTR in CD34^ 
selected BCR-ABL* CP cells, BP PBL (with a median of 55% blasts) and a limited 
number of BP CD34'*’ selected samples (n=3). Myeloid BP samples were seen to 
have significantly lower +a+(3 hTERT levels (by Q-RT-PCR) than CP CD34^ cells 
(p=0.01), while the opposite was true for lymphoid BP (p=0.02. Figure 6-9).
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Figure 6-9 Comparison of CP CML CD34 cells with BP PBL of myeloid and 
lymphoid lineages
These data confirm the impression from Chapter 5 of significant lineage 
dependent differences in hTERT expression, in this case emphasised by 
comparison with CP CD34^ cells. MBP, myeloid BP; LBP, lymphoid BP.
These differences were also apparent on comparing splice variant distribution and 
estimated quantities of total hTERT transcripts {i.e. all differentially spliced
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species) as previously outlined in Figure 6-6 (Figure 6-10). Only 4 LBP samples 
were available for splice variant PCR, however the greater proportion of full-length 
(+0+P) hTERT observed was in keeping with the LightCycler data from Figure 
6-9. These data suggest a greater than 2-fold increase of all hTERT transcripts in 
LBP samples as compared to CP CD34^ cells, with a 2-fold reduction seen in MBP 
samples.
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Figure 6-10 Total hTERT expression in CML and non-CML CD34* cells in 
comparison to BP samples
By combining data from +a+p hTERT Q-RT-PCR and splice variant RT-PCR, a 
complete picture of steady state hTERT expression could be estimated for 
samples with complete data available. Total transcript levels (as indicated by 
histogram height) were reduced in MBP samples (n=12) as compared to CP 
CD34* cells, although they contained a similar mean proportion of +a+(3 transcripts 
(27% vs 24% respectively, as indicated by the height of the solid black bar). On 
the other hand (although numbers were small) LBP samples displayed a greater 
full-length (+o+p) transcript proportion (n=4, mean 42%).
Limited availability of primary BP material of sufficient quality and quantity 
unfortunately precluded an extensive analysis of CD34^ selected cells from all 
stages. Given the presence of mature (hTERT mRNA'°) cells in the BP samples, it 
is possible that these could ‘dilute-out’ the hTERT positive CD34* cells in MBP. In 
answer to this possibility we analysed CD34'" -selected 3 MBP samples on which
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material was available and in which hTERT expression was low in whole PBL 
(Figure 6.12). Although no statistically-supported conclusions can be drawn from 
these data TRAP activity and +a+p hTERT expression was indeed confirmed to be 
low in these specimens. The PB and CD34^ selected data from all 3 MBP samples 
is given in Table 6-4.
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Figure 6-11 Comparison of TRAP activity and full-length (+a+P) hTERT 
expression in CD34+ selected CP and MBP samples
CD34 selected MBP samples (89, 91.6 and 93.8% pure respectively) exhibited low 
TRAP activity and full-length (+a+p) hTERT expression in comparison to CP 
samples. Statistical analysis was not performed due to the small sample size.
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C D & r
+a+p hTERT/PBGD% 
(+Q+P % of all 
transcripts)
PBL
+a+(3 hTERT/PBGD% 
(+a+(3 % of all 
transcripts)
MBP 1 0.9 (17.3) -
MBP 2 2.6 (17.4) 0.9(12.1)
MBPS 3.0 (16.5) 1.1 (0)
Table 6-4 +a+p hTERT expression data from CD34^ selected MBP samples 
with their respective unselected PBL values.
It can be seen that all MBP CD34^ samples have levels of hTERT expression 
below the median for CP CD34^ cells (3.6%). The hTERT expression is clearly 
enriched upon CD34^ selection, as compared to the respective PBL values. This 
demonstrates that cell mix is indeed a factor in determining overall hTERT levels 
in BP, with the more mature cells that are present in PBL BP samples diluting the 
relevant {i.e. blast) population.
Thus low-level +a+p hTERT expression in MBP samples would appear to be a 
genuine finding, reproducible at the CD34^ cell level.
If hTR is indeed limiting for telomere maintenance in CML CD34^ cells during CP 
disease, it may be predicted that progression to the aggressive acute leukaemia­
like BP stage would be accompanied by an increase in hTR to permit telomere 
maintenance. In keeping with this, the mean hTR level from 9 BP PBL samples 
was 1645% (±1900%, mean+SD), compared to 698% for CP CML CD34‘** cells 
(p=0.07, Figure 6-12). The data concerning hTR: hTERT ratios referred to in 
Section 6.1.5 are illustrated in Figure 6-13 plus the corresponding data from 7 
MBP PBL samples on which complete data was available. Non-CML CD34^ 
samples had a significantly greater ratio than CML CP CD34"' cells (p=0.0001). BP 
samples had a significantly greater hTR: hTERT ratio than CP cells (p=0.03).
Chapter 6, 175
however there was no difference as compared to the non-CML population 
(p=0.84).
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Figure 6-12 Trend to increased hTR expression with progressive (BP) 
disease
Material from BP samples was unfortunately limited. However 9 PB samples (7 
MBP and 2 LBP) from BP patients exhibited a trend towards increased hTR levels 
as compared to CP CD34^ cells. The PBL specimens, by their nature, have many 
mature (/.e hTR low) cells and this may actually be an underestimate of levels in 
the blast (CD34*) population. Numbers did not permit separate analysis of LBP 
and MBP samples.
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Figure 6-13 Altered hTR;hTERT ratios in CP and BP CML
Comparison of CD34^ selected CML and non-CML samples in comparison to MBP 
PBL expression.
Thus, on progression to BP CML, there is a significant (partly) lineage-dependent 
alteration in expression of the major telomerase components. What is not apparent 
from these data is how this is related to telomere length; indeed the low-level 
TRAP activity and hTERT expression in the myeloid BP specimens raises the 
possibility of alternative mechanisms of telomere maintenance being involved. We 
therefore analysed the BP flow-FISH data with respect to evidence for ALT.
6.1.8 No evidence for ALT as a mechanism of telomere 
maintenance in BP CML
It is well established that the ALT mechanism of telomere maintenance is 
associated with an enormously wide range of telomere length, resulting in
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extremely long TRF fragments on Southern blotting (Bryan, et al 1995). Flow-FISH 
provides similar telomere length distribution data, with the fluorescence profile in 
FL-1 indicative of the range of telomere length (as determined by the CV). We 
reappraised all BP flow-FISH profiles (17 MBP and 4 LBP) for any suggestion of 
an ALT-like (i.e. excessively wide) distribution; however none was observed 
(Figure 6-14).
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Figure 6-14 No evidence for an ALT phenotype in myeloid BP samples
Flow-FISH profiles of 3 representative myeloid BP samples, A B and C. After 
gating on the 2N population (as described in Chapter 3) FSC/SSC analysis (Panel 
A1-C1) revealed a moderately homogenous population of cells. These consisted 
of a mix of (largely) blasts, myeloid lineages in various sates of maturation and 
occasional lymphocytes and monocytes (based upon standard morphological 
indices obtained during routine clinical assessment). Despite this the CVs of 
telomere probe fluorescence (solid grey histogram, unstained open histogram 
panels A2-C2) were comparable to those of normal cells (CV values for stained 
population 16.9, 22.3 and 18.9 respectively). Near-normal telomere-length 
distribution profiles (see Figure 3-4) argue against a significant role for ALT in 
myeloid BP telomere maintenance.
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The Interaction between telomere shortening and telomerase activity is thought to 
be a dynamic one: progressive telomere sequence loss may result in ever greater 
selection pressure for telomerase expressing cells to predominate. This 
mechanism would predict for late upregulation of telomerase activity. Alternatively, 
it may be an early event in some cancers. At what stage this happens in tumour 
evolution is not clear, therefore we correlated BP telomere length with expression 
of hTERT and hTR.
6.1.9 hTERT expression is associated with critically short 
telomeres in MBP
In an attempt to clarify whether expression of telomere components are related to 
telomere length, we correlated levels of the major telomerase components with 
telomere length as measured by flow-FISH. 14 MBP samples had complete data 
for analysis. Conversely only 4 LBP samples were complete (all incidentally having 
high hTERT expression and telomere lengths of 4.0, 5.2, 9.2 and 14.4 kMESF), 
which prevented a similar analysis for this lineage. The MBP samples showed a 
striking (and highly statistically significant) inverse correlation of full-length (+a+(3) 
hTERT mRNA expression with telomere length. This is consistent with a model of 
late hTERT expression: i.e. at or near critical telomere lengths (approx 5 kMESF, 
or 2.5 kb, according to this model).
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Figure 6-15 Increased +a+p hTERT expression is associated with short 
telomere length in MBP samples
A significant inverse correlation was seen between telomere length and +a+p 
hTERT
Only 7 MBP samples had complete hTR and flow-FISH data available, so 
correlation was not performed (although there was of course a trend towards 
increased expression of hTR in myeloid BP Figure 6-13).
6.1.10 Discussion
In summary we have, for the first time, completely characterised the expression of 
hTERT (and its splice-variants), hTR and TRAP activity in a purified leukaemic 
progenitor / stem-cell population. By incorporating non-malignant CD34'" cells as a 
normal control, we have established the threshold expression of telomerase 
components in equivalent polyclonal cell types with which to compare leukaemic 
cells.
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Our data explain, at least in the context of CML, the paradox of increased TRAP 
activity in association with greatly reduced telomere length: an increased 
proportion of cycling GD34^ cells in CML results in greater detectable TRAP 
activity. Our demonstration that peripheral blood CML CD34^ cells display 
increased cycling activity is not particularly surprising in itself, and is in agreement 
with a previous study (Holyoake, eta l 1999a).
Many other investigators have demonstrated a clear pattern of TRAP activity in 
proliferating tissues such as oral mucosa (Kannan, et al 1997) and endometrium 
(Kyo, et a! 1997). Our detection of low TRAP activity within Go-rich samples is in 
agreement with previous studies demonstrating a clear correlation with TRAP and 
cell cycle activity in tumours (Belair, et a! 1997) and with down regulation of activity 
on entry into a quiescent state (Holt, et a! 1997). In the haemopoietic system a 
similar relationship between proliferation and TRAP status exists: activity is 
repressed in CD34^CD38' (quiescent) cells, with upregulation upon proliferation 
and expansion in the CD34^CD38^ compartment prior to down regulation upon 
differentiation (Engelhardt, et a! 1997). Thus it seems that in normal tissues, 
primary solid tumours and leukaemias the overriding determinant of TRAP status 
is the percentage of cells in the cycling compartment, as previously hypothesised 
(Ohyashiki, et a! 2002). One way of avoiding this, while allowing detection of 
genuine cell-to-cell and sample-to-sample differences in telomerase activity, is to 
compare cell-cycle stage specific {i.e. S-phase) selected samples, and these 
studies are currently underway in our laboratory.
Given the problems in interpreting TRAP data, one alternative is to focus on 
expression levels of the major telomerase components hTERT and hTR which are 
the key components that are required for active telomerase. In this regard we 
showed no significant correlations between cell cycle status and expression levels
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of hTERT or hTR, and in addition there was no obvious relationship between these 
parameters and TRAP activity in quantitative terms. At first sight this may appear 
somewhat surprising given the oft-quoted role of hTERT as the major determinant 
of TRAP activity. Many of these studies have however expressed this relationship 
simpiy in qualitative terms: i.e. presence or absence of full-length (+a+p) hTERT 
correlates with the presence or absence of TRAP activity (demonstrated in Section 
5.1.5), and in this regard, we demonstrate a 100% correlation. Post-translational 
telomerase regulatory mechanisms may of-course preclude any attempt to 
correlate the relationship between hTERT and TRAP in quantitative terms.
Comparable median levels of full-length +a+p hTERT mRNA transcripts (as 
measured by Q-RT-PCR) were detected in CML CD34^ cells vs. non-CML. By 
combining two PCR techniques and analysing on a sample-to-sample basis, we 
demonstrated a close correlation between absolute full-length +a+p transcript 
levels and the percentage of all hTERT transcripts (by splicing pattern RT-PCR) 
that these represented. This is not simply a mathematical inevitability; an 
alternative scenario would be that splicing patterns remained static and 
transcriptional control solely determined absolute hTERT transcript levels. Thus, 
on a sample-to-sample basis there would appear to be a regulatory role for 
splicing in determining functional +a+p hTERT levels: in other words by reducing 
hTERT mRNA splicing activity a cell can increase the proportion of full-length 
+a+p transcripts, an increase which is detectable in absolute terms. As far as we 
are aware this is the first time such a quantitative relationship has been detected; 
previously, a qualitative (i.e. on-off) relationship has been observed in foetal 
development (Ulaner, et ai 1998), with a remarkably consistent splicing pattern 
observed in tumour cell-lines (Yi, et a /2001). Cell lines are of course, by nature, a 
highly selected cell population and patterns of telomerase expression in such
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samples cannot be extrapolated to primary material. Certainly the use of a highly 
pure fraction of primary cells facilitates such analysis.
A primary aim of this Section was to determine if there were any CML-related 
differences in expression levels of hTERT or hTR. The 5-fold reduction in mean 
levels of the latter was of particular interest given that it has now been shown to be 
limiting for telomere homeostasis in-vivo (Mitchell, et a! 1999b). Additionally, 
several studies have detailed low hTR levels resulting in telomere shortening with 
no detectable fall in TRAP activity (Hathcock, et a! 2002, Liu, et al 2000b). Such 
data would support a model in which CML cells expressing sub-normal levels of 
hTR (but not obviously deficient in TRAP activity) undergo progressive telomere 
shortening as a result. hTR may only become limiting transiently, as a cell requires 
maximal telomerase function {i.e. during S phase). Thus it may have no detectable 
effect on baseline TRAP activity, or the latter may be insufficiently sensitive to 
detect it. Whether the ratio of hTR to hTERT is significant in this regard is entirely 
speculative, but is an intriguing possibility. Additionally, the mechanism of reduced 
hTR should be clarified; for example is it a direct effect of the BCR-ABL kinase 
function, perhaps via transcriptional alteration, is a stabilising factor {e.g. dyskerin) 
altered in its expression or activity, or are epigenetic events {e.g. promoter 
méthylation) involved? All these mechanisms can be tested on primary cells. 
Differential regulation of telomerase components was also apparent on stimulation 
of CML 0034^ cells in-vitro. While (in retrospect) it may have been more 
meaningful to look at a 24 hr time-point re gene expression, the fact that hTERT 
was still elevated at 3 days in the non-CML cells (by over 100%) as compared to 
CML (a 30% fall) despite near identical degrees of cell-cycle activation is at least 
suggestive of telomerase dysregulation in CML. An alternative explanation may be 
that differentiation was further advanced in the CML population by that stage, and 
that hTERT was being down regulated as a consequence. The fall in hTR levels
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(by approximately 30%) may have been for similar reasons. The fact that >80% of 
cells analysed at day 3 were CD34^ however argues against this as a mechanism.
By establishing a ‘baseline’ of hTERT and hTR expression in CP CML CD34^ cells, 
we were able to fully interpret levels of these components in the BP samples 
described in Chapter 5. We confirmed that myeloid BP samples expressed 
significantly lower levels of hTERT (and probably TRAP activity) than the CP 
progenitor population, and that lymphoid samples were significantly higher in this 
regard. Thus lineage determined hTERT expression would appear to be a genuine 
phenomenon in CML. All lymphoid BP samples were immunophenotyped as B-cell 
in nature. In this regard it is interesting to note that in Ohyashiki’s recent review of 
TRAP activity in haematological malignancy the B-cell malignancies consistently 
have the greatest proportion of high TRAP activity tumours (namely acute 
lymphoblastic leukaemia and non-Hodgkin's lymphoma) (Ohyashiki, et al 2002). 
These cells may have the fewest barriers in place to hTERT upregulation by the 
nature of their phenotype. The low level hTERT detectable in myeloid BP samples 
prompted a review of flow-FISH profiles for patterns suggestive of an ALT 
mechanism; however there was no evidence for this. What was apparent was that 
myeloid BP samples appeared to up regulate hTERT only in association with very 
short telomeres.
Thus a picture emerges whereby lymphoid BP emerges as a B-cell lineage 
telomerase-competent high-hTERT expressing clone (perhaps with longer 
telomeres) contrasting with myeloid BP, a telomerase incompetent lineage. 
Further telomere shortening in the latter would appear to select for hTERT 
expression. Intriguingly we also demonstrated elevated hTR levels (albeit not with 
statistical significance) in the BP samples as compared to CP. If hTR is indeed
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limiting for telomere maintenance during CP CML this may be a prerequisite for
BP disease.
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7. Discussion and Conciusions
To establish the validity of telomere dynamics and telomerase expression as 
meaningful prognostic indices or as therapeutic targets in leukaemia, they must be 
extensively characterised in primary material, both normal and malignant. We 
have studied almost 200 samples form normal individuals and those with CML, a 
disorder that lends itself to such study.
We and others have demonstrated that telomere shortening correlates significantly 
with prognosis and conventional risk-score systems, which supports (but does not 
prove) the notion that telomere length could be an index of the process that drives 
disease progression. Demonstrating that telomere shortening actually contributes 
to the genomic instability of the disorder is a much more difficult proposition 
however; long-term animal models containing primary CML HSC are extremely 
difficult to generate, and inevitably of limited life-span. Candidate BCR-ABL^ HSC 
rapidly differentiate in-vitro, and are impossible to propagate in significant numbers 
for any duration beyond a few days in culture. Furthermore the established CML 
cell-lines are all from BP disease and display extremely high telomerase activity 
(with additional mutations) and are not representative of the CP disorder. The 
recent rapid progress in identifying stem-cell genes involved in self-renewal, such 
as bmi-1 (Park, et a! 2003), may however make it possible to manipulate 
leukaemic HSC for extended periods in culture or in murine models, thereby 
facilitating study of telomere dynamics and disease evolution.
One argument against critical telomere erosion being a major factor in the clonal 
evolution of CML is the overwhelming predominance of non-random karyotypic 
abnormalities seen during evolution of the disease. Catastrophic telomere loss 
usually results in end-to-end fusion of chromosomes and ring forms, abnormalities
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which should be readily visible within a disorder that is probably the best 
characterised (in a karyotypic sense) human malignancy. It may of course be the 
case that different cell types vary in their response to telomere shortening or loss 
(Gonzalez-Suarez, efa/2000).
Additionally, we and other investigators have also shown that TRAP and hTERT 
expression are only elevated in a proportion of BP cases. While this may be partly 
dependent upon cell-lineage {i.e. myeloid vs. lymphoid) there are clearly some 
cases of advanced disease with no demonstrable upregulation of telomerase 
activity or its components (in fact we observed low levels of hTERT in myeloid 
BP). Having determined that ALT is an unlikely mechanism of telomere 
maintenance in these cases, either such levels are adequate to maintain telomere 
length or there has been no selection pressure exerted to express high telomerase 
activity at this stage of the disease. The former argument is possible; paradoxically 
BP disease would appear to have significantly slower cell cycle kinetics than CP 
MNCs (Handa, et a! 1997). It may be the case that maturation block, perhaps in 
conjunction with up regulated anti-apoptotic mechanisms, is adequate for large 
numbers of blast cells to accumulate at a rapid rate. There may therefore be no 
real requirement for high telomerase activity to facilitate telomere maintenance in 
what is a relatively low-turnover population (and as we have shown telomerase 
activity correlates with cell-cycle activity of the sample). In MBP, increased hTERT 
strongly correlated with very short telomere lengths; thus some cases of CP CML 
have progressed to BP (via clonal evolution) without the need for any obvious 
increase in their telomere maintenance. Only at extreme degrees of telomere 
shortening (an average of approximately 2.0 - 2.5kb, Figure 6-15) would hTERT 
expression appear to be increased. It is therefore possible that hTERT 
measurement could be of prognostic value in this scenario; however the prognosis 
of BP CML is universally poor and it would be of more value to test such a
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hypothesis in a similar condition such as AML where prognostic indices would be 
of genuine value for patient management Several small studies have looked at 
TRAP activity in AML, with most demonstrating high values to be a poor 
prognostic indicator (Li, et al 2000b, Ohyashiki, et a! 1997a) (although the most 
recent suggested just the opposite (Verstovsek, et a! 2003b) in adult disease). To 
further clarify this we are currently quantifying hTERT expression in several 
hundred samples from the MRC AML trials sample bank.
As compared to solid tumours, leukaemias do not require the development of a 
blood supply, the capacity for anchorage independent growth, the ability to invade 
or metastasise. Indeed Gilliland’s 'two-hit' hypothesis, in relation to AML, suggests 
a minimum number of genetic events are involved in its pathogenesis, in this 
model acute leukaemias arise from the consequence of a collaboration between 
one class of mutations or gene rearrangements that confer a proliferative and/or 
survival advantage to haematopoietic progenitors, and a second class that 
primarily act to impair differentiation and subsequent apoptosis of cells (Kelly and 
Gilliland 2002). Solid tumours potentially require many more cell divisions to 
propagate and stabilise the many mutations needed for the full malignant 
phenotype, thereby accruing greater telomere attrition and random karyotypic 
abnormalities in the process.
As far as CML is concerned, it is likely that the rapid rate of telomere loss 
observed is due to several mechanisms. Telomerase dysfunction (via reduced 
hTR expression), ROS mediated damage, reduced DMA repair (via DNA-PKc 
down regulation) and increased HSC turnover potentially contribute to the process 
of telomere attrition, a process that may act as a surrogate marker of genomic 
instability as well as contribute to it (Figure 7-1). A very recent paper defined an 
intriguing link between localisation of hTERT and cellular oxidative stress; in a cell-
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line model both transfected and endogenous hTERT were seen to be excluded 
from the nucleus subsequent to ROS generation and /or exogenous oxidative 
stress (Haendeler, et al 2003). This was corroborated functionally by a marked 
reduction in nuclear TRAP activity with a proportional rise in that detectable in the 
cytosol. Furthermore, overall cellular TRAP activity remained unchanged despite 
this. It is conceivable that such a mechanism operates in BCR-ABL* cells where 
ROS generation is significantly increased. Loss of hTERT protein from the nucleus 
may indirectly reduce hTR levels, due to reduced binding / stabilisation of this 
critical component, thereby compromising telomere homeostasis. Thus 
intracellular compartmentalisation of telomerase may affect telomere maintenance 
in the face of unchanged whole-cell telomerase activity. Sub-cellular localisation 
and function of telomerase require to be defined in future studies.
increased HSC turnover Reduced hTR expression
CML HSC
Genetic Instability
Reduced DNA-PKc Increased ROS
Figure 7-1 Potential effectors of telomere shortening during progression of 
CML
Chapter 7, 189
The fact that telomerase upregulation is not consistently observed in BP CML 
does not mean that this disorder is unsuitable for treatment with telomerase 
inhibitors. The consistent presence of short telomeres (at least in myeloid BP) 
would allow leukaemia selectivity to such agent to be exploited. At least in theory, 
it may not matter whether the clone expresses a lot of telomerase or not. Indeed 
less activity may facilitate a greater degree of inhibition. Promoter driven therapies 
however (as developed by W. N. Keith (Plumb, et al 2001)) may be less 
applicable, in contrast, treatment of CP disease may raise some concerns. A 
recent paper on arsenic induced ROS and telomere damage encapsulated 
potential problems with this strategy; arsenic, chronically administered in low- 
moderate doses (from environmental contamination) is likely to be tumourigenic 
via this mechanism (Liu, et al 2003). However, give in pharmacological doses it 
has a clear anti-tumour effect, apparently via a similar route. These findings 
complement the tumour suppressor / tumour facilitator paradox of telomere 
biology, and suggest that caution must be exercised in treating CP CML with 
telomerase inhibitors as clonal evolution may be precipitated. Preferential 
selection of an ALT dependent clone could be imagined as the worst case 
scenario in this case.
There is now a weight of evidence to suggest that telomere length is of prognostic 
significance in CML. Since May 2000, when this project was commenced, 
treatment options for CML have however changed radically. The introduction of 
the orally administered selective tyrosine-kinase inhibitor imatinib mesylate has 
revolutionised not only the treatment of CML, but the approach to cancer therapy 
in general. As a selective inhibitor of the BCR-ABL tyrosine kinase, imatinib is able 
to block downstream phosphorylation events and ultimately kill the cell which 
would seem to be dependent on kinase activity for its survival (Druker, et al 1996). 
This has been translated into spectacular clinical success, with a high incidence of
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complete cytogenetic remissions (76% at 18 months (O'Brien, et al 2003)), and 
levels of disease only detectable by sensitive nested or Q-RT-PCR (Lin, F W, 
Drummond MW et al, Blood, in press) in CP patients treated with imatinib 
monotherapy. It is too early as yet to detect a survival advantage; however the 
likelihood of disease progression with imatinib (as compared to IFN, the previous 
gold-standard non-transplant therapy) is significantly less (O'Brien, et al 2003). It 
now appears likely that treatment-specific prognostic indices (e.g. whether or not a 
complete cytogenetic response will be obtained) will assume more importance 
than leukaemia specific indices (generally based on diagnostic findings). The 
Hasford score would appear not to be predictive of response to imatinib as yet, 
although these studies will take many years to complete. It is however clear that 
imatinib is much less efficacious in AP and in particular BP disease (Kantarjian, et 
al 2002), thus identifying how ‘far down the line’ a patient is at diagnosis may 
predict their response to the drug. In this context telomere length is worthy of 
assessment, and we would advocate prospective analysis of telomere length 
within a randomised clinical trial involving imatinib therapy. By identifying those 
patients unlikely to respond to the drug and progress quickly, alloSCT could be 
planned at the outset.
The complexity of the telomerase holoenzyme will almost certainly frustrate 
attempts to achieve a rapid understanding of its biology and regulatory 
mechanisms. Essentially two ‘extremes’ of investigative techniques have been 
used by our own, and most other, groups. Firstly the TRAP assay, which gives a 
crude whole cell lysate based semi-quantitative measurement of telomerase 
activity, and secondly the highly specific quantitation of expression of individual 
telomerase components. Crucial studies, such as post translational regulation 
(including localisation studies) need to be performed on relevant primary cell 
populations. For example next to nothing is known about how (and where) the
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enzyme is assembled and delivered to its site of action. These studies are to be 
performed on human embryonic stem cells and primary HSC in our laboratory in 
the near future, and will allow comparison with leukaemic cells. Successfully 
targeting telomerase enzyme activity in this population remains a highly desirable 
goal.
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Sample
Number Stage
hTERT mRNA 
(+a+P) 
(hTERT/PBDG%)
%
+Q+P
mRNA
%
-a+p
mRNA
%
+a-p
mRNA
%
-a-p
mRNA
1 Diag CP 1.5 46.3 3.9 41.9 7.9
2 Diag CP 5.0 15.6 0 81.9 2.5
3 Diag CP 4.8 ND ND ND ND
4 Diag CP 5.4 0 18.1 81.9 0
5 Diag CP 3.5 0 0 100 0
6 Diag CP 0.0 0 0 59.3 40.7
7 Diag CP 2.8 14.8 0 85.2 0
8 Diag CP 0.0 0 0 74.1 25.9
9 Diag CP 1.25 0 0 100 0
10 Diag CP 3.0 25.8 0 67.2 7.0
11 Diag CP 0.0 0 0 83.8 16.2
12 Diag CP 0.1 0 0 100 0
13 Diag CP 2.5 0 0 100 0
14 Diag CP 2.8 ND ND ND ND
15 Diag CP 4.4 ND ND ND ND
16 Diag CP 0.0 8.3 0 91.7 0
17 Diag CP 3.4 0 0 100 0
18 Diag CP 0.5 0 0 100 0
19 Diag CP ND 36.6 1.7 51.1 10.6
20 estCP^ 1.5 0 0 100 0
21 estCP 2.7 0 0 100 0
22 estCP 0.2 ND ND ND ND
23 estCP 0 0 0 0 100
24 estCP^ ND 0 0 100 0
25 estCP 0.8 13.2 0 86.8 0
26 estCP 0 0 0 100 0
27 estCP 5.2 15.4 0 84.6 0
28 estCP 0 23.4 0 76.6 0
29 AP 3.7 0 0 100 0
30 AP 0.9 26.3 0 53.9 19.7
31 AP 8.1 11.2 0 82.0 6.7
32 AP 5.0 0 0 100 0
33 AP 0.7 24,5 0 75.5 0
34 AP 5.7 11.8 0 88.2 0
35 AP 11.4 7.2 0 92.8 0
36 AP ND 13.5 0 86.5 0
37 AP 7.6 10.5 0 89.5 0
38 AP 27.5 ND ND ND ND
39 AP 8.1 22.6 0 77.4 0
40 AP 3.2 11.9 0 88.1 0
41 AP 2.1 ND ND ND ND
42 AP^ 7.6 7.6 0 74.8 8.6
43 BP(M) 2.7 19.7 2.6 67.9 9.8
44 BP(M) 0.7 14.4 0 78.4 7.1
45 BP(M) 5.1 34.3 0 65.7 0
46 BP(M) 7.6 21.9 2.2 72.6 3.3
47 BP(M) 8.0 12.5 1.1 80.6 5.7
48 BP(M) 6.2 45.5 0 54.5 0
49 BP(M) 3.3 ND ND ND ND
50 BP(M) 1.9 11.9 0 79.7 8.4
51 BP(M) 0.9 53.1 8.3 38.7 0
52 BP(M) 0.2 0 0 100 0
53 BP(M) 1.3 ND ND ND ND
54 BP(M) 0.2 36.7 0 43.0 20.3
55 BP(M) 1.3 49.5 0 50.5 0
56 BP(M) 10.5 15.7 1.8 76.5 6.0
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Sample
Number Stage
hTERT mRNA 
(+0+P) 
(hTERT/PBDG%)
%
+a+p
mRNA
%
-a+p
mRNA
%
+a-p
mRNA
%
-a-p
mRNA
57 BP(M) 0.9 12.6 1.0 84.8 1.6
58 BP(L) 11 ND ND ND ND
59 BP{L) 4.0 ND ND ND ND
60 BP(L)^ 34.4 100 0 0 0
61 BP(L) 4.6 22.2 0 77.8 0
62 BP(L)^ 23.8 42.4 22.0 35.6 0
63 BP(Lf 26.3 12.1 4,7 79.1 4.1
hTERT expression profile in CML PBL from ail stages of disease
This table summarises the data which is partly described in Chapter 5. ND, not 
done. DiagCP, diagnostic CP; AP, accelerated phase; BP, blastic phase; M, 
myeloid BP; L, lymphoid BP.
